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GenerAL InTroDuCTIon
Tumor immunology: an evolutionary perspective
The elegant laws of natural selection (1) have guided life from single celled organisms 
to increasingly complex species. The existence of complex multicellular biology requires 
the preservation of homeostasis, which means individual cells behave in a way that is 
beneficial to the whole. However, individual cells are not immune from the laws of natu-
ral selection (2). Thus, if the constrains imposed upon individual cells are successfully 
challenged, and removed, cancer can develop. Through the “misapplication” of normal 
developmental and homeostatic biologic mechanisms cancer cells strive to “survive” 
without consideration for the rest of the organism.
Cancer is almost as old as life itself. While the first description of human cancers come 
from deciphered Egyptian papyri, dated to 2,500 B.C. (3), cancer can unmistakably be 
found in the fossil records, dating hundreds of millions of years ago (4). With these time-
frames in mind one can imagine an ongoing evolutionary war, where increasing cellular 
complexity leads to new developmental and homeostatic pathways, that not only help 
an organism survive but also provide new pathways, to a damaged individual cell, to 
successfully transform into cancer. The organism must then evolve new constrains to 
control cellular behavior and prevent cancer development. Fundamental biological 
systems, such as growth suppression genes (i.e. retinoblastoma and TP53 genes), apop-
tosis, contact inhibition, the TGF-β pathway and telomere based replicative mortality, 
have evolved to be, at least partly, responsible for cancer control. One additional system, 
whose initial purpose may or may not have been cancer control, is the immune system.
Tumor immunology: a historical perspective
The role of the immune system in cancer control was not always appreciated (5). In 
fact, even up to 15 years ago, when Hanahan and Weinberg published their now fa-
mous “hallmarks of cancer” paper (6), the immune system was not recognized as such. 
It would take several more years, and the unquestionable clinical success of immune 
specific therapies, before “avoiding immune destruction” would be widely recognized 
as one of the fundamental hallmarks of cancer (7). However, evidence for the strong 
relationship between cancer and the immune system dates back to centuries. For ex-
ample, spontaneous regression of cancers, almost always following severe infections, 
have been described since at least the 18th century (8), while Virchow microscopically 
observed immune cell infiltration in tumors as early as 1863 (9). In the 1890’s Coley went 
as far as to inoculate cancer patients with his so called “Coley’s toxin”, a mixture a killed 
bacteria species, and was able to reproduce durable clinical responses (10). Ironically, 
Coley attributed the success of his therapy to “competition” of the streptococcus bacteria 
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with the parasitic organisms responsible for the cancer, since the infectious etiology of 
cancer still prevailed scientific thought at the time. The inconsistent success of “Coley’s 
toxin” in the subsequent years, the occasional severe toxicity, and the acquired clonal 
deletion theory of Burnet (11), according to which tumor are “self” and thus cannot be 
recognized and attacked by the immune system, led the scientific community away 
from this promising cancer therapeutic strategy.
In a stunning reversal of opinion however, Burnet and Thomas proposed their cancer im-
munosurveillance hypothesis in 1957 (12, 13). At about the same time it was recognized 
that animals could be successfully immunized against transplantable tumors (14) and 
immunosuppression was linked to cancer (15). In the 1980’s the first tumor associated 
antigens were discovered (16). In the 1990’s peripheral T-cell tolerance, preventing tu-
mor-specific immunity, was demonstrated (17). Gradually the first therapeutic immune 
targets, namely molecules and immune cell subtypes that limit effective anti-tumor 
activation of the immune system, were recognized and explored (18).
Tumor associated immunosuppressive mechanisms in cancer
A developing cancer attracts the attention of the immune system. Immune cells then 
infiltrate the cancer site. However, by the time a cancer becomes clinically apparent, 
it is able to induce local and systemic immunosuppression, which in turn allows the 
cancer to evade the immune response (18). There are several mechanisms for this to 
happen. Cancer cells secrete immunosuppressive cytokines, such as TGF-β and IL-10, 
which shift the nature of the immune cells in the tumor microenvironment from an anti-
tumor, or Th1, state to a pro-tumor, or Th2 state (18). Effector T-cells become inactivated 
and instead the function of regulatory T-cells, which are immunosuppressive in nature, 
is promoted (19, 20). In addition, tumoricidal macrophages, such as M1 type macro-
phages, transform into M2 type macrophages, further promoting immunosuppression 
(21). Recently recognized myeloid derived suppressor cells (MDCS), found in the tumor 
microenvironment as well as in the circulation, also aid in the process of cancer induced 
immunosuppression (22). In this type of immunosuppressive environment NK and NKT 
cell activation is also inhibited (23, 24). As a result, despite the fact that cancer cells 
downregulate MHC class I expression, they are not targeted by NK cells. Downregulation 
of tumor associated antigens may be another mechanism of immune system evasion in 
cancer (25).
Another way cancer cells evade the immune system is by upregulation of immune 
inhibitory molecules that directly inhibit effector T-cells at the cancer site. Several 
members of the B7 immunoglobulin superfamily are such inhibitory molecules (26). Up-
regulation of B7-H1 (PD-L1), B7-H3, B7-H4, B7-H5 and B7-H7 have been shown to inhibit 
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T-cell activation in various cancers. The expression of Galectin-9, one of the molecules 
belonging to the galectin family of glycoproteins, also inhibits effector T-cells as well 
as promotes the function of T-regulatory cells (27-29). HVEM, a molecular switch with 
dual stimulatory and inhibitory function, can also be expressed by cancer cells, and the 
inhibitory function can be dominant in tumors because of selective expression of its 
inhibitory receptor on tumor-infiltrating T-cells (30, 31). Expression of the enzyme IDO 
in cancer cells inhibits T-cells by breaking down tryptophan, an essential amino acid for 
T-cell survival, and by generating metabolites that inhibit T-cell function (32). Finally, 
non-classical MHC type molecules, such as HLA-G, are also known to be expressed by 
cancer cells and inhibit T-cells (33, 34).
The above immunosuppressive mechanisms re-inforce each other (23, 35) and create an 
immune environment ideal for tumor growth. While these mechanisms are reviewed in 
more detail in chapter 2 of the current thesis, with a specific focus on pancreatic cancer, 
the principles are similar for all malignancies. Current immunotherapeutic strategies aim 
at reversal of these immunosuppressive mechanisms.
overcoming the limitations: Immunotherapeutic strategies
Various immunotherapeutic strategies are currently being employed against cancer 
aiming at re-invigoration anti-tumor immunity (36). While Coley was somewhat success-
ful in achieving that goal back in the 19th century (10), his method, causing erysipelas 
infections to patients, may not be suitable for our times. Vaccination strategies using 
tumor associated antigens aim at re-training the immune system to recognize cancer 
cells, similar to the way it can be trained to recognize diphtheria or measles. However, 
the analogy may be simplistic, since simple inoculation with tumor associated antigens 
is not enough, due to local immunosuppressive mechanisms in the tumor microenvi-
ronment. The fact, for example, that the first modern immunotherapy to be approved 
against cancer was a vaccination strategy against prostate cancer (37) comes in sharp 
contrast with the fact that many large recent vaccination trials have had negative results 
(38). However, cancer vaccines are improving in sophistication and complexity (39), 
with attention focused on many aspects such as vaccine adjuvants (40), combination 
strategies (39) and novel antigen formats (41). With currently hundreds ongoing vac-
cination clinical trials worldwide, success cannot be far. Adoptive cell transfer therapy, 
the collection and ex vivo manipulation and expansion of autologous T-cells, with the 
purpose of returning them to the patient with cancer, has been associated with remark-
able anti-tumor clinical responses (42). While it may also become an established treat-
ment strategy in the near future, the need to overcome logistic complexities, as well as 
the short half-life of the infused cells, has kept this otherwise remarkable strategy from 
being clinically available for the time being (42).
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Of all the immunotherapeutic strategies, immune checkpoint inhibitors have been the 
most successful to date (43-47). First in melanoma and now in lung cancer, renal cell 
carcinoma and bladder cancer, these therapies are rapidly transforming the overall 
oncologic treatment of cancer. These antibodies directly interrupt inhibitory interac-
tion between co-inhibitory receptors expressed on T-cells (i.e. CTLA-4, PD-1) and their 
ligands (members of the B7 immunoglobulin family) expressed on cancer cells and/
or tumor-infiltrating leukocytes. Clinical trials are ongoing, not only with the currently 
approved antibodies but also with new antibodies and combination treatments (48). 
Agonistic antibodies that target co-stimulatory molecules that directly activate T-cells 
are also in development (48). The above immunotherapeutic strategies are reviewed 
in detail in chapter 2 of the current thesis, with a focus on pancreatic cancer. However, 
similar strategies are currently being employed for HCC (49) and colorectal cancer (50).
need for immune biomarker development
While the above types of immunotherapy are welcome additions in the war against 
cancer they are not without pitfalls. The nonspecific activation of the immune system 
can lead to severe, and occasionally lethal, side effects (51-53). Amongst others, colitis 
and pneumonitis are well characterized complications. In addition, while there is all the 
reason for optimism, long term cures are still uncommon. In fact many patients have no 
clinical benefit from immune checkpoint inhibitors whatsoever. Differentiating patients 
that will probably benefit from patients that are unlikely to benefit from immunotherapy 
is of the paramount importance. Such biomarkers would allow patients and doctors to 
make more informed decisions, such as sparing patients from toxicities associated with 
the use of these agents. In addition, they would help clinical trials to properly enrich 
patient cohorts with the right patients and help lower the enormous costs of these 
compounds. Patients likely to benefit from immunotherapeutics would enter immu-
notherapeutic clinical trials, while patient unlikely to benefit would enter other types 
of trials. The problem currently is that such biomarkers do not exist. PD-L1 expression 
assays, while associated with patient clinical responsiveness to therapies targeting the 
PD-1/PD-L1 axis, are currently poor biomarkers due to lack of standardization and poor 
negative predictive value. Thus immune specific biomarkers are urgently needed (54).
Aims of the thesis
In the current thesis we aim to examine the expression of multiple immune related 
molecules in gastrointestinal cancers with the goal of identifying possible suitable 
targets for immunotherapy as well as propose promising immune specific biomarkers. 
We focus on hepatocellular carcinoma, colorectal cancer and pancreatic cancer. With 
pancreatic cancer we also include patients with ampulary cancer. We focus on the im-
munohistochemical determination of expression of biomarkers in tumor tissues, as well 
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as circulating biomarkers, since they have the best chance of clinical translation. Since 
PD-L1, by itself, appears to be a poor biomarker, we study the expression of multiple 
immune inhibitory molecules, as well as tumor infiltrating lymphocytes, in conjunction 
with PD-L1. We hope that the context provided will improve the performance of the 
proposed biomarkers.
We focus on expression of molecules by cancer cells that are ligands for co-inhibitory 
receptors expressed by T-cells. This means that their receptors are not studied in the 
current thesis due to the fact that they are expressed exclusively by lymphocytes. In ad-
dition, co-stimulatory ligand-receptor pairs, such as 4-1BB and OX-40 and their ligands, 
while promising for cancer immunotherapy, are not studied. To limit the number of im-
mune inhibitory molecules examined at this stage, we focus on molecules of which the 
biology is relatively well understood (for example a respected receptor is identified on T-
cells). This means these molecules can, in principle, become targets for immunotherapy 
in the near future. In addition, we focus on molecules for which reliable antibodies for 
immunohistochemical detection in paraffin-embedded formalin-fixed tissue are avail-
able. The above criteria have limited our work on the following molecules, which at first 
sight might appear randomly put together: PD-L1, Galectin-9, HVEM, IDO and HLA-G, in 
addition to evaluation of tumor infiltrating CD8+ and FoxP3+ lymphocytes.
Finally, in a related activity, we aim to examine the expression of tumor associated 
antigens in hepatocellular carcinoma. The goal of developing vaccination strategies 
against HCC requires identification of proper tumor antigens. However, since tumors 
can downregulate tumor associated antigens in order to evade the immune system, we 
also look on the possible prognostic role or tumor associated antigen expression in HCC.
outline of the thesis
In chapter 1 we give a general introduction on the importance of the immune system 
in cancer and the rationale behind the work of this thesis. In chapter 2 we continue 
our introduction by focusing, in more detail, on immune inhibitory mechanisms, as well 
as experimental immunotherapies, in pancreatic cancer. In chapters 3 and 4 we use 
tissue microarrays to investigate the expression and potential prognostic value of the 
inhibitory molecules PD-L1, Galectin-9, HVEM, IDO, HLA-G and CD8+ TILs and FoxP3+ TILs 
in hepatocellular carcinoma, pancreatic cancer and ampullary cancer. In chapter 5 we 
move beyond tissue microarrays and examine the importance of CD8+ and FoxP3+ TILs 
in colorectal cancer liver metastasis, using full tissue slides. This allows us to comment 
on the importance of TIL location in the tumors. In chapters 6 and 7 we move beyond 
cancer cell expression of biomarkers and discuss circulating biomarkers. In chapter 6 
we discuss what is known about routine immune laboratory tests and their association 
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to cancer survival. In chapter 7 we investigate the prognostic value of circulating PD-L1 
and Galectin-9 in patients with hepatocellular carcinoma. In chapter 8 we investigate 
expression of tumor associated antigens as possible targets for vaccination in hepa-
tocellular carcinoma, as well as comment on the prognostic role of tumor associated 
antigen expression. In chapter 9 we provide a general discussion of our thesis. We focus 
on issues that require more discussion, such as providing additional hypothesis that 
explain our findings. We also discuss technical aspects of our thesis, as well as ideas 
for future research, with the goal of successfully developing clinically useful, immune 
specific, biomarkers for the era of cancer immunotherapy.
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ABsTrACT
Traditional chemotherapeutics have largely failed to date to produce significant 
improvements in pancreatic cancer survival. One of the reasons for the resilience of 
pancreatic cancer towards intensive treatment is that the cancer is capable of high jack-
ing the immune system: during disease progression the immune system is converted 
from a system that attacks tumor cells into a support structure for the cancer, exert-
ing trophic actions on the cancer cells. This turn-around of immune system action is 
achieved through mobilization and activation of regulatory T cells, myeloid derived 
suppressor cells, tumor-associated macrophages and fibroblasts, all of which suppress 
CD8 T cells and NK cells. This immune suppression occurs both through the expression 
of tolerance-inducing cell surface molecules, such as PD-L1, as well as through the pro-
duction of ‘‘tolerogenic’’ cytokines, such as IL-10 and TGF-b. Based on the accumulating 
insight into the importance of the immune system for the outcome of pancreatic cancer 
patients multiple new immunotherapeutic approaches against pancreatic cancer are 
being currently tested in clinical trials. In this review we give an overview of both the 
immune escaping mechanisms of pancreatic cancer as well as the new immune related 
therapeutic strategies currently being tested in Pancreatic cancer clinical trials.
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InTroDuCTIon
Pancreatic cancer is the 5th leading cause of cancer related death in the developed world 
with more than 260,000 deaths annually worldwide [1]. Due to its aggressive nature and 
late presentation 5-year survival is a dismal 6%. Research efforts have mainly focused 
on improvements in surgical technique, radiation therapy and chemotherapeutics. 
However, advancements in traditional chemotherapeutics have been especially slow, 
and despite the recent success of the FOLFIRINOX regiment in metastatic disease long 
term significant benefit has not materialized.
Recently, research efforts have focused on the role of the immune system in the de-
velopment and progression of cancer. It is now known that both the innate and the 
adaptive immune system are active against human cancers [2]. Effective anticancer 
function of the immune system requires cytotoxic CD8 T cells, T helper-1 (Th1) cells, ma-
ture dendritic cells (DCs), activated pro-inflammatory macrophages (M1) and NK cells. 
However, cancer cells induce both local and systemic immune dysfunction thus avoid-
ing detection by the immune system [3]. Under the tumor induced immunosuppressive 
environment T helper cells acquire a T helper cell type 2 phenotype (Th2), which does 
not support cytotoxic CD8 T cell responses and is tolerant toward tumors, macrophages 
CD8+ CTL NK cells Mature DCs
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Th1 CD4+ helper cells
Treg cells
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IL-2
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figure 1: Changes in the tumor immune microenvironment during cancer progression.
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switch to the immunosuppressive M2 state, while T regulatory cells (Tregs) and myeloid 
derived suppression cells (MDCS) inhibit effector immune responses (Fig. 1).
Tumor immune modulation and evasion starts at the level of the cancer cell. Cancer cells 
use at least three mechanisms to modulate the immune system and avoid detection by 
effector immune cells: contact dependent factors (expression of immune system check-
point ligands such as PD-L1), secretion of soluble immunosuppressive factors (such as 
IL-10, TGF-b and VEGF) and interference with MHC class I peptide presentation (through 
down-regulation of MHC class I expression or disabling of the antigen degradation or 
antigen insertion into the MHC class I grove). Despite the fact that downregulation of 
MHC class I makes cancer cells the target of NK cells, cancer cells influence the cytotoxic 
activity, the presence of activating receptors, and the numbers and proliferation of NK 
cells, thus further avoiding detection and destruction. Through these mechanisms can-
cer cells have a profound local and systemic immunomodulating effect which leads to 
general immunosuppression and tumor progression.
It is safe to predict that immune modulation strategies in pancreatic cancer will be 
widely explored in the years to come in view of the increasing scientific knowledge in 
the field, the success of immunotherapeutic strategies in other cancers, and the evident 
inadequacy of competing treatment modalities. In this review we describe the immune 
escape mechanisms of cancer, with a primary focus on pancreatic cancer, and we discuss 
immune modulating treatment strategies tested in pancreatic cancer clinical trials. We 
focus primarily on recent scientific insights, as well as clinical trials that are characteristic 
of the given treatment strategies.
In pancreatic cancer a dysfunctional immune system aids rather than controls 
cancer
Immune cells in pancreatic cancer promote an immunosuppressive and anti-
inflammatory environment (Fig. 1)
T regulatory cells.
Of all the different types immune cells, Tregs have gotten the most attention in tumor 
immunology research. They are generally defined as CD4+CD25+FoxP3+ cells and 
they are found in the tumor microenvironment at increased numbers. By expression 
of CTLA-4 and secretion of IL-10 and TGF-b, among others, Tregs suppress exaggerated 
immune responses and are essential in the prevention of auto-immune diseases. In 
cancer however, they produce a local immunosuppressive environment ideal for tumor 
growth [4,5]. Patients with pancreatic cancer have increased numbers of Tregs both in 
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the circulation and at the tumor site. Moreover, the presence of Tregs at the tumor site 
correlates with more advanced presentation of disease [6,7], a lower chance of surgi-
cal resection and a worse survival after resection [8], while low Treg percentage in the 
circulation one year post resection correlates with improved survival [8]. In addition, as 
levels of Treg cells increase, levels of the CD8+ effector cells decrease [7]. Hence the Treg 
compartment represents an attractive target in pancreatic cancer.
Myeloid derived suppressor cells
MDSCs are immature myeloid cells that suppress both innate and adaptive immunity [9]. 
Factors contributing to their action in immunity include sequestration of cysteine (an 
essential amino acid for T cell activation), expression of high levels of arginase (resulting 
in depletion of L-arginine which is required by T cells for protein synthesis), increased 
production of reactive oxygen species, impairment of T cell homing to lymph nodes 
and secretion of TGF-b. These factors inhibit the function of effector T cells and NK cells 
and promote the development of Tregs. In a mouse model of spontaneous pancreatic 
cancer development the extent of immune suppression induced by MDSCs increased 
during the progression from premalignant lesions to pancreatic cancer [10]. Patients 
with pancreatic cancer have increased MDSCs in the circulation compared to healthy 
controls, and MDSCs levels correlate with levels of the Th2 cytokine IL-13 and Treg cell 
numbers [11]. Increased levels of circulating MDSC is an independent poor prognostic 
factor in patients with pancreatic cancer [11].
Tumor associated macrophages (TAMs)
TAM tumor infiltration is associated with worse prognosis in multiple cancers. Macro-
phages, due to stimuli from the tumor microenvironment such as IL-10, TGF-b and other 
cytokines, switch their differentiation from M1 (pro-inflammatory or classically activated 
macrophages) to M2 (anti-inflammatory or alternatively activated macrophages) which 
have pro-tumor properties, such as promotion of angiogenesis, matrix remodeling and 
tumor metastasis, as well as suppression of adaptive immunity [12,13]. TAMs interact 
with the immune system by multiple mechanisms such as through secretion of IL-10 
and TGF-b or by expression of immune inhibitory ligands such as PD-L1. In pancreatic 
cancer TAMs are significantly increased in tumor tissue [14]. In addition, the presence of 
M2 polarized TAMs is associated with worse prognosis in pancreatic cancer [15].
Dysfunctional immune effector cells in pancreatic cancer
Cytotoxic and helper T cells
In general both the number and function of cytotoxic and helper T cells is known to be 
affected in various cancers. In general, the presence of increased numbers of cytotoxic T 
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cells in the tumor is associated with a better prognosis while both cytotoxic and helper 
T cells are functionally impaired under the influence of immunosuppressive cytokines, 
leading to predominately Th2 (tumor tolerating) rather than Th1 (tumor killing) re-
sponses. In patients with pancreatic cancer circulating functional tumor-reactive CD8 
T cells can be detected both in the circulation and in the bone marrow [16], while the 
presence of both CD8 and CD4 T cells in the tumor is correlated with better prognosis 
[17]. In addition when pancreatic lesions progress from premalignant to malignant, 
CD8+ effector cells decrease in number while the presence of Treg cells are increased [7]. 
At the same time both circulating CD8+ cytotoxic T cells and CD4 T cells from patients 
with pancreatic cancer have impaired function while Th2, rather than Th1, responses 
predominate [18,19].
Dendritic cells (DC)
Dendritic cells play a critical role in the anti-tumor response. They belong together with 
macrophages to a class of cells called antigen-presenting cells (APC), which in contrast 
to all other cells in our body, express MHC class II and can therefore present antigenic 
peptides to CD4 T cells. By virtue of their efficient machinery to internalize (tumor) 
antigens, degrade them into peptides and present them on both MHC class I and II 
molecules to CD4 and CD8 T cells respectively, they are the most professional APCs. They 
can prime tumor specific effector T cells to start attacking cancer cells. However, due 
to the immunosuppressive tumor microenvironment their maturation and survival in 
cancer is significantly impaired. In pancreatic cancer patients while the presence of DCs 
in the circulation, or in the tumor tissue, is associated with prolonged survival [20], DCs 
also display maturation defects [21], suggesting that therapy aimed at improving DC 
functionality could be beneficial.
NK cells
Through MHC class I loss, which is a common event in pancreatic cancer [22], pancreatic 
cancer cells become the target of NK cells. However, pancreatic cancer cells can escape 
control by this system. Indeed, NK cell activity is diminished in patients with pancreatic 
cancer [23]. Activating receptors, such as NKG2D, which are necessary for the activation 
of NK cells, are reduced on the surface of NK cells in patients with pancreatic cancer 
and reduced levels are associated with advanced disease [24]. On the other hand higher 
absolute levels of NK cells in the circulation are associated with improved survival [25], 
indicating that the immune system, through NK cells, still exerts control on cancer 
growth despite disease progression.
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Contact dependent mechanisms of immune modulation: expression of co-stimulatory 
and co-inhibitory immune ligands and receptors by pancreatic cancer cells
T cells are activated by a complex interaction of ligands and receptors (Fig. 2). Specifi-
cally, APCs present antigenic peptides on both MHC class I (to stimulate CD8 T cells) and 
II (to activate CD4 T helper cells) molecules to the T cell receptor (TCR) on the surface 
of T cells. A complex balance of multiple stimulatory and inhibitory receptors on the 
surface of T cells ensures the proper function of the immune system. Binding of the 
MHC molecule to the TCR is not sufficient to initiate activation of the T cell. Activation re-
quires additional ligand binding to co-stimulatory receptors such as CD28, CD40, OX40, 
and 4-1BB. Activated CD4 T cells express CD40-ligand, which activates APC via ligation 
of CD40, thus forming a stimulatory loop between APC and T cells. On the contrary, 
receptors such as CTLA-4 and programmed death 1 (PD-1) expressed on the surface 
of activated T cells inhibit T cell activation upon binding to their ligands CD80/CD86 
and PD-L1/ PD-L2 respectively. In cancer this mechanism of immune co-stimulation and 
co-inhibition has been found to be extremely important [26].
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figure 2: Immune co-stimulatory and co-inhibitory ligands and receptors and soluble immune modulat-
ing factors involved in T-cell activation and inhibition.
Pancreatic cancer cells express a number of ligands that are meant to inactivate cytotoxic 
T-cells in the local tumor microenvironment. For example the ligand for PD-1 (PD-L1) is 
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expressed by pancreatic cancer cells and its expression is associated with reduced cyto-
toxic T-cell infiltration, advanced stage of disease and poor prognosis [27,28]. Pancreatic 
cancer cells express both CD40 and CD40L resulting in the secretion of several pro- and 
anti-inflammatory cytokines in the tumor microenvironment [29]. High expression of 
CD40L on tumor cells has been associated with good prognosis in pancreatic cancer 
patients [29]. Other immune inhibitory ligands with a role in pancreatic cancer are B7-H3 
and B7-H4, the receptors of which are still unknown. The expression, for example, of the 
immune inhibitory ligand B7-H3 has been associated with better prognosis in pancre-
atic cancer patients [30], while blockade of the B7-H3 ligand interaction leads to tumor 
shrinkage in animal models [31]. Even direct expression of FoxP3 by pancreatic cancer 
cells, mimicking thus Treg cells, has been detected [32]. Thus the pancreatic cancer cell 
is clearly under selection pressure to express immunosuppressive molecules providing 
hope that targeting this escape mechanism can be therapeutically meaningful.
Direct secretion of soluble immunosuppressive factors by pancreatic cancer cells (Fig. 2)
Direct secretion of immunosuppressive factors by pancreatic cancer cells is another 
mechanism of escaping the immune system. TGF-b induces tumors to secrete VEGF and 
matrix metaloprotein-2 which are associated with advanced stage of disease and metas-
tasis [33,34]. Tumor derived TGF-b and IL-10 inhibit the development of Th1 responses 
whereas they promote Th2 responses [19]. Secretion of multiple cytokines by pancreatic 
cancer cells contribute to the general immunosuppressive micro-environment of pan-
creatic cancer by switching the balance from a Th1 to a Th2 state [35].
Indoleamine 2,3-dioxygenase (IDO) is an enzyme upregulated in pancreatic cancer 
cells and catabolizes tryptophan into kynurenine. Depletion of tryptophan, as well as 
secretion and accumulation of kynurenine in the tumor microenvironment, inhibits T 
cell activation and stimulates Treg differentiation [36]. In pancreatic cancer expression 
of IDO attracts Tregs to the tumor microenvironment [37]. Inhibitors of IDO are already 
under phase I investigation.
Galectins are soluble immunomodulating glycoproteins that are involved in T-cell ho-
meostasis, preservation of fetal-maternal tolerance and suppression of autoimmunity. 
In cancer galectins have been shown to contribute to the immunosuppressive tumor 
microenvironment and evasion of immune responses. The best studied galectins in 
cancer immunomodulation are Gal-1, Gal-3, and Gal-9. Gal-1, is known to promote a Th2 
cytokine profile in cancer, induce IL-10 production in Tregs and is important in immune 
cell trafficking and DC physiology [38]. In pancreatic cancer Gal-1 is overexpressed by 
tumor cells [39] and has been identified as a proteomic biomarker highly correlated 
with stage of disease [40]. Gal-1 is also expressed on stellate cells and contributes to 
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stellate cell activation [41] and maintenance of the immunosuppressive microenviron-
ment [42]. ‘‘At the same time, Gal-1 is found underexpressed on the stromal tissues of 
long term pancreatic cancer survivors [43], indicating that the prognostic significance 
of Gal-1 expression is promising’. Blocking molecules for Gal-1 have entered phase I 
clinical trials, but not yet in pancreatic cancer. While Gal-9, partly through its complex 
interaction with TIM-3, modulates T cell, NK cell and MDSC activity [44], it’s precise role 
in pancreatic cancer has not yet been investigated. Another galectin with an important 
role in immune modulator in cancer is Gal-3 [45]. Gal-3 is overexpressed in pancreatic 
cancer cells, secreted in the serum of pancreatic cancer patients and is associated with 
tumor differentiation [46,47]. However, not much is known about the role of Gal-3 as an 
immune modulator in pancreatic cancer.
Cancer associated fibroblasts (CAFs) and the immune system
The immune infiltrate of pancreatic cancer is but a part of the tumor microenvironment. 
Cells of mesenchymal origin (tumor associated fibroblasts), associated with extra cel-
lular matrix proteins and tumor associated vasculature, are other important compo-
nents. A dense desmoplastic stroma reaction has long been recognized as a hallmark 
of pancreatic cancer and it is known to actively promote tumorigenesis and resistance 
to therapy. CAFs, however, also interact with the immune system in ways that promote 
tumor progression (Fig. 2). CAFs attract TAMs to the tumor microenvironment, though 
an NF-jb related mechanism, resulting in increased fibrosis and tumor growth [48]. In 
addition CAFs secrete fibroblast activation protein (FAP-a) which further suppresses 
effector T cells through interfering with TNF-a and IFN-c related activation [49]. FAP-a 
is found overexpressed on both the pancreatic cancer stroma and on pancreatic cancer 
cells [50] while anti-FAP-a monoclonal antibodies are currently in clinical development. 
Another treatment strategy that affects both the immune system (TAMs) and the CAFs is 
the use of CD40 agonists, to be discussed later.
Treatment strategies based on the interaction of pancreatic cancer with the 
immune system
Several immunotherapeutic strategies are being actively tested in clinical trials. We 
will discuss strategies aimed at antigenic stimulation of T cells (vaccination), increas-
ing the number of tumor specific cytotoxic T cells (adoptive cell transfer), interfering 
with co-stimulatory and inhibitory receptors and ligands and depleting Treg (Fig. 3). An 
overview of the clinical trials is provided in Table 1.
Vaccination strategies
Tumor antigens are expressed by a significant portion of pancreatic tumors. They can 
be normal proteins, present on normal tissues, albeit at much higher concentrations 
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on cancer cells, such as MUC-1, CEA, WT1, VEGF-R and mesothelin, or mutated proteins, 
present exclusively on pancreatic cancer cells, such as mutated K-ras. They can be ad-
ministered in various formats such as whole proteins, peptide fragments, DNA or RNA 
(Fig. 3). In animal models, administration of protein and peptide vaccines can cause 
antigen specific T-cell responses that lead to tumor eradication. In humans, antigen 
specific T-cell responses are also commonly observed, although actual tumor responses 
are less common.
One of the most promising tumor antigens is mutated K-ras, which is uniquely expressed 
in pancreatic cancer cells. In one clinical study vaccination with mutated K-ras resulted 
in 20% long term survivors [51]. The majority of survivors expressed antigen specific T 
cell responses, while none of the patients that progressed demonstrated such response. 
Although not all studies have been equally promising [52], a recent randomized phase-II 
study suggested a 2.8 months improvement in overall survival in patients receiving a 
recombinant mutated K-ras vaccine [53]. A randomized phase II placebo controlled trial 
using recombinant mutated K-ras protein for vaccination in combination with gem-
citabine, in patients with resected pancreatic cancer, is currently ongoing [54].
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figure 3: Diagrammatic representation of immune treatment strategies under investigation in pancreatic 
cancer.
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MUC-1 is a membrane bound glycoprotein known to promote pancreatic cancer epi-
thelial to mesenchymal transition and invasiveness. It also induces CD8 T cell responses 
and the production of anti-MUC antibodies is associated with improved survival [55]. 
However, in a large randomized phase-III clinical trial of 255 patients vaccination with a 
MUC-1 and CEA expressing viral vector showed no overall survival benefit [56].
A phase II vaccination trial in pancreatic cancer using WT-1 as antigen is ongoing [57], 
while a mesothelin vaccine, using genetically modified live attenuated listeria as a vec-
tor for the antigen, has also entered clinical trials [58]. Two peptide vaccine studies using 
VEGF-R1 and VEGF-R2 are completed but have not reported results yet [59,60]. Telom-
erase reverse transcriptase (hTERT) is a highly immunogenic antigen and has been the 
target in several vaccination studies. A small phase I/II study in patients with pancreatic 
cancer showed T cell responses in 63% of vaccinated patients, and prolonged survival in 
patients exhibiting T cell responses [61]. However, a large phase III study failed to show 
a survival benefit in pancreatic cancer [62]. Finally vaccination against Her2/neu is also 
being tested in a phase I study in patients with pancreatic cancer [63].
Whole tumor cell vaccines are another strategy that has shown promise in pancreatic 
cancer. The advantage of using whole tumor vaccines is that the vaccine contains all 
possible tumor antigens and can be patient specific. These are more challenging to 
develop because of the difficulty of obtaining sufficient numbers of tumor cells from 
pancreatic cancer patients and the time it takes to process the tumor cells. To bypass 
these problems allogeneic tumor cell lines, modified to increase immunogenicity, have 
been developed to serve as vaccines. In a phase I clinical study, tumor cells, which were 
modified to express the immunomodulating cytokine GM-CSF, where given to 14 pa-
tients [64]. Three patients had delayed-type hypersensitivity responses to autologous 
tumor cells and those 3 patients had a longer disease free survival. In a subsequent 
phase-II study with a similar approach, 60 patients with resected pancreatic cancer were 
treated, yielding a disease free survival of 17 months and an overall survival of 24 months 
[65]. While the results were not superior to historical controls other studies using similar 
approaches, or combining whole tumor vaccination with cyclophosphamide alone, or 
with conventional chemotherapy, are ongoing [66–69].
Antigen pulsed DCs is another vaccination strategy where patient DCs are isolated, 
pulsed with peptides, autologous, or allogeneic tumor lysate, or transfected with RNA, 
and injected back to the patients. In a study of 12 patients (10 with pancreatic cancer), 
where MUC-1 pulsed DCs were given as adjuvant therapy following resection, 4 of the 
12 patients were alive at 4 years [70].
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One reason for the apparent lack of significant objective responses in human studies 
may not be the choice of the antigen bur the inability of the antigen to be properly 
presented by APCs. Intact tumor proteins need to be internalized by APCs and degraded 
to peptides. They are then presented on MHC class II molecules, thus stimulating CD4 
T cells well, but not CD8 T cells. This issue may be overcome by the process known as 
‘‘cross-presentation’’ where DCs can, through receptor mediated endocytosis, process 
glycosylated proteins and present them on MHC class I molecules thus stimulating 
CD8+ cells. Cross-presentation is an active area of research in tumor immunology. On 
the other hand tumors antigens can be presented through vaccines as a mix of synthetic 
peptides that fit the groove of MHC class I molecules, thus bypassing the need for uptake 
and degradation. These peptides can stimulate CD8 T cells well but not CD4 T cells. Since 
CD4 T cells are necessary for the effective function of CD8 T cells this may explain the 
lack of apparent success in many of these trials.
Given the limitations encountered with protein and peptide vaccinations both DNA and 
RNA have been used to induce antigen presentation in APCs. The genetic material is 
either injected subcutaneously, or electroporated ex vivo into autologous dendritic cells 
which are subsequently transferred to the patient. Use of messenger RNA (mRNA) is of 
particular interest recently since it is not integrated into the genome and therefore RNA 
vaccination is not regarded as gene therapy. Dendritic cells exposed to mRNA are able 
to present peptides of the encoded antigen on both MHC class I and class II molecules, 
and therefore activating both CD4 and CD8 T cells. Major advantages of using mRNA 
vaccines are that they lead to sustained CD4 and CD8 T cell immunity, are easy to apply, 
are cost efficient, and are safe in human studies [71]. While these techniques have only 
been tested in animal models of pancreatic cancer, multiple human clinical studies are 
ongoing for other cancers.
Adoptive cell transfer (ACT)
In this strategy T-cells are removed from the tumor tissue (TILs), expanded ex-vivo, 
and ‘‘manipulated’’ before being returned to the host in massive numbers. This allows 
manipulation of the T-cells, such as priming of the cells to tumor antigens, or transfec-
tion with recombinant DNA encoding for T cell receptors specifically directed towards 
tumor-antigens. Obviously, it is a much more cumbersome technique than vaccination 
and, at least initially, the half-life of the infused cells was very short for therapeutic ben-
efit, a problem that is now largely overcome.
A typical protocol involves isolation of TILs from original biopsy sites, or metastatic sites, 
followed by rapid expansion. In the meanwhile, during the rapid expansion process, the 
patient is receiving chemotherapy, usually low dose cyclophosphamide and/or fluda-
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rabine, at doses aiming to promote prolonged lymphodepletion, although anti-CD45 
antibodies, total body irradiation or myeloablative chemotherapy can be used in the 
right clinical setting. The expanded TILs are then re-infused in combination with immune 
adjuvant therapy such as IL-2. Using this approach results have been very encouraging 
in melanoma human studies with response rates in selected patients of over 50% [72].
Genetically modified TCRs
Since abundant patient tumor material is not always available genetic modification 
of autologous isolated peripheral lymphocytes is another option. In these protocols 
lymphocytes are isolated peripherally (not from the tumor) and then exposed to retro-
viral vectors encoding for specific genetically modified T cell receptors (TCR) designed 
to target specific tumor antigens. In melanoma targeting the tumor antigens MART-1 
or gp-100 led to response rates of 30% and 19%, respectively but severe uveitis and 
necrotic skin rashes were a significant problem [73,74]. Targeting tumor antigens that 
are not expressed in normal tissues, such as the testis associated antigen NY-ESO-1, has 
led to 45% response rate without noticeable toxicity [75]. Studies in renal cell carcinoma 
underline the importance of choosing the right tumor antigen and transduction method 
in order to bypass on-target toxicity and anti-immune reactivity against the transduced 
T-cells [76].
Chimeric antigen receptors (CARs)
Another related approach is with the use of lymphocytes genetically engineered to carry 
chimeric antigen receptors (CARs) [77]. The extracellular domain of CARs is an Fab frag-
ment of an antibody that is designed to recognize a specific tumor associated antigen. 
The intracellular domain of CARs is the signal transducing intracellular domain of the 
TCR. Thus T-cells target specific tumor antigens and they are activated upon binding. In 
addition, domains of costimulatory molecules have been engineered into the intracel-
lular domain of CARs in order to further increase T-cell activation upon binding. The 
advantage of CARs over genetically engineered TCRs is that several different receptors 
recognizing different tumor antigens and targets, or expressing several co-stimulatory 
molecules, can be engineered into the T-cells, thus broadening the choice of tumor 
targets and tissue specificity. Clinical trials using CAR engineered T-cells are ongoing in 
multiple cancers.
In pancreas cancer results in mouse models using adoptive cell therapy have been 
successful [78]. Human studies are few but responses have been seen using expanded 
TILs in combination with MUC-1 pulsed DC’s [79]. In a study using CTLs expanded from 
PBMCs and exposed to a MUC-1 expressing pancreatic cancer cell line only 1 out of 8 
unresectable patients developed hepatic metastasis [80]. A study with a genetically 
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engineered TCR targeting CEA, and likely to include pancreatic cancer patients, is ongo-
ing [81]. A study using anti-mesothelin CAR engineered lymphocytes is also ongoing in 
mesothelin expressing patients, which will include pancreatic cancer patients [82].
Strategies targeting co-stimulatory and inhibitory receptors and ligands
Various monoclonal antibodies have been developed that either act as inhibitors of the 
inhibitory receptor-ligand interaction on T-cells and tumors (i.e., CTLA-4/CD-80/CD86, 
PD-1/PDL1), or act as agonist of co-stimulatory receptors on T-cells (i.e., CD40, OX40, 
4-1BB). The suppressive receptor CTLA-4, expressed on Tregs and exhausted CD8 T-cells 
was the first to be successfully targeted. Ipilimumab is a monoclonal antibody that 
binds and inhibits CTLA-4. In metastatic melanoma, in previously untreated patients, 
ipilimumab added to dacarbazine improved overall survival, compared to dacarbazine 
alone, from 6.4 to 10.1 months [83], while in previously treated patients, ipilimumab 
alone again improved overall survival from 6.4 to 10 months [84]. Given these impres-
sive results ipilimumab, together with tremelimumab another anti-CTLA-4 antibody, 
are currently being tested in multiple clinical trials in pancreatic cancer [85–88]. In the 
first reposted results [85], out of 27 patients with advanced pancreatic cancer who were 
treated with single agent ipilimumab, only 1 experienced a delayed response, indicat-
ing that single agent ipilimumab may not be effective in this disease and combination 
therapies might be necessary.
Much like antibodies to CTLA-4, antibodies against PD-1, and its ligand (PD-L1), have en-
tered clinical trials with great success producing response rates of 17–38% in advanced 
melanoma and 10–18% in advanced non-small cell lung cancer [89–91]. Expression of 
PD-L1 on the cancer cells appears predictive to response to therapy since only patients 
expressing the ligand responded to anti-PD1 therapy [92]. In the study with the anti-
PD-L1 antibody however, from the 14 patients with pancreatic cancer included none 
responded [89]. Despite this observation, given the small sample size of included pan-
creatic cancer patients, as well as the recurrent observation that PD-L1 overexpression 
in pancreatic cancer is associated with advanced disease and poor prognosis [27,93], 
clinical studies in pancreatic cancer are currently planned [94].
More recently the combination of anti-CTLA-4 and anti-PD1 therapy has been tested in 
53 patients with advanced melanoma [95]. The combination produced a response rate 
of 40% while at the maximal tolerated dose the response rate was 53%. Responses were 
rapid and durable while toxicity was similar to that seen with monotherapy. Obviously 
this is another strategy that will be tested in pancreatic cancer should monotherapy 
with these drugs proves to have insufficient activity.
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The combination of CD40 agonist and gemcitabine against pancreatic cancer was 
associated with some clinical responses in a clinical trial [96], although these tumor 
responses were difficult to differentiate from responses to gemcitabine alone. However, 
replication of the study in mice showed that the tumor was infiltrated with tumoricidal 
CD40 activated macrophages which led to the depletion of the tumor stroma [96]. This 
process was independent of the presence of gemcitabine, indicating that the CD40 
agonists therapeutic effect is through activation of macrophages and antagonizing the 
effect of CAFs. Further studies are ongoing [97]. Anti-OX40 antibodies and IDO inhibitors 
are currently undergoing testing in various cancers but not yet in pancreatic cancer.
Strategies to deplete Treg cells
Given the importance of Tregs in attenuating anti-tumor activity by the immune system, 
one obvious strategy is to target Tregs directly. At least 2 different types of compounds 
have been developed and tested in clinical trials. In one such strategy denileukin difti-
tox, an IL-2-diptheria toxin fusion protein that binds to the IL-2 receptor alpha chain 
(CD25), and is highly expressed on Treg, has been successful in melanoma and renal 
cell carcinoma clinical trials in partially depleting Tregs and improving vaccine induced 
cytotoxic T cell responses [98,99]. Significant clinical responses were seen in 5 out of 16 
patients in one of the studies [99], including a near complete response. However, not 
all studies have been encouraging [100]. In another strategy, a monoclonal antibody 
directed against CD25 has been developed and has shown durable reduction of Treg 
cell numbers [101].
Back in the 1970’s and early 1980’s scientists noticed that low dose cyclophosphamide 
had ‘‘chemoimmunologic’’ effects by depleting ‘‘T-suppressor cells’’ and enhancing de-
layed type hypersensitivity reactions if given before vaccination. It has now been clearly 
demonstrated that low dose cyclophosphamide temporarily depletes Tregs, augments 
T cell responses and is frequently given prior to cancer vaccination protocols [102]. This 
property is not unique to cyclophosphamide but it is shared with other chemotherapeu-
tics such as fludarabine and low dose weekly paclitaxel. High doses of chemotherapy do 
not have the same effect as they result in depletion of both Tregs and cytotoxic T cells. 
This strategy is sometimes referred to as ‘‘metronomic’’ chemotherapy and it’s known to 
have anti-angiogenic effects as well. Clearly this represents a cheaper immunomodulat-
ing strategy, it is widely available worldwide, and it is used in several immunotherapy 
related clinical trials including in pancreatic cancer [58]. In addition, a strategy combin-
ing metronomic cyclophosphamide and an anti-CD25 monoclonal antibody has been 
successful in synergistically enhancing vaccine efficacy in a pancreatic adenocarcinoma 
mouse model [103].
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ConCLusIon
The immune system plays a pivotal role in the progression of pancreatic cancer. While 
tumor immunology research in pancreatic cancer has traditionally lagged behind mela-
noma and renal cell carcinoma, this is largely due to a lack of focus rather than differ-
ences in the ‘‘immunogenicity’’ between the two types of cancer (although differences 
do exist). Several different immunotherapeutic strategies are now underway in various 
cancers and most, but not all strategies, are being tested in pancreatic cancer. It is likely 
that combination strategies will be necessary to both overcome the cancer induced im-
munosuppression (i.e., Treg depletion, anti-PD1, anti CTLA-4 antibodies) and target the 
cancer cells themselves (traditional chemotherapeutics, vaccination, ACT). Clinicians 
should be aware of both the mechanisms by which pancreatic cancer interacts with the 
immune system as well as the major treatment
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ABsTrACT
Novel systemic treatments for Hepatocellular Carcinoma (HCC) are strongly needed. 
Immunotherapy is a promising strategy that can induce specific anti-tumor immune 
responses. Understanding the mechanisms of immune resistance by HCC is crucial for 
development of suitable immunotherapeutics. We used immunohistochemistry on 
tissue-microarrays to examine the co-expression of the immune inhibiting molecules 
PD-L1, Galectin-9, HVEM and IDO, as well as tumor CD8+ lymphocyte infiltration in HCC, 
in two independent cohorts of patients. We found that at least some expression in 
tumor cells was seen in 97% of cases for HVEM, 83% for PD-L1, 79% for Gal-9, and 66% 
for IDO. In the discovery cohort (n=94) we found that lack of, or low, tumor expression of 
PD-L1 (p<.001), Galectin-9 (p<.001) and HVEM (p<.001), and low CD8+TIL count (p=.016), 
were associated with poor HCC-specific survival. PD-L1, Galectin-9 and CD8+TIL count 
were predictive of HCC-specific survival independent of baseline clinicopathologic 
characteristics and the combination of these markers was a powerful predictor of HCC-
specific survival (HR 0.29; p<.001). These results were confirmed in the validation cohort 
(n=60). We show that low expression levels of PD-L1 and Gal-9 in combination with low 
CD8+TIL count predicts extremely poor HCC-specific survival and it requires a change in 
two of these parameters to significantly improve prognosis. In conclusion, intra-tumoral 
expression of these immune inhibiting molecules was observed in the majority of HCC 
patients. Low expression of PD-L1 and Galectin-9 and low CD8+TIL count are associated 
with poor HCC-specific survival. Combining immune biomarkers leads to superior pre-
dictors of HCC mortality.
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InTroDuCTIon
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death 1. Curative 
treatments such as resection, local ablation or liver transplantation are only applicable 
in the 20% of patients with early stage disease 2. For selected patients with advanced 
disease median survival can be modestly extended with the use of sorafenib 3. However, 
cure at this stage is no longer possible.
Immunotherapeutic strategies, such as tumor vaccination, adoptive cell therapy and 
immune modulating antibodies, may provide alternative therapeutic options in HCC.4,5 
Indeed, immune modulating antibodies against CTLA-4 (Ipilimumab) or PD-1 (Nivolum-
ab, Pembrolizumab) and PD-L1 (Atezolizumab) have already been approved for various 
cancers such as melanoma, lung, kidney and bladder cancer.6-10 These so-called ‘immune 
checkpoint’ antibodies interrupt immune resistance mechanisms exploited by tumors to 
evade natural anti-tumor immunity. Reported immune resistance mechanisms include, 
among others, the expression of molecules that suppress intra-tumoral T-cell responses 
by ligating inhibitory receptors on T cells, such as PD-L1, galactin-9 and HVEM and the 
expression of enzymes that generate T-cell inhibitory metabolites, such as IDO.11
Binding of PD-L1 to its receptor PD-1, on activated T cells, suppresses T-cell responses.12 
PD-L1 is expressed in numerous tumors, including HCC, and in-vitro abrogation of the 
PD-1/PD-L1 interaction has been shown to reinvigorate tumor-specific responses of T-
cells isolated from HCC patients.13-19 Galectin-9 (Gal-9) is a carbohydrate-binding protein 
that is involved in T-cell homeostasis.20 Contrasting effects of Gal-9 on anti-tumor im-
munity have been described. On the one hand binding of Gal-9 to its receptor TIM-3, 
expressed on activated T cells, causes T cell dysfunction and apoptosis in tumors21 while 
binding of Gal-9 to CD44 promotes the differentiation of T-regulatory cells.22 Conversely, 
Gal-9 can enhance T-helper 1 type anti-tumor immunity 23, inhibit NK cell chemotaxis to 
the tumor microenvironment24 and exert anti-metastatic potential on tumor cells.25,26 
Like PD-L1, Gal-9 is expressed in several cancers, including HCC.21,27 HVEM is a “molecular 
switch” with dual immune-stimulatory and inhibitory functions.28 By ligation of LIGHT, 
HVEM stimulates T-cell responses, while binding to BTLA or CD160 leads to inhibition 
of T-cells. HVEM is known to be expressed in melanoma29 and most recently in HCC.30 
IDO is the rate limiting enzyme in the catabolism of the essential amino-acid trypto-
phan.31 Tryptophan depletion, as well as accumulation of tryptophan catabolites such 
as kynurenine, induce T-cell anergy and apoptosis. IDO inhibitors are currently in clinical 
development. IDO expression has been demonstrated in several cancer types, including 
HCC.32
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As clinical efficacy of immune checkpoint antibodies seems dependent on expression 
of their target molecules in tumors33,34 knowledge of their expression patterns in HCC 
may establish which of these molecules, or combinations, might be promising to target. 
No published study has systematically examined co-expression of multiple immune in-
hibitory molecules in a homogeneous cohort of HCC patients before. Thus, the primary 
aim of the present study was to examine the patterns of co-expression, as well as the 
relationship with the tumor infiltrating lymphocytes (TIL) and cancer-related survival, of 
several immune inhibitory molecules in HCC tumor tissue and adjacent non-tumorous 
tissue. PD-L1, Gal-9, HVEM and IDO were chosen for study because their mechanism 
of interaction with the immune system is generally understood while at the same 
time a reliable primary antibody is available. Tissue microarrays were constructed, and 
expression of the above molecules on tumor cells and hepatocytes was examined, by 
immunohistochemistry, in two separate patient cohorts.
PATIenTs AnD MeTHoDs
Patient population and tissue samples
Archived formalin fixed paraffin-embedded tissue samples from 154 patients who 
underwent hepatic resection for HCC at Erasmus MC-University Medical Center (EMC, 
n=94) or Amsterdam Medical Center (AMC, n=60), between June 2001 and July 2014, 
were used for this study. Fresh frozen tissue, which was available from 20 additional 
patients, was used for RNA extraction. Patients with HCC were selected for the study 
if they had undergone surgery with curative intent. Clinical information was collected 
retrospectively from the electronic record. The clinical information collected included 
etiologic factors, HCC recurrence, patient death, cause of death, as well as known prog-
nostic clinicopathologic characteristics, such as tumor differentiation, vascular invasion, 
number of lesions, largest tumor size and pre-operative α-fetoprotein (AFP) level. The 
study was approved by the local medical ethical committee. In addition, the study pro-
tocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki.
Tissue microarray (TMA) construction
Three or four 0.6mm cores were taken from the tumorous area of 154 patients and two 
0.6mm cores were taken from the corresponding tumor free liver (TFL) area of 133 of 
these patients. Areas with vital tumor and TFL tissue were marked by experienced pa-
thologists (KB or JV) using archived H&E glass slides. The TMAs were made using either 
an automated tissue-arrayer ATA-27 (Beecher Instruments, Silver Springs MD, USA) or a 
fully manual tissue-arrayer MTA-1 (Beecher Instruments).
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Immunohistochemistry and scoring
Complete information on the immunohistochemistry protocols can be found in the 
supplementary methods section. Complete information in the primary antibodies used 
can be found in Supplementary Table 1. Scoring was performed by two independent in-
vestigators (KS and HS) blinded to clinical outcome and differences resolved by mutual 
agreement. Scoring was performed on cancer cells (tumor cores) or hepatocytes (TFL 
cores). Intensity was scored in a scale from zero to three. Intra-core heterogeneity of 
staining intensity of tumor cells or hepatocytes was rarely observed in our cohort, thus 
only staining intensity was taken into consideration. In the case of CD8 staining the posi-
tive cells per core were counted manually and average counts were used for analysis.
Table 1. Patient characteristics
Characteristics Discovery cohort N=94 Validation cohort N=60
Male/female (%) 63/31 (67/33) 48/12 (80/20)
Hepatitis-Ba/Hepatitis-Cb (%) 23/11 (25/12) 14/19 (23/32*)
Cirrhosis (%) 32 (34) 20 (33)
Tumor differentiation (1-3) 26/47/20 (28/50/22) 15/34/10 (25/58/17)
Vascular invasion 58 (68*) 13 (42)
single lesions (%) 72 (77) 50 (83)
Median size (range) 5.9 cm (0.5-25.0) 5.0 cm (1.0-29.0)
Median AfP (range) 8.5 ug/l (1-63.000) 9.0 ug/l (2-29.000)
recurrence 50 (53) 28 (47)
Death 44 (47) 21 (35)
HCC related death 29 (31) 13 (22)
aHBsAg(+) and/or anti-HBc positive, banti-HCV positive
*There is statistically significant more Hepatitis-C in the AMC cohort and vascular invasion in the EMC co-
hort.
PCr amplification
All primers for the target genes were intron spanning and sequences are listed in 
Supplementary Table 2. The RT-PCR amplification technique and primer sources are 
described in detail in the supplementary methods section.
statistical analysis
All analysis was performed in duplicate. The discovery phase was performed in the EMC 
cohort while the validation phase was performed in the AMC cohort. The differences in 
expression of immune inhibitory molecules between tumor and TFL tissue was analyzed 
with the paired T-test. The associations between clinicopathologic parameters with the 
expression of immune inhibitory molecules, as well as the co-expression of the immune 
inhibiting molecules with each other, were examined using the χ2 tests or the T-test 
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as appropriate. Survival (time to recurrence or HCC-specific death) was calculated from 
the date of surgery to the date of event (recurrence or death from HCC respectively), 
or the date of last follow up. Patients lost to follow-up were censored as of the last day 
of follow-up. Patients who died from causes other than HCC were censored at the date 
of death. Survival curves were estimated by the Kaplan-Meier method. For sensitivity 
analysis the survival analysis was repeated by excluding the patients who died from 
post-operative complications within 3 months after surgery. Optimal high vs low values 
were established by examining a grid of cutoffs and choosing the cutoff with the low-
est -2 log likelihood, taking into consideration to maximize the proportion of patients 
identified by the cutoff value when possible. The Breslow test was used to asses differ-
ences between survival curves of different groups, while for parameters with three or 
four linearly associated levels the linear trend for factor levels was used. Given that we 
examined the expression of five individual parameters (PD-L1, Gal-9, HVEM, IDO, CD8+TIL 
count) Bonferroni’s correction required a p-value of < .01 for statistical significance in 
the discovery cohort. For multivariate analysis, the Cox proportional Hazard regression 
analysis was used. The statistical analysis was performed using the SPSS© 21 software.
resuLTs
Patient cohorts and baseline clinicopathologic characteristics
Clinicopathologic characteristics of patients in the EMC discovery cohort and the AMC 
validation cohort can be seen in Table 1, while complete information on etiology of liver 
disease can be found in Supplementary Table 3. Median time to recurrence and overall 
survival were 19.4 months and 37.2 months for the EMC cohort and 23.5 months and 
31.8 months for the AMC cohort. Recurrence was seen in seventy-eight patients while 
forty-two patients died from HCC. A complete list with the causes of death can be found 
in Supplementary Table 4. From the known clinicopathologic prognostic factors an 
Table 2. Cox-proportional Hazard regression analysis of patients’ HCC-specific survival in the discovery 
cohort
Univariate Multivariate
Variables HR 95% CI p-value HR 95% CI p-value
AFP>100 ug/l 2.67 1.17-6.13 .020 4.83 1.85-12.6 .001
One vs multiple lesions 3.53 1.63-7.67 .001 2.37 1.01-5.56 .048
PD-L1 0.19 0.86-0.43 <.001 0.30 0.13-0.72 .007
Gal-9 0.31 0.15-0.66 .003 0.33 0.14-0.80 .014
HVEM 0.21 0.09-0.50 <.001 0.50 0.20-1.25 .718
CD8+TIL count 0.22 0.05-0.93 .040 0.18 0.04-0.82 .027
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α-fetoprotein (AFP) level above 400 µgl-1 (p=.002), multiple lesions (p=.043) and tumor 
size >3cm (p=.024) were associated with poor HCC-specific survival in the combined 
cohort (Supplementary Figure 1). Tumor grade and vascular invasion were not associ-
ated with HCC-specific survival.
Tumor TFL Positive control
PD-L1
Gal-9
HVEM
IDO
CD8
Healthy liver
figure 1. representative stainings of tumor tissues and corresponding TfL tissues, positive control 
tissues, and normal liver. Positive controls tissues shown are placenta for PDL1, pancreatic cancer for 
HVEM, and tonsil for Gal-9, IDO and CD8. The positive control tissues stain as expected from prior literature. 
Note the hepatocyte staining seen for all molecules (except CD8) in the TFL tissue area and the general lack 
of hepatocyte staining in normal liver tissue. For Gal-9 characteristic Kupffer cell staining can be seen in the 
normal liver tissue.
Description of immune inhibitory molecule expression in the combined cohorts
Figure 1 shows representative stainings in tumor tissue, TFL tissue, positive control tis-
sues and healthy liver tissues, while Supplementary Figure 2 shows examples of various 
expression levels observed in tumor tissues, for all the molecules examined in our study. 
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At least some cytoplasmatic expression in tumor cells was seen in 82.9% of cases for PD-
L1, 78.8% for Gal-9, 96.6% for HVEM and 66.4% for IDO. In addition to their expression 
in the tumor tissues, PD-L1, Gal-9, HVEM and IDO were also expressed by hepatocytes 
in the surrounding TFL tissue. At least some cytoplasmatic expression in hepatocytes, 
in TFL tissue, was seen in 95.8% of cases for PD-L1, 93.5% for Gal-9, 100% for HVEM and 
92.6% for IDO. No relationship was found between the expression of any molecule in tu-
mor, or in the TFL tissue, with etiologic factors, or other clinicopathologic characteristics, 
after Bonferroni correction (Supplementary Table 5). Tumor expression correlated with 
TFL tissue expression in all cases. Figure 2 depicts the level of expression of each mol-
ecule in tumor cells and in hepatocytes in corresponding TFL tissues for the combined 
cohort. Note that there is a statistically significant under-expression of all molecules in 
the tumor tissue. In order to confirm that these molecules are indeed expressed in TFL 
tissues, we quantified mRNA expression in paired tumor and TFL tissues of 20 resected 
HCC patients, from which fresh frozen tissue was available. In Supplementary Figure 3 
we show that mRNA encoding for all these immune molecules is indeed expressed in 
the TFL tissues, at levels comparable to the levels seen in the tumor tissues. Our results 
indicate that the investigated immune inhibitory molecules are frequently expressed 
not only in the tumor, but also in the TFL compartment of HCC patients.
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figure 2. Comparison of protein expression levels of PD-L1, Gal-9, HVeM and IDo in the tumor tis-
sues and the corresponding TfL tissues in the combined cohort. Boxplots representing protein expres-
sion in tumor cells vs TFL tissue. p values were determined by the paired T-test.
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Immune inhibitory molecule expression: association with survival and 
recurrence in the discovery (eMC) cohort
Next we investigated the relationship between immune inhibitory molecule expression 
and survival in the EMC cohort. Optimal cut-offs for low versus high staining were made 
as described in the statistical methods. Patients were considered to have low PD-L1 
(n=16) or Gal-9 (n=18) staining when there was complete absence of staining, while 
low HVEM included patients with either complete absence of staining or very faint 
staining (n=9). Low IDO (n=63) included patients with complete absence, or at most +1, 
staining intensity. We found that expression in tumor tissue, but not in surrounding TFL 
tissue, was significantly associated with HCC-specific survival for three out of the four 
molecules examined (Figure 3A). Specifically, no or low tumor expression of PD-L1 (p< 
.001), Gal-9 (p< .001) and HVEM (p< .001) was associated with poor HCC-specific survival, 
while expression of IDO was not associated with HCC-specific survival (p= .953). Hazard 
ratios and 95% confidence intervals can be found in Table 2. In addition, we quantified 
the numbers of CD8+TIL. The relationship of CD8+TIL count with HCC-specific survival 
was not significant after Bonferroni’s correction (p= .016). For HCC recurrence the rela-
tionship with expression of these molecules followed the same trends (Supplementary 
Figure 4). Low tumor expression of PD-L1 (p< .001), Gal-9 (p= .009), HVEM (p= .004), 
and also low CD8+TIL count (p= .007) were significantly associated with shorter time to 
HCC recurrence, while tumor expression of IDO was not associated with recurrence after 
Bonferroni’s correction (p= .029). The results did not differ when analyses was performed 
by excluding the 9 patients who died at EMC in the post-operative period from causes 
other than HCC.
Based on a multivariate analysis, where all parameters with p values < .02 were entered 
in a single model, we derived that tumor expression of PD-L1 and Gal-9, CD8+TIL count, 
AFP level and number of lesions were independent predictors of HCC-specific survival 
in the EMC cohort (Table 2). HVEM was not independently associated with HCC-specific 
survival when examined together with the other immune parameters.
Because of the ability of the immune inhibitory molecules to predict HCC-specific 
survival we wondered whether combining all three independently prognostic immune 
parameters would improve the prediction. Figure 4 shows that low levels of two or three 
of these parameters in tumor tissue predicts poor survival, while low level of none, or 
only one, parameter predicts good HCC-specific survival. Concordantly, the combination 
of PD-L1, Gal-9 and CD8+TIL as a single biomarker was a powerful independent predictor 
of HCC-specific survival in multivariate analysis (p< .001, HR 0.29, 95%CI 0.18-0.48).
58 Chapter 3
PD-L1
Gal-9
HVEM
IDO
CD8 TIL
A) EMC cohort - tumor B) AMC cohort - tumor C) Combined - tumor
0 50 100
0
20
40
60
80
100 Low (n=25)
High (n=121)
Survival (%) p < .001
0 50 100
0
20
40
60
80
100 Low (n=32)
High (n=119)
Survival (%) p < .001
0 50 100
0
20
40
60
80
100 Low (n=107)
High (n=46)
Survival (%) p = .003
0 50 100
0
20
40
60
80
100 Low (n=31)
High (n=86)
Survival (%) p = .649
0 50 100
0
20
40
60
80
100 Low (n=35)
High (n=88)
Survival (%) p = .233
0 50 100
0
20
40
60
80
100 Low (n=21)
High (n=95)
Survival (%) p = .629
0 50 100
0
20
40
60
80
100 Low (n=43)
High (n=79)
Survival (%) p = .521
0 50 100
0
20
40
60
80
100 Low (n=91)
High (n=40)
Survival (%) p = .896
0 50 100
0
20
40
60
80
100
Survival (%) p < .001
Low (n=16)
High (n=70)
Months Months Months Months
Months Months Months Months
Months Months Months Months
Months Months Months Months
Months Months Months Months
0 50 100
0
20
40
60
80
100 Low (n=18)
High (n=73)
Survival (%) p < .001
0 50 100
0
20
40
60
80
100 Low (n=9)
High (n=80)
Survival (%) p < .001
0 50 100
0
20
40
60
80
100 Low (n=63)
High (n=26)
Survival (%) p = .953
0 50 100
0
20
40
60
80
100 Low (n=69)
High (n=24)
Survival (%) p = .016
0 50 100
0
20
40
60
80
100 Low (n=13)
High (n=136)
Survival (%) p < .001
0 50 100
0
20
40
60
80
100
Low (n=9)
High (n=51)
Survival (%) p = .010
0 50 100
0
20
40
60
80
100
Low (n=14)
High (n=46)
Survival (%) p = .047
0 50 100
0
20
40
60
80
100 Low (n=4)
High (n=56)
Survival (%) p = .068
0 50 100
0
20
40
60
80
100
Low (n=46)
High (n=14)
Survival (%) p = .084
0 50 100
0
20
40
60
80
100
Low (n=38)
High (n=22)
Survival (%) p = .092
0 50 100
0
20
40
60
80
100 Low (n=109)
High (n=40)
Survival (%) p = .548
D) Combined - TFL
P -L1
al-9
VE
I
C 8 TIL
) E  cohort - tu or B)  cohort - tu or ) o bined - tu or
0 50 10
0
20
40
60
80
10 Low (n=25)
High (n=121)
Survival ( ) p < .001
0 50 10
0
20
40
60
80
10 Low (n=32)
High (n=119)
Survival ( ) p < .001
0 50 10
0
20
40
60
80
10 Low (n=107)
High (n=46)
Survival ( ) p = .003
0 50 10
0
20
40
60
80
10 Low (n=31)
High (n=86)
Survival ( ) p = .649
0 50 10
0
20
40
60
80
10 Low (n=35)
High (n=88)
Survival ( ) p = .233
0 50 10
0
20
40
60
80
10 Low (n=21)
High (n=95)
Survival ( ) p = .629
0 50 10
0
20
40
60
80
10 Low (n=43)
High (n=79)
Survival ( ) p = .521
0 50 10
0
20
40
60
80
10 Low (n=91)
High (n=40)
Survival ( ) p = .896
0 50 10
0
20
40
60
80
10
Survival ( ) p < .001
Low (n=16)
High (n=70)
onths onths onths onths
onths onths onths onths
onths onths onths onths
onths onths onths onths
onths onths onths onths
0 50 10
0
20
40
60
80
10 Low (n=18)
High (n=73)
Survival ( ) p < .001
0 50 10
0
20
40
60
80
10 Low (n=9)
High (n=80)
Survival ( ) p < .001
0 50 10
0
20
40
60
80
10 Low (n=63)
High (n=26)
Survival ( ) p = .953
0 50 10
0
20
40
60
80
10 Low (n=69)
High (n=24)
Survival ( ) p = .016
0 50 10
0
20
40
60
80
10 Low (n=13)
High (n=136)
Survival ( ) p < .001
0 50 10
0
20
40
60
80
10
Low (n=9)
High (n=51)
Survival ( ) p = .010
0 50 10
0
20
40
60
80
10
Low (n=14)
High (n=46)
Survival ( ) p = .047
0 50 10
0
20
40
60
80
10 Low (n=4)
High (n=56)
Survival ( ) p = .068
0 50 10
0
20
40
60
80
10
Low (n=46)
High (n=14)
Survival ( ) p = .084
0 50 10
0
20
40
60
80
10
Low (n=38)
High (n=22)
Survival ( ) p = .092
0 50 10
0
20
40
60
80
10 Low (n=109)
High (n=40)
Survival ( ) p = .548
) o bined - TFL
figure 3. HCC-specific survival Kaplan-Meier curves of PD-L1, Gal-9, HVeM, IDo and CD8+TIL count 
in the tumor and TfL compartments. (A) Survival curves in relation to tumor expression for the discovery 
(EMC) cohort. (B) Survival curves in relation to tumor expression for the validation (AMC) cohort. Optimal 
high vs low values were established by examining a grid of cutoffs and choosing the cutoff with the lowest 
-2 log likelihood. For determination of the p values Breslow test was used.
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figure 3 (continued). (C) Survival curves in relation to tumor expression for the combined cohorts. (D) 
Survival curves in relation to TFL tissue expression for the combined cohorts. Optimal high vs low values 
were established by examining a grid of cutoffs and choosing the cutoff with the lowest -2 log likelihood. 
For determination of the p values Breslow test was used.
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Validation in the AMC cohort
External validation of the above findings was performed in the cohort from AMC. Low 
tumor expression of PD-L1 (p= .010) and Gal-9 (p= .047) were also significantly associ-
ated with poor HCC-specific survival (Figure 3B). Low tumor CD8+TIL count showed a 
trend towards poor HCC-specific survival (p= .092), with a hazard ratio (HR 0.36, 95%CI 
0.08-1.64) that was of similar magnitude and direction as in the discovery (EMC) cohort 
(HR 0.22, 95%CI 0.05-0.93). The combination of PD-L1, Gal-9 and CD8+TIL as a single 
biomarker (Figure 4) predicted HCC-specific survival (p= .020, HR 0.43, 95%CI 0.24-0.77) 
and was validated as an independent predictor of HCC-specific survival in multivariate 
analysis in the AMC cohort (p= .005).
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figure 4. HCC-specific survival Kaplan-Meier curves of the combined PD-L1, Gal-9 and CD8+TIL 
count biomarker. Combination of PD-L1, Gal-9 and CD8+TIL count in relation to HCC-specific survival in 
the discovery (EMC) cohort, validation (AMC) cohort and combined cohort. For determination of the p 
values the linear trend for factor levels was used.
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Co-expression patterns and survival
Low levels of expression of either PD-L1, Gal-9 or HVEM were significantly associated 
with low levels of expression of the other 2 ligands (Supplementary Table 6). Such a 
relationship was not seen with IDO. The CD8+TIL count showed a significant but weak 
correlation with PD-L1 expression (p= .046) but not with Gal-9, HVEM or IDO. Specifically, 
high expression of PD-L1 was correlated with a high CD8+TIL count and vice-versa.
Having established the predictive power of the individual and combined expression 
of immune inhibitory molecules we wondered how the relationship of each molecule 
to survival related to tumor lymphocyte infiltration. It has been previously shown that 
tumor expression of PD-L1 in melanoma carries different prognostic values in the set-
ting of high vs low TIL counts 33,35. Figure 5A shows that low PD-L1 tumor expression in 
combination with low CD8+TIL count is associated with very poor HCC-specific survival 
while high PD-L1 and high CD8+TIL count is associated with good HCC-specific survival 
(p< .001, HR 0.29, 95%CI 0.17-0.50). The presence of either high PD-L1 or high CD8+TIL 
count alone is associated with intermediate survival. A similar observation was made for 
the combination of Gal-9 tumor expression and CD8+TIL count (p< .001, HR 0.29, 95%CI 
0.17-0.49) (Figure 5B).
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figure 5. HCC-specific survival Kaplan-Meier curves of tumor PD-L1 and Gal-9 expression in relation 
to CD8+TIL count in the combined cohorts. (A) Combination of PD-L1 and CD8+TIL count in relation to 
HCC-specific survival. (B) Combination of Gal-9 and CD8+TIL count in relation to HCC-specific survival. For 
determination of the p values the linear trend for factor levels was used.
DIsCussIon
In two independent cohorts, we found that low tumor expression of PD-L1 and Gal-9, 
as well as low CD8+TIL count, are independent predictors of poor HCC-specific survival. 
HVEM expression, on the other hand, while individually an independent predictor of 
HCC-specific survival, was not independent when other immune parameters were taken 
into consideration. The combination of tumor PD-L1 and Gal-9 expression and CD8+TIL 
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count appeared to be a powerful independent predictor of HCC-specific survival. We 
show that there is a group of patients with extremely poor prognosis who express low 
levels of PD-L1 and Gal-9 and have low CD8+TIL count. It requires a change in two of 
these parameters to significantly affect prognosis.
Similar to our results, low expression of PD-L1 was found to be associated with poor 
survival in melanoma,33 gastrointestinal-stromal tumors,36 colorectal cancer,37 and non-
small cell lung cancer.38 On the other hand, other studies in melanoma39, colorectal40 and 
renal cell cancer41 have shown the opposite. Moreover, in a third melanoma study42, and 
in studies in squamous-cell lung cancer,43 urothelial cancer44 and breast cancer,45 tumor 
PD-L1 expression has shown no prognostic significance. In addition, and in contrast to 
our results, two prior studies in HCC have suggested that lower PD-L1 expression is asso-
ciated with better survival,15,18 while one recent study reported that lower PD-L1 staining 
is associated with better 2-year chance of recurrence.46 These conflicting results on the 
association between PD-L1 expression and prognosis, are probably related to the lack of 
specificity of several anti-PD-L1 antibodies for immunohistochemical staining of PD-L1 
in formalin-fixed paraffin-embedded tissues.15,18,38,39,42 Specifically, in the study by Gao 
et.al.,15 the PD-L1 clone MIH1 was used on paraffin-embedded HCC tissue. This particular 
clone has been shown to be non-specific on paraffin embedded tissue in prior studies 
38,42. To further confirm these prior observations we stained a number of control tissues 
and TMA cores with the MIH1 clone and compared the findings to our results. We show, 
in Supplementary Figure 5, that the MIH1 clone failed to properly stain placenta and 
tonsil tissue, and also provides positive stainings of tumor cores that were found to be 
negative for PD-L1 using the 9A11 antibody clone. Importantly, the anti-PD-L1 antibody 
that we used (clone 9A11) has been extensively validated for this purpose,41,44,47,48 and 
we show that it provides the correct staining pattern in control tissues, namely selective 
staining of the syncytiotrophoblast layer in placenta tissue and staining of the crypt 
regions in tonsil tissue (Figures 1 and Supplementary Figure 5). Moreover, in a previous 
study,49 we showed that this antibody gives similar, but more intense, staining patterns 
as the well-validated 5H1 clone.50 The use of imaging software to analyze PD-L1 density, 
as performed in the studies by Gao et.al., and Wu et.al., is another possible explanation 
for the differing results.15,18 Imaging software can inadvertently include expression of 
PD-L1 by stroma and TIL, in addition to tumor. Differences in the characteristics of the 
included patients, may be another factor. For example the study of Calderaro et.al.,46 
which examined a large cohort of patients using another validated anti-PD-L1 antibody, 
did not report on long term mortality endpoints, while information on recurrence was 
available in a little over half the patients, making direct comparisons with our study 
not possible. Finally, it is well known that both cytoplasmatic and membranous PD-L1 
staining has been described in various cancers, and we are not the first to describe a 
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pre-dominance of cytoplasmatic staining over membranous staining for PD-L1. In fact, 
studies using well validated antibodies have demonstrated both types of staining in 
various cancers before33,50 and other prior studies in HCC have also predominately 
demonstrated cytoplasmatic staining.16 It has recently been hypothesized that cytoplas-
matic tumor staining represents intracellular stores of PD-L1 ready to be transported to 
the membrane upon contact with immune cells.33 Alternatively, cytoplasmic PD-L1 may 
be released as a functional soluble molecule into the extracellular microenvironment.51
Regarding the prognostic significance of Gal-9 expression in tumors there is more con-
sensus. Similar to our findings, under-expression of Gal-9 has been associated with poor 
outcome in HCC,27 and also in melanoma, breast, cervical and gastric cancers.25,26,52,53 
However, one recently published study in renal cell cancer54 showed the opposite. It is 
possible that the significance of expression of Gal-9 may be tumor specific. In renal cell 
cancer for example the results for both PD-L1 and Gal-9 are opposite to ours.41,54
One may wonder why low expression of these molecules signifies high risk of HCC 
death, since their expression in itself is supposed to inhibit effector immune responses. 
It is known that several of these molecules are overexpressed in response to IFN-γ and 
TIL infiltration, a process called adaptive immune resistance.33,55-57 Therefore, expression 
of immune inhibitory molecules in cancer cells may not only be induced by intrinsic 
mechanisms (i.e. mutations, epigenetics e.c.t.) but also by tumor-infiltrating immune 
cells. Probably, their presence in the tumor microenvironment reflects an active im-
munologic attack that is beneficial to patients. Low or no expression of such molecules 
could indicate that the cancer is beyond detection by the immune system or that the 
anti-tumor immune response is ineffective.
Several studies have shown that expression of PD-L1 is associated with TIL infiltration in 
various cancers.33,38,43 Our study is the first to describe this association in HCC. Stratifica-
tion of tumors, based on the expression of PD-L1 and the presence or absence of TILs, 
has been recently proposed.33,35 We show that HCC patients with low tumor PD-L1 ex-
pression and CD8+TIL infiltration (type II tumors), which suggests tumors with immune 
ignorance, according to the model by Teng et.al.,35 have the worst prognosis (Figure 5A), 
while patients with high tumoral PD-L1 expression and TIL infiltration (type I tumors), 
which suggest adaptive immune resistance, have the best prognosis, as predicted. Taken 
together, our data demonstrate that HCC may behave according to this novel prediction 
model, and also suggest that type I tumors, that is tumors with an ongoing anti-tumor 
immune response (high PD-L1 and high TIL count), may be the ones to benefit from PD-
L1 or PD-1 blockade. Indeed recent observations from clinical trials show that patients 
who express PD-L1 are the ones that seem to benefit from anti-PD1 therapy.34 A similar 
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prediction model might be true for Gal-9 in HCC, as we show in Figure 5B. We support 
the idea that the use of TILs as a biomarker should be studied in the context of the 
expression of immune inhibitory molecules and that PD-L1 and Gal-9 are two of the 
molecules to be taken into consideration.
While the tumor expression status of these molecules in HCC has been reported, the 
expression of these molecules in the surrounding TFL tissue is much less understood. 
While PD-L1 and IDO have been shown, in single studies, to be indeed expressed in TFL 
tissue of patients with HCC,13,58 that has never been shown for Gal-9 or HVEM before. 
We here show, both by immunohistochemistry and qPCR, that all four immune inhibit-
ing molecules are present in both the tumor and the TFL compartments. We did not 
observe under-expression of mRNA levels in tumor tissue compared to TFL, while such 
an under-expression was seen by IHC. Possible explanations for the difference could 
be that we examined mRNA expression only in 20 paired samples. Another explana-
tion could be translational and post-translational regulation of mRNA. The presence of 
these molecules in the TFL tissue of HCC patients may be explained by the production of 
cytokines by the infiltrating lymphocytes .33,55-57 This observation suggests that therapies 
targeting these molecules may not only enhance anti-tumor immune responses but also 
anti-hepatitis-B virus or anti-hepatitis-C virus immune responses and thereby contribute 
to viral clearance. Conversely, such treatments harbor the theoretical danger of evoking 
undesired immunologic effects.
In our opinion, our study has several strong characteristics. We have studied a homog-
enous group of patients, have studied the expression of multiple immune inhibitory 
molecules in tumor, as well as surrounding TFL, tissue and have validated our findings 
in an independent cohort. Our study is the first to study the co-expression of multiple 
immune inhibitory molecules in HCC. There are of course also limitations in our study. 
Our selected panel of immune inhibitory molecules is by no means exhaustive. We 
focused on molecules for which there is solid evidence for their immune inhibitory role 
in cancer, for which a reliable antibody was available for immunohistochemistry and of 
which the corresponding mechanism of interaction with immune cells is well under-
stood. However, as our understanding of the immune inhibiting mechanisms of cancer 
expands other molecules should be added. In addition, while the use of TMAs to study 
such questions has clear benefits, such as the rapid analysis of large number of tissue 
cores over identical experimental conditions and preservation of valuable patient tissue 
for future studies, there are also drawbacks. One is the inability of TMAs to represent 
the complex spatial interactions of immune inhibiting molecules in the complete tumor 
microenvironment. For this reason we did not evaluate the expression of immune inhibi-
tory molecules by tumor infiltrating lymphocytes, as performed, for PD-L1, in the study 
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by Calderaro et.al.,46 but focused on the expression of these molecules in tumor cells. 
Depending on the types of immune cells under study the relationship of expression of 
these molecules to outcome may be affected.59 Another limitation of TMAs is that it is 
not ideal to evaluate the presence of uncommon cell types. While CD8+ lymphocytes are 
abundant, FoxP3+ T-regulatory cells are much less common and thus more difficult to 
systematically evaluate using TMAs.
In conclusion, we show that low tumor expression of PD-L1 and Galectin-9, as well as low 
CD8+TIL count, are associated with poor HCC-specific survival in patients with resected 
HCC. PD-L1 and Galectin-9 expression in tumors may be induced in response to immu-
nologic pressure which may explain why their presence is associated with prolonged 
survival. PD-L1 and Galectin-9 may be promising immunotherapeutic targets in HCC 
patients with tumors expressing these co-inhibitory molecules.
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supplementary figure 1. Kaplan-Meier curves of HCC-specific survival in relation to baseline clini-
copathologic characteristics for the combined cohort of patients.
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supplementary figure 2. representative immunohistochemical stainings, showing variable expres-
sion of immune inhibitory molecules and CD8+TIL infiltration, in tumor tissues. Numbers in the top 
indicate intensity scores while numbers in the bottom indicate CD8+ counts per tissue core.
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supplementary figure 3. mrnA expression of PD-L1, Gal-9, HVeM and IDo in tumor and TfL tissue. 
Boxplot of mRNA expression levels in 20 HCC patients with available fresh frozen tissue from the tumor and 
TFL area. Real Time RT-PCR data are corrected with the geomean of three housekeeping genes: GUS, PMM1, 
HPRT1. Note that these 20 patients are not part of the study cohort.
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supplementary figure 4. Kaplan-Meier curves of time to recurrence in relation to immune inhibi-
tory molecule expression in tumors for the eMC cohort.
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supplementary figure  5. Comparison between the anti-PD-L1 antibody clones 9A11 and MIH1. 
Note that the MIH1 antibody does not selectively stain trophoblastic cells in human placenta FFPE tissue or 
the crypt regions of human tonsil FFPE tissue. In addition, in 5/6 cores, HCC tumor cells not stained with the 
9A11 clone are stained with the MIH1 clone. This indicates a lack of specificity for the MIH1 clone.
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supplementary tables
supplementary table 1. Primary antibodies used
Antigens Antibody source Clone retrieval buffer Dilution
PD-L1 Dr. G. Freemana 405.9A11 Tris EDTA 1:50
Gal-9 R&D systemsb Goat polyclonal Tris EDTA 1:200
HVEM Milliporec 2G6-2C7 Citric acid 1:200
IDO Millipored 10.1 Citric acid 1:200
CD-8e Dakof C8/144b
a  Kindly provided by Dr. Gordon J Freeman, Dana-Farber Cancer Institute, Boston, MA Choueiri TK et.al., Ann 
Oncol.2014: 25:2178-84
b  http://www.rndsystems.com/Products/AF2045 Mengshol JA et. al.PLoS One.2010: 5:e9504
c  http://www.merckmillipore.com/NL/en/product/Anti-TNFRSF14-Mouse-mAb-%282G6-2C7%29,EMD_
BIO-AP1159?CategoryName=000000260002b67900020023&CategoryDomainName=Merck-MerckMilli-
pore
d  http://www.merckmillipore.com/NL/en/product/Anti-Indoleamine-2%2C3-dioxygenase-Antibody%2C-
clone-10.1,MM_NF-MAB5412?bd=1#documentation Soliman H et.al., Cancer Immunol Immunother. 2013: 
62: 829–837
e  CD8 staining performed under standard clinical laboratory conditions
f  http://www.dako.com/nl/ar38/p102650/prod_products.htm?setCountry=true&purl=ar38/p102650/
prod_products.htm?undefined&submit=Accept%20country Mason DY, et.al., J Clin Pathol 1992:45:1084-8
supplementary Table 2. Primers used
Gene Symbol Forward primer Reverse primer
Glucuronidase, beta GUSB 5’-CAGGTGATGGAAGAAGTGG-3’ 5’-GTTGCTCACAAAGGTCACAG-3’
Phosphomannomu-
tase 1
PMM1 5’-CGAGTTCTCCGAACTGGAC-3’ 5’-CTGTTTTCAGGGCTTCCAC-3’
Hypoxanthine 
phosphoribosyltrans-
ferase 1
HPRT1 5’-GCTATAAATTCTTTGCTGACCTGCTG-3’ 5’-AATTACTTTTATGTCCCCTGTTGACTGG-3’
TNF receptor super-
family, member 14
HVEM 5’-CACCGAGAGTCAGGACAC-3’ 5’-GAAACCACCATACCCAGTG-3’
Lectin, galactoside-
binding, soluble, 9
Gal-9 5’-TCTGGGACTATTCAAGGAGGTC-3’ 5’-CCATCTTCAAACCGAGGGTTG-3’
CD274 PD-L1 5’-GTGACCAGCACACTGAGAAT-3’ 5’-CCAGAATTACCAAGTGAGTCC-3’
Indoleamine 2,3-di-
oxygenase 1
IDO1 5’-GCCAGCTTCGAGAAAGAGTTG-3’ 5’-ATCCCAGAACTAGACGTGCAA-3’
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supplementary Table 3. Etiology of liver disease*
Type of liver disease N (%)
No known liver disease 50 (32.5)
Hepatitis B 30 (19.5)
Hepatitis C 30 (19.5)
Alcoholic liver cirrhosis 15 (9.7)
NASH 14 (9.1)
Hemochromatosis 5 (3.2)
Cryptogenic cirrhosis 3 (1.9)
Primary biliary cirrhosis 2 (1.3)
Porphyria 1 (0.6)
*When two etiologic factors where present in a single patient only the most dominant etiologic factor was 
considered, as determined by an experienced hepatologist. Thus the liver disease of seven patients with 
Hepatitis-B sero-positivity was attributed to other concurrent etiologic factors (Hepatitis-C x4, alcoholic 
liver cirrhosis x2, NASH x1). Etiologic information was missing from 4 patients.
supplementary Table 4. Causes of death
Cause of death N (%)
HCC 42 (27.3)
Postoperative complications (<3 months post HCC surgery) 14 (9.1)
Other cancer (not HCC)1 4 (2.6)
Other cause (not HCC)2 5 (3.2)
Alive 89 (57.8)
1Lung cancer x1, urothelial carcinoma x1, cholangiocarcinoma x1, colorectal cancer x1
2Severe lung disease x1, cardiovascular x2, pneumonia x1, unknown (sudden death) but not HCC (negative 
workup just before death) x1
supplementary Table 5. Correlations of immune biomarker expression with clinicopathologic character-
istics
Clinicopathologic characteristics PD-L1 
Tumor
Gal-9 
Tumor
HVEM 
Tumor
IDO 
Tumor
PD-L1 
TFL
Gal-9 
TFL
HVEM 
TFL
IDO 
TFL
Hepatitis-B .247 .259 .540 .364 .459 .112 .210 .573
Hepatitis-C .513 .334 .536 .411 .369 .288 .422 .056
Cirrhosis .113 .571 .135 .045 .465 .032 .401 .024
Tumor differentiation .429 .804 .768 .247 .963 .802 .541 .906
Vascular invasion .122 .286 .408 .349 .008 .157 .174 .337
One vs multiple lesions .446 .316 .045 .249 .246 .118 .509 .498
Tumor Size > 3cm .315 .318 .037 .442 .413 .032 .109 .578
AFP>100 ug/l .159 .157 .064 .065 .403 .297 .503 .105
Results provided as p-values. Note that after Bonferroni correction none of the associations reach statistical 
significance.
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supplementary table 6. Co-expression patterns of immune inhibitory molecules and CD8+ TIL counts in 
tumors. Tables 6a, 6b, 6c are 2x2 tables showing co-expression patterns of inhibitory molecules . Table 6d is 
a 2x2 table of CD8+ TIL count and PD-L1 expression
a
Gal-9 p =.001
Low High Total
PD
L1 Low 12 13 25
High 20 101 121
Total 32 114 146
b
HVEM p <.001
Low High Total
PD
L1 Low 8 16 24
High 5 116 121
Total 13 132 145
c
HVEM p <.001
Low High Total
G
al
-9 Low 10 22 32
High 3 114 117
Total 13 136 149
d
PD-L1 p =.046
Low High Total
CD
8 Low 21 83 104
High 3 38 41
Total 24 121 145
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ABsTrACT
Understanding the mechanisms of immune resistance in pancreatic and ampullary 
cancers is crucial for the development of suitable biomarkers and effective immuno-
therapeutics. Our aim was to examine the expression of the immune inhibiting mol-
ecules PD-L1, Galectin-9, HVEM, IDO and HLA-G, as well as CD8+ and FoxP3+ tumor 
infiltrating lymphocytes (TIL), in pancreatic and ampullary cancers, and to relate their 
individual, as well as their combined expression, to cancer survival. Tumor tissue from 
224 pancreatic and ampullary cancer resection patients was used to construct tissue-
microarrays. Expression of immune inhibitory molecules and TIL was examined by 
immunohistochemistry. We show that immune inhibitory molecules are prevalently 
expressed. Moreover, high tumor expression of PD-L1 (p=.002), Gal-9 (p=.003), HVEM 
(p=.001), IDO (p=.049), HLA-G (p=.004) and high CD8/FoxP3 TIL ratio (p=.006) were 
associated with improved cancer-specific survival. All immune biomarkers, with the 
exception of IDO, were individually predictive of cancer-specific survival when adjusted 
for clinicopathologic characteristics. For every additional immune biomarker present 
survival was almost two-fold prolonged (HR 0.57 95%CI 0.47-0.69, p<.0001). We con-
clude that pancreas and ampullary cancers are rich in expression of immune-inhibitory 
molecules. These molecules can be targets for future immunotherapeutics, as well as 
form powerful immunological biomarkers. We propose that such immune biomarker 
panels be included in future prospective immunotherapy trials.
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InTroDuCTIon
Pancreatic cancer is a leading cause of cancer related death and more than 260,000 
people die of the disease, every year, worldwide 1. Due to its aggressive nature and late 
presentation 5-year survival is a dismal 6%. Only 15-20% of patients are candidates for 
surgical resection with the 5-year survival, in these patients, improving to 22%. Tradi-
tional chemotherapy is minimally effective, despite some recent success 2, 3. Thus, novel 
therapeutic strategies against pancreatic cancer are needed.
The recognition of the critical importance of the immune system in cancer surveillance 
and elimination 4 has led to the development of various immunotherapeutic strategies 
against cancer 5. Immune checkpoint inhibitors, such as antibodies against CTLA-4 or 
PD-1, have been the most successful to date 6. These so-called immune checkpoint 
inhibitors interrupt immune resistance mechanisms exploited by tumors to evade 
natural anti-tumor immunity. Reported immune resistance mechanisms include, among 
others, the expression of molecules that suppress intra-tumoral T-cell responses, by 
ligating inhibitory receptors on T cells, such as PD-L1, galectin-9, HVEM or HLA-G, and 
the expression of enzymes that generate T-cell inhibitory metabolites, such as IDO. 
The tumor microenvironment of pancreatic cancer is rich in such immune suppressive 
mechanisms 7.
PD-L1 binds to its receptor PD-1 on activated T cells and suppresses T-cell responses 8. 
PD-L1 is expressed in numerous tumors and in-vitro abrogation of the PD-1/PD-L1 
interaction can reinvigorate tumor-specific T-cell responses. Galectin-9 (Gal-9) is 
involved in T-cell homeostasis 9 by either binding to TIM-3 expressed on activated T 
cells and causing T cell dysfunction and apoptosis 10 or by binding to CD44 promoting 
T-regulatory cell differentiation 11. Conversely, Gal-9 can also enhance T-helper 1 type 
anti-tumor immunity 12 and exert anti-metastatic potential on tumor cells 13, 14. HVEM is 
a “molecular switch” with dual stimulatory and inhibitory functions, although its inhibi-
tory function is likely dominant 15. Binding of HVEM to BTLA or CD160, members of the 
immunoglobulin (Ig) superfamily, leads to inhibition of T-cells 16. IDO is the rate limiting 
enzyme in the catabolism of the essential amino-acid tryptophan. Tryptophan deple-
tion, as well as accumulation of tryptophan catabolites such as kynurenine, induce T-cell 
anergy and apoptosis, while IDO inhibition enhances proliferation of TIL and decreases 
T-regulatory cells 17. IDO inhibitors are currently in clinical development. Finally, HLA-G is 
a non-classical MHC class I molecule with a role primarily in preventing fetal rejection in 
pregnancy 18. HLA-G and is known to induce, upon ligation of inhibitory receptors such 
as ILT-2 and ILT-4, inhibition of NK cells, CD4+ and CD8+ lymphocytes 19.
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As clinical efficacy of immune checkpoint antibodies seems partially dependent on 
expression of their target molecules in tumors 20, 21 immunological biomarkers will likely 
become extremely useful as prognostic and/or predictive tools in the future. However, 
given the complexity of cancer, and that of the immune system, it is unlikely that a single 
biomarker, like PD-L1 for example, will be able to discriminate prognostically, or predict 
success to therapy, in a clinically useful manner. In fact, the role of PD-L1 as a single 
biomarker predicting efficacy of anti-PD-1 and anti-PD-L1 therapies has come into 
question. Thus the primary aim of the present study was to examine the expression and 
co-expression of multiple immune inhibitory molecules in pancreatic and ampullary 
cancer and relate their expression to the tumor infiltrating lymphocytes, baseline known 
adverse clinicopathologic factors and outcome. We hypothesized that the expression 
of combinations of these immune inhibitory molecules would create a strong immune 
biomarker panel. The molecules chosen for study (PD-L1, Gal-9, HVEM, IDO, HLA-G) were 
chosen because their mechanism of interaction with the immune system is generally 
known and because a reliable primary antibody is available.
MATerIALs AnD MeTHoDs
Patient population and tissue samples.
Archived formalin fixed paraffin-embedded tissue from 224 patients who underwent 
pancreatic cancer (n=148) or ampullary cancer (n=76) resection at the Erasmus University 
Medical Center Cancer Institute between December of 2000 and December 2014 were 
retrieved from the pathological archive. Supplementary Table 1 lists the exact histologi-
cal diagnosis and precise anatomic location for each cancer. Baseline clinicopathologic 
characteristics and information on the use of chemotherapy, cancer recurrence and 
patient survival was retrospectively collected from the electronic record. The rational 
for including both patients with pancreatic and ampullary cancer in our study was that 
cancers arising from the ampulla of Vater are frequently clinically indistinguishable 
from, and often treated similarly with, cancers arising from the pancreas. Patients with 
duodenal and extrahepatic bile duct carcinomas, as well as all endocrine neoplasms 
were excluded. In addition we excluded patients who died from post-operative compli-
cations. The study protocol conforms to the ethical guidelines of the 1975 Declaration of 
Helsinki and was approved by the Medical Ethical Committee of Erasmus MC.
TMA construction.
Five 1-mm cores were taken from the tumorous area of 224 patients. The tumorous areas 
were marked by an experienced pathologist (KB) using archived H&E glass slides. The 
TMAs were made using an automated tissue-arrayer ATA-27 (Beecher Instruments, Silver 
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Springs MD, USA). In order to ensure that the stainings observed in the TMA cores were 
representative of the entire tumor, ten tissue blocks were chosen from which full slides 
were cut and stained. The purpose was to compare the findings between the TMA cores 
and the full slides and assess if staining heterogeneity was an issue.
Immunohistochemistry.
Immunohistochemistry was performed as previously described 22, 23 (see also supple-
mentary methods section). Complete information on the primary antibodies used can 
be found in Supplementary Table 2. For PD-L1 staining we used a validated anti-PD-L1 
antibody (clone 9A11), and a subset of cores was also stained with a second validated 
anti-PD-L1 antibody (clone 5H1). Stainings of appropriate control tissues to evaluate the 
specificity of all antibodies can be found in Supplementary Figure 1.
Table 1. 
Baseline characteristics N=224 (% or range)
Age 67.2 (33.4-85.2)
Gender (male/female) 132 (58.9) / 92 (41.1)
Positive margins a 81 (36.8)
Lymph node metastasis 139 (62.1)
CA-19.9 (kU/l) 67 (1-6,500)
Differentiation Good 19 (8.5)
Moderate 135 (60.5)
Poor 69 (30.9)
Peri-neural invasion 136 (73.1)
Origin (pancreas/ampulla) 148 (66.1) / 76 (33.9)
T-stage b (pancreas/ampulla) T1 8 (5.4) / 10 (13.2)
T2 24 (16.2) / 19 (25.0)
T3 116 (78.4) / 44 (57.9)
T4 NA / 3 (3.9)
Adjuvant chemotherapy 82 (37.6)
Systemic chemotherapy c 99 (47.4)
Recurrence 146 (65.8)
Cancer specific death d 136 (60.7)
a  Margins ≤1mm included as positive.
b  T-stage classification differs between pancreas and ampullary cancers (AJCC/UICC 2010)
c  Any systemic adjuvant or palliative chemotherapy
d  6 patients died from causes other than pancreas or ampulary cancer (cerebrovascular accident x2, myo-
cardial infarction x1, multiple comorbidities x1, adjuvant chemo-radiation related x1, urothelial carci-
noma x1).
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evaluation of immunohistochemistry staining.
Scoring focused on expression on cancer cells while expression on dysplastic, atypical 
or normal cells or TIL was noted but not scored. Figure 1 shows typical staining patterns, 
and respected scores, given for all molecules under study. Scoring was performed by 
two independent investigators (KS and KY) blinded to clinical outcome, and differences 
resolved by mutual agreement. Staining intensity was scored, for each core, from a scale 
of 0-3 and the proportion of positive cells was determined, for each core, in quadrilles. 
A composite score was given from a scale from 0-3 which reflected the cytoplasmatic 
staining intensity (scale 0-3) multiplied by the proportion of positive cells (0-100%) for 
the cases where focal expression was seen. For example if the staining intensity was +2 
but the staining was only present in 50% of tumor cells then the composite score was 
1. When membranous staining was detected this was separately scored using the same 
methodology. Average scores from the 5 tumor cores were used for analysis. For CD8 
and FoxP3 the positive cells per core were counted manually and average counts were 
used for analysis. Cutoffs were optimized to produce the most discriminating biomark-
ers for cancer-specific survival, as further discussed in the statistical methods. For PD-L1 
Table 2. Univariate Cox proportional Hazard regression analysis of patients’ survival
Variables* HR 95% CI p-value
Tumor differentiation 1.79 1.32-2.43 <.001
T stage 1.57 1.19-2.09 .002
Margin status 2.12 1.56-3.13 <.001
Lymph node status 3.24 2.16-4.85 <.001
CA-19.9 (log10) 1.49 1.18-1.95 .001
Peri-neural invasion 2.46 1.55-3.89 <.001
Pancreas vs ampulla 1.54 1.06-2.22 .021
Systemic chemotherapy 1.36 0.96-1.92 .086
Age 1.00 0.98-1.03 .910
IDO 0.58 0.35-1.00 .049
PD-L1 0.54 0.36-0.79 .002
Gal-9 0.58 0.41-0.83 .003
HVEM 0.45 0.28-0.72 .001
HLA-G 0.43 0.24-0.76 .004
CD8+TIL 0.65 0.44-0.95 .026
FoxP3+TIL 0.69 0.49-0.97 .034
CD8/FoxP3 ratio 0.55 0.36-0.84 .006
*In all cases hazard ratios reflect the presence, or higher level, of a clinicopathologic characteristic or high 
level of immune biomarkers. Note that the presence, or higher levels, of all clinicopathologic characteristics 
predicts worse survival (except for use of chemotherapy and age), while high levels of any of the immune 
biomarkers is protective.
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figure 1. representative stainings showing variable expression levels of immune inhibitory mol-
ecules and TIL on pancreas cancer cells. For PD-L1 and IDO there was little to no variability in the % of 
positive tumor cells per case thus only staining intensity was scored. Optimal cutoffs were a score of +1 or 
stronger for PD-L1 and a score of +2 or stronger for IDO. For Gal-9 and HVEM there was significant variability 
in the % of positive tumor cells thus both staining intensity and % of positive tumor cells was scored (pic-
tures provided demonstrate this variability for Gal-9 only; red circled areas and arrows point to negatively 
stained tumor cells). Optimal cutoffs were a score of 0.4 (out of 3) for Gal-9 and a score of 1.7 (out of 3) for 
HVEM. For HLA-G relatively few cases showed expression at any level, thus any level of staining was consid-
ered positive. For CD8 and FoxP3 the number of positive cells were manually counted and averaged over 
the 5 tumor cores. Optimal cutoffs were for CD8: 142 TILs per core, for FoxP3: 25 TILs per core and for the 
CD8/FoxP3 ratio, a ratio of 6.5. Please also refer to the methods section for more information.
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and IDO, where very little intra-core or inter-core heterogeneity was observed, only the 
intensity of cytoplasmatic staining was taken into consideration. IDO was considered 
high when the intensity score was +2 or stronger while PD-L1 was considered high 
when the intensity score was +1 or stronger (Figure 1). For HVEM and Gal-9 intra-core 
heterogeneity was observed, thus composite scores, including intensity and proportion 
of positive tumor cells, were calculated. Optimal cutoff values for cytoplasmatic HVEM 
staining was 1.7 (out of 3) and for Gal-9 it was 0.4 (out of 3). For HLA-G we detected stain-
ing in only 14.6% of cases, thus any case with positive staining was considered high and 
all negative cases were considered low. Finally the most optimal cutoffs for CD8 was 142 
TILs per core, for FoxP3 was 25 TILs per core and for the CD8/FoxP3 ratio a ratio of 6.5.
statistical analysis.
All analysis was performed in duplicate. Survival curves were estimated by the Kaplan-
Meier method. Cancer-specific survival and recurrence-free survival were calculated 
from the date of surgery to the date of event (death from cancer or recurrence of cancer 
respectively). In case of no event patients were censored at last follow-up. The log-rank 
test was used to evaluate differences between survival curves of different groups. Opti-
mal high vs low values were established by examining a grid of cutoffs and choosing the 
cutoff with the lowest -2 log likelihood. For multivariate analysis, the Cox proportional 
Hazard regression analysis was used with backward variable selection. Patients with 
missing values for the co-variates of interest were excluded from the statistical analysis. 
The associations between clinicopathologic parameters and the expression of immune 
inhibitory molecules, as well as the co-expression of the immune inhibiting molecules 
with each other, were examined using the χ2 tests or the T-test as appropriate. For 
these associations a Bonferroni correction was applied to the p-values (0.05/8 immune 
biomarkers = 0.0063 for statistical significance). Internal validation was performed by 
generating 1,000 bootstrapped datasets. Sensitivity analysis was performed by exclud-
ing the patients who received neo-adjuvant treatment (n=4). In addition, further sensi-
tivity analysis was performed by examining our findings between the a priori division of 
patients with cancers originating at the pancreas versus ampullary region. The statistical 
analysis was performed using the SPSS© 21 software.
resuLTs
Patients and baseline clinicopathologic characteristics.
Median survival was 17.5 months and median time to recurrence was 13.5 months. 
Baseline clinicopathologic characteristics can be seen in Table 1. The univariate hazard 
ratios for all the baseline clinicopathologic characteristics can be seen in Table 2, while 
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the respective Kaplan-Meier curves are depicted in Figure 2A. Similar associations with 
time to recurrence are shown in Supplementary Table 3 (univariate hazard ratios) and 
Supplementary Figure 2a respectively (Kaplan-Meier curves). In multivariate analysis of 
the clinicopathologic characteristics (Table 3a) margin status, lymph node status, tumor 
grade and pre-operative CA-19.9 level were independent predictors of cancer-specific 
survival, while T stage, tumor location (pancreas vs ampullary), use of systemic chemo, 
and age were not independent predictors of cancer-specific survival.
Table 3a Multivariate Cox proportional Hazard regression analysis of clinicopathologic parameters
Variables HR 95% CI lower limit 95% CI upper limit p-value
Margin status 2.02 1.36 3.00 .001
Lymph node status 2.77 1.76 4.36 <.001
Tumor differentiation 1.59 1.12 2.24 .009
CA-19.9 (log10) 1.31 1.00 1.71 .047
T stage 0.92 0.65 1.29 .613
Systemic chemotherapy 1.09 0.74 1.59 .676
Age 1.00 0.98 1.02 .714
Pancreas vs ampulla 0.98 0.63 1.51 .917
Table 3b Multivariate Cox proportional Hazard regression analysis of individual immune biomarkers ad-
justed for clinicopathologic characteristics*
Variables HR 95% CI lower limit 95% CI upper limit p-value
Clinicopathologic model + IDO 0.71 0.41 1.21 .205
Clinicopathologic model + PD-L1 0.55 0.35 0.87 .010
Clinicopathologic model + Gal-9 0.58 0.37 0.88 .010
Clinicopathologic model + HVeM 0.49 0.29 0.81 .006
Clinicopathologic model + HLA-G 0.53 0.28 1.01 .055
Clinicopathologic model + CD8+TIL 0.77 0.50 1.17 .214
Clinicopathologic model + FoxP3+TIL 0.85 0.58 1.25 .411
Clinicopathologic model + CD8/foxP3 0.57 0.36 0.91 .017
* In Table 3b only the hazard ratios and 95%CI of the immune biomarkers adjusted for the clinicopathologic 
characteristics (clinicopathologic model) are shown. Margin status, lymph node status and tumor differ-
entiation remained strong independent predictors of cancer-specific survival, in all cases, while T stage, 
age, the use of systemic chemotherapy and anatomic location (ampulla vs pancreas origin) remained non-
significant in all cases, just as in Table 3a. CA-19.9 was significant, or bordered significance, in all cases.
Description of immune inhibitory molecule expression.
Figure 1 shows representative stainings for all molecules in cancer cells. At least some 
level of HVEM, PD-L1, Gal-9, IDO and HLA-G cancer cell cytoplasmatic staining was seen 
in 97.3%, 90%, 77%, 36%, and 14.6% of cases. Median CD8+TIL number per tumor core 
was 116 (range 6-550) and median FoxP3+TIL number per tumor core was 25 (range 
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figure 2. Pancreas cancer survival Kaplan-Meier graphs.
(A) Clinicopathologic characteristics. (B) Immune inhibitory molecules and TIL. (C) Combined immune bio-
markers (PD-L1, Gal-9, HVEM and CD8/FoxP3 ratio) and combined clinicopathologic characteristics (margin 
status, lymph node status, tumor grade, CA19-9).
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0-136). Supplementary Figure 3 shows the comparison between the two anti-PD-L1 
antibodies (9A11 and 5H1) which was performed for selected cases. While the 5H1 
antibody exhibited less intense staining, all positive cases with the 9A11 antibody were 
also positive with the 5H1 antibody, while all negative cases were negative with both 
antibodies without exception. Supplementary Figure 4 shows the expression of the im-
mune inhibitory molecules in the TMA cores in comparison to their representative full 
section slides. This was done for a total of ten cases (four pairwise cases per antibody are 
shown). The expression patterns of all molecules in the TMA cores and their representa-
tive full slides were identical.
Associations of immune inhibitory molecule expression and TIL infiltration with 
clinicopathologic characteristics.
Cutoffs were optimized to produce the most discriminating biomarkers for cancer-
specific survival and they are presented in the supplementary methods section. After 
Bonferroni correction it was found that high PD-L1 expression was associated with lower 
CA-19.9 (p<.001) and lower T-stage (p=.002), high Gal-9 was associated with lower tumor 
grade (p=.004), high HLA-G was associated with peri-neural invasion (p=.001) and high 
CD8+TIL was associated with lower T-stage (p<001). In addition, PD-L1 expression was 
positively correlated with Gal-9 (p<.001), Gal-9 expression was positively correlated the 
CD8/FoxP3 ratio (p=.005) and HLA-G expression was positively correlated with HVEM 
(p<.001). Another notable association was between high PD-L1 and high CD8+TIL 
(p=.028), which, despite not meeting the Bonferroni correction cutoff for significance, 
was nevertheless an a priory hypothesis 24.
Associations of immune inhibitory molecule expression and TIL with survival 
and recurrence.
Figure 2B shows the Kaplan-Meier curves for overall survival in relation to the optimized 
cut-offs of the immune inhibitory molecules and TIL under study and Table 2 shows the 
respected univariate hazard ratios. High cytoplasmatic expression levels of PD-L1, Gal-9, 
HVEM, IDO, and HLA-G as well as high CD8+TIL and FoxP3+TIL infiltration were associated 
with improved cancer-specific survival. Furthermore, an a priori hypothesis was that the 
ratio of CD8+TIL to FoxP3+TIL infiltration would predict better survival. Indeed, high CD8/
FoxP3 ratio was associated with improved cancer-specific cancer survival (Figure 2B, 
Table 2). The results were similar for time to cancer recurrence (Kaplan-Meier curves in 
Supplementary Figure 2b, univariate hazard ratios in Supplementary Table 3).
Multivariate analysis.
We first examined the individual performance of each immune inhibitory molecule and 
TIL parameter adjusting for all the baseline clinicopathologic characteristics (Table 3b). 
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PD-L1, Gal-9, HVEM and the CD8/FoxP3-TIL ratio were each independent predictors of 
cancer-specific survival, while HLA-G showed a strong statistical trend. IDO, CD8+TIL, and 
FoxP3+TIL were not independent predictors of cancer-specific survival. We then investi-
gated, in multivariate analysis, how all tested immune biomarkers and clinicopathologic 
characteristics behaved together in order to examine if the immune biomarkers were 
independent of each other (Table 4). Margin status, lymph node status, tumor grade, 
Gal-9, HVEM and CD8/FoxP3 ratio remained independent predictors of cancer-specific 
survival while PD-L1 (p=.062), and to a lesser degree HLA-G (p=.125), showed a strong 
trends towards such independence. IDO expression, age, systemic chemotherapy, T-
stage, CA-19.9 and tumor location were not independent predictors of cancer-specific 
survival.
Table 4 Multivariate Cox proportional Hazard regression analysis of all immune biomarkers and all clinico-
pathologic characteristics*
Variables HR 95% CI lower limit 95% CI upper limit p-value
Margin status 2.39 1.56 3.64 <.001
Lymph node status 2.65 1.66 4.24 <.001
Tumor differentiation 1.50 1.04 2.16 .030
PD-L1 0.65 0.41 1.02 .062
Gal-9 0.62 0.40 0.97 .038
HVEM 0.49 0.28 0.87 .014
HLA-G 0.55 0.26 1.18 .125
CD8/FoxP3 ratio 0.51 0.29 0.87 .014
*Age, systemic chemotherapy, tumor location, T-stage, CA-19.9 (log10) and IDO are not independent. 
CD8+TIL and FoXP3+TIL were not individually included in the analysis due to the obvious interaction with 
the CD8/FoxP3 ratio and because they are not independent in Table 3b.
Co-expression patterns and survival.
Given the independent prognostic nature of the tested immune biomarkers, we inves-
tigated whether we could develop an even more informative predictive immunohisto-
chemical biomarker panel. We chose to combine the immune biomarkers with the stron-
gest prognostic ability, namely PD-L1, Gal-9, HVEM and the CD8/FoxP3-TIL ratio. Figure 
2C (left panel), shows the Kaplan-Meier curve of the combined immune biomarker in 
relation to cancer-specific survival (HR 0.57 95%CI 0.47-0.69, p<.0001). In figure 2C (right 
panel), we contrasted these findings with the combined presence of the independently 
prognostic clinicopathologic characteristics, namely margin status, lymph node status, 
tumor differentiation and CA-19.9 (HR 2.08 95%CI 1.74-2.47, p<.0001). The ability of the 
immune biomarkers to prognosticate patients with resected pancreatic and ampullary 
cancers is comparable to the prognostication ability of known clinicopathologic char-
acteristics.
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Validation.
To internally validate our final results 1,000 bootstrapped datasets were generated. The 
combined immune biomarker remained significant during validation (HR 0.58 95%CI 
0.47-0.73, p<.0001). Sensitivity analysis performed by excluding the patients who re-
ceived neo-adjuvant therapy (n=4) did not significantly affect any of the univariate or 
multivariate analysis in our study. In addition, further sensitivity analysis was performed 
in the subgroups of cancers arising from the pancreas versus the ampullary region. 
Firstly, when looking into the individual immune biomarkers (Supplementary Table 4) 
it is apparent that the hazard ratio of each independent immune biomarker (PD-L1, 
Gal-9. HVEM, CD8/FoxP3 ratio) has comparable magnitude and the same direction in 
the pancreatic and ampullary cancer cohorts. Moreover, the hazard ratio of the com-
bined immune biomarker for patients with pancreatic cancer was 0.62 (95%CI 0.48-0.79, 
p<.0001) and for patients with ampullary cancer was 0.52 (95%CI 0.37-0.72, p<.0001), 
thus of comparable magnitude and direction.
DIsCussIon
Pancreas cancer is one of the deadliest cancers known and therapeutic advances have 
been slow. We show, here, that multiple immune inhibitory molecules are expressed 
by pancreas and ampullary cancer cells and these molecules can, in principal, become 
interesting targets for immunotherapy. This is especially the case for PD-L1, Gal-9 and 
HVEM, and their respective receptors on immune cells, namely PD-1, TIM-3 and BTLA. 
Antibodies targeting these interactions are already in clinical practice for other cancer 
types 6, or are in preclinical and clinical development 25.
These immune inhibitory molecules have hardly been studied in relation to pancreatic 
cancer survival before. IDO has been shown to indeed be expressed in pancreas cancer, 
in 2 small studies 26, 27, however, the relationship of IDO expression to survival was not ex-
amined. PD-L1 expression and survival has been investigated in 2 small studies of 40 and 
81 patients respectively 28, 29, while HLA-G expression has been examined in 3 studies, 2 
of which have examined a relationship to survival (122 and 158 patients) 30-32. Gal-9 and 
HVEM expression have never been studied in relation pancreatic cancer survival before.
We show that high expression of immune-inhibitory molecules and TIL counts are as-
sociated with better cancer-specific survival. However, while both high CD8+TIL and 
FoxP3+TIL counts are associated with better survival, it is only the CD8/FoxP3 ratio that is 
an independent predictor of cancer-specific death. In fact, a low CD8/FoxP3 ratio is one 
of the strongest independent predictors of cancer death in our study. One may question 
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why a high level of FoxP3+TIL would be associated with better survival, since FoxP3+ 
lymphocytes are known to be immunosuppressive and aid in cancer progression 7. In 
fact, this same observation has been made in colorectal cancer 33. One explanation is 
that FoxP3+ regulatory T cells are recruited into tumors as a consequence of CD8+ T 
cell infiltration 34. Thus, the presence of a FoxP3+ infiltrate in a tumor simply signifies 
the concurrent presence of an active infiltrate of CD8+TIL. It is only when the FoxP3+TIL 
dominates that the prognosis becomes worse.
A similar argument can be made as to why high expression of PD-L1, Gal-9, HVEM and 
HLA-G are, counterintuitively, associated with better survival. One hypothesis is that 
their expression, especially the simultaneous expression of multiple molecules, is a 
signal of an active immunologic attack that is beneficial to patients with cancer. This 
phenomenon, called adaptive immune resistance, where immune inhibitory molecules 
are known to become overexpressed on cancer cells in response to IFN-γ and TIL infiltra-
tion, has been well described recently 24, 34-36. The positive correlation between PD-L1 
(p=.028) and HLA-G (p=.047) expression with numbers of CD8+ TIL and the positive 
correlation of Gal-9 (p=.005) expression with the CD8/FoxP3 ratio in our study supports 
the idea that expression of these molecules on pancreatic and ampullary cancer cells 
may be related to this phenomenon.
Interestingly, the prior studies on PD-L1 and HLA-G expression in pancreatic cancer 
have suggested the opposite; namely that high PD-L1 or high HLA-G expression are 
associated with poor survival 28-31. One possible explanation for the differences is the 
scoring techniques used. While we focused our scoring on cancer cells, the study by 
Wang et.al.  29 used imaging software to examine total PD-L1 expression. This may 
include expression by stroma cells, TILs and especially expression on non-cancerous 
cells with atypia, which could certainly give different results. In our study we observed 
PD-L1 staining in non-neoplastic cells but were careful to distinguish neoplastic from 
non-neoplastic cells, prior to the TMA construction process. The respected photographs 
of PD-L1 expression in the Wang et. al. 29 study, but also in the Nomi et. al. study 28 (fig-
ures 1B and 1A in the respective publications) certainly raise the possibility of having 
included non-tumorous, atypical cells in the scoring methodology of these studies. 
Another explanation for the differences could be the use of non-validated antibodies. 
Both prior studies in pancreas cancer 28, 29 have used the MIH1 anti-PD-L1 clone for im-
munohistochemistry. This clone has been shown in multiple studies to not perform well 
when compared to other validated antibodies 37, 38. The PD-L1 antibodies we used have 
been well validated 21, 39. In the case of HLA-G, one prior study 32 used clone 4H84 which 
has been shown to be non-specific in binding its intended target 40, 41, a second study 
used a polyclonal antibody 31, while the third study did not provide information on the 
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antibody used 30. Again, we used an HLA-G antibody that has been validated in previous 
studies 42, 43. In addition, we provide the expected positive control staining in placenta 
tissue for both PD-L1 and HLA-G (Supplementary Figure 1), which was not provided by 
the above mentioned studies in either PD-L1 28, 29 or HLA-G 31, 32, 41.
We show that the expression of these immune inhibitory molecules can, in combination, 
form clinically relevant biomarkers. The independent nature of these immune biomark-
ers means that they influence prognosis irrespective of traditional clinicopathologic 
characteristics, such as lymph node metastasis or margin status. In our cohort, while ev-
ery additional independent adverse clinicopathologic characteristic doubled the risk of 
cancer death, the presence of high levels of each additional immune biomarker reduced 
that risk to nearly half. This indicates the potential of our immune biomarker panel to 
aid in the prognostication of patients with pancreatic and ampullary cancers. While 
further standardization of the staining techniques is required for clinical development, 
tumor tissue from resected patients is readily available and immunohistochemistry is a 
standard, cost effective, clinical laboratory technique.
PD-L1 expression has already emerged as a biomarker of response to anti-PD-1 antibod-
ies 6. However, PD-L1, as a single biomarker, is not perfect. In melanoma, anywhere from 
6-41% of patients who are considered PD-L1 negative do actually respond to anti-PD-1 
antibodies, while half or more of the patients considered to be PD-L1 positive, do not 
respond 44. It is likely that a broader immune biomarker panel, one which takes into con-
sideration multiple immune inhibitory molecules, as well as the immune lymphocytic 
infiltrate, would lead to improved prediction of the patients likely to benefit from im-
mune checkpoint inhibitors. Thus, we propose incorporation of such biomarker panels 
in prospective immunotherapy clinical trials.
In addition, in the case of PD-L1, an ongoing issue is the proper histological evaluation 
of PD-L1 expression. Both cytoplasmatic and membranous PD-L1 staining have been 
observed in various cancers before 24, 45, 46 and we, in our study, observed predominately 
cytoplasmatic staining. It has recently been hypothesized that cytoplasmatic tumor 
staining represents intracellular stores of PD-L1 ready to be transported to the mem-
brane upon contact with immune cells 24. In fact this phenomenon is well demonstrated 
for another immune inhibitory molecule expressed on T-cells, namely CTLA-4 47, 48. While 
debate is ongoing, as to the respective importance of cytoplasmatic versus membra-
nous PD-L1 staining in the various cancer types 24, it is likely that cytoplasmatic PD-L1 
expression is biologically important and should not be ignored.
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We show that the results of the expression of the immune biomarkers do not substan-
tially differ between pancreatic and ampullary cancers (Supplementary Table 4). In 
addition, in multivariate analysis, the hazard ratios for the combined immune biomarker 
are of similar magnitude and direction in the pancreatic and ampullary cohorts. Thus 
our results are not cancer specific. In addition, tumor location (pancreas vs ampulla) is 
not an independent predictor of cancer-specific survival (Table 3a) or cancer recurrence 
(Supplementary Table 3). Thus, it does not appear that cancers arising from the ampulla 
behave biologically different than cancers arising from the pancreas, when correcting 
for adverse clinicopathologic factors. However, we cannot generalize our findings to a 
broader definition of peri-ampullary tumors, which frequently include duodenal can-
cers and distal cholangiocarcinomas, since we have excluded these tumors from our 
cohort. As a result, while our study provides information on the immunologic profile of 
ampullary cancers, a type of cancer that rarely attracts research attention, further work 
is needed to immunologically characterize all different kinds of peri-ampullary tumors.
Our study has several strengths. This is the first study to examine the relationship of the 
expression of Gal-9 and IDO with survival in pancreatic and ampullary cancer and the 
largest study to, similarly, examine the expression of PD-L1 and HLA-G. In addition, the 
examination of multiple immune biomarkers in a single, large, homogeneous cohort is 
a novel approach, which allows for evaluating the interactions between these biomark-
ers. Furthermore, the size of our cohort allowed for confident internal validation of our 
main results by bootstrapping. This method has been shown to be the preferred internal 
validation method of such datasets 49. Additional strengths are the successful use of 
TMAs in our study. We used five 1-mm cores to construct our TMAs which resulted in a 
substantial amount of cancer cells to evaluate. This is despite the fact that pancreas can-
cer is generally associated with significant amounts of stroma tissue. We also show that 
expression of these molecules in full slides were in complete agreement with our TMA 
findings (Supplementary Figure 4). Thus, the use of TMAs in assessing tumor expression 
patterns of these molecules, in pancreas cancer, is possible.
However, our study has also limitations. We had limited potential to systematically ex-
amine the surrounding peri-tumoral tissue. While general observations could be made, 
we were not able to systematically examine the non-neoplastic cells. In addition, our 
choice of immune biomarkers studied is not exhaustive. As our understanding of tumor 
immunology improves, additional molecules may become interesting to study.
In conclusion, pancreas and ampulary cancers are rich in expression of immune in-
hibitory molecules. High cancer cell expression of PD-L1, Gal-9, HVEM and HLA-G, and 
high CD8/FoxP3 TIL ratio are associated with improved cancer-specific survival. The 
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combination of such immune biomarkers can be a powerful prognostication tool for 
these patients. Such panels of immune biomarkers should be considered for inclusion in 
future immunotherapy clinical trials.
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supplementary figure 1. Positive and negative control tissues.
PD-L1 stains the microvillous membrane in placenta tissue as described by:
Velcheti V, et al, Lab Invest (2014) 94, 107-116.
Gal-9 stains kupffer cells but not hepatocytes in healthy liver in accordance with:
Mengshol JA, et al, PlosONE (2010) 5, e9504
HVEM stains islets of Langerhans in pancreas tissue in accordance with:
http://www.proteinatlas.org/ENSG00000157873-TNFRSF14/tissue/pancreas
IDO stains lymphocytes in tonsil lymphoid tissue underlying the mucosal epithelium in accordance with 
Munn DH, et al, Science (2002) 297, 1867-1870.
HLA-G stains exlusively extravillous trophoblastic cells in placenta tissue in accordance with:
Apps R, et al, Trends Immunol (2008) 29, 313-321.
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supplementary figure 2. Time to recurrence Kaplan-Meier curves. (A) clinicopathologic characteris-
tics, (B) immune biomarkers.
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supplementary figure 3. representative PD-L1 stainings using two validated anti-PDL1 antibodies. 
(A-D) Positive tumor cases. (E) Normal colon tissue shows similar staining patern with both antibodies. (F-
H) Negative tumor cases. Note in G that while tumor cells are negative with both antibodies, TIL cells are 
similarly positive.
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PD-L1
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HVEM
Case 1 full slide Case 1 TMA core Case 2 full slide Case 2 TMA core
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supplementary figure 4. side by side comparison of TMA cores and full slides.
Four representative pairs are shown per antibody. For IDO and HLA-G see next page
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IDO
HLA-G
Case 1 full slide Case 1 TMA core Case 2 full slide Case 2 TMA core
Case 3 full slide Case 3 TMA core Case 4 full slide Case 4 TMA core
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Case 3 full slide Case 3 TMA core Case 4 full slide Case 4 TMA core
supplementary figure 4 (continued). side by side comparison of TMA cores and full slides.
Four representative pairs are shown per antibody.
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supplementary tables
supplementary Table 1. Tumor location and histology
Location number of patients (%)
Pancreas head 122 (54.5)
Pancreas body 10 (4.5)
Pancreas tail 16 (7.1)
Ampulla of Vater 76 (33.9)
Histology number of patients (%)
Adenocarcinoma 214 (95.5)
Adeno-squamous 4 (1.8)
Acinus-cell 3 (1.3)
Anaplastic 3 (1.3)
supplementary Table 2. Primary antibodies used
Antigens Antibody source Clone Retrieval buffer Dilution
PD-L1 G. Freemana 9A11 Tris EDTA 1:50
PD-L1 Haidong Dongb 5H1 Tris EDTA 1:50
Gal-9 R&D systemsc Goat polyclonal Tris EDTA 1:200
HVEM Millipored 2G6-2C7 Citric acid 1:200
IDO Milliporee 10.1 Citric acid 1:200
HLA-G Exbiof MEM-G1 Citric acid 1:200
CD-8 Ventanag SP-57 CC1h Ready to use
Fox-P3 e-biosciencei 236A/E7 CC1h 1:100
a  Kindly provided by Dr. Gordon J Freeman, Dana-Farber Cancer Institute, Boston, MA (Mahoney KM, et.al., 
Cancer Immunol Res 2015; 3: 1308-1315).
b  Kindly provided by Dr. Haidong Dong, Mayo Clinic, Rochester, MN (Dong H, et.al., Nat Med 2002; 8: 793-
800)
c  http://www.rndsystems.com/Products/AF2045 (Mengshol JA, et.al., PLoS One 2010; 5: e9504)
d  http://www.merckmillipore.com/NL/en/product/Anti-TNFRSF14-Mouse-mAb-%282G6-2C7%29,EMD_
BIO-AP1159?CategoryName=000000260002b67900020023&CategoryDomainName=Merck-MerckMilli-
pore
e  http://www.merckmillipore.com/NL/en/product/Anti-Indoleamine-2%2C3-dioxygenase-Antibody%2C-
clone-10.1,MM_NF-MAB5412?bd=1#documentation (Soliman H, et.al., Cancer Immunol Immunother 
2013; 62: 829-837)
f  http://www.exbio.cz/products/clone.py?idclone=CLO000000000000078 (Boyson JE, et.al., Proc Natl 
Acad Sci U S A 2002; 99: 16180-16185)
g  http://ventana.com/product/33?type=28
h  Cell Conditioning Solution (CC1 Ventana Ref.: 950-124)
i  http://www.ebioscience.com/human-foxp3-antibody-purified-236a-e7.htm (Banham AH et.al., Vet Im-
munol Immunopathol 2009; 127: 376-381)
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supplementary Table 3. Univariate Cox proportional Hazard regression analysis of patients’ recurrence-
free survival
Variables HR 95% CI p-value
Tumor differentiation 1.89 1.40-2.56 <.001
T stage 1.64 1.23-2.01 .001
Margin status 2.03 1.44-2.84 <.001
Lymph node status 2.52 1.74-3.65 <.001
CA-19.9 log(10) 1.48 1.17-1.86 .001
Peri-neural invasion 2.73 1.72-4.32 <.001
Pancreas vs ampulla 1.66 1.16-2.38 .005
Adjuvant chemotherapy 1.14 0.81-1.59 .458
Age 0.99 0.98-1.01 .410
IDO 0.64 0.39-1.03 .066
PD-L1 0.50 0.35-0.73 <.001
Gal-9 0.60 0.43-0.85 .004
HVEM 0.56 0.37-0.85 .006
HLA-G 0.51 0.30-0.84 .008
CD8-TIL 0.58 0.40-0.84 .004
FoxP3-TIL 0.65 0.47-0.91 .011
CD8/FoxP3 ratio 0.52 0.35-0.80 .002
supplementary Table 4. Univariate Cox proportional Hazard regression analysis of patients’ Cancer-spe-
cific survival
Variables
Full cohort (as in Table 2) Pancreas cancer Ampulla cancer
HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
Differentiation 1.79 1.32-2.43 <.001 1.59 1.11-2.26 .011 2.10 1.15-3.84 .016
T stage 1.57 1.19-2.09 .002 1.29 0.90-1.84 .168 1.82 1.18-2.84 .007
Margin status 2.12 1.56-3.13 <.001 2.05 1.35-3.13 .001 1.99 0.91-4.32 .084
Lymph node status 3.24 2.16-4.85 <.001 3.36 2.03-5.57 <.001 3.04 1.53-6.07 .002
CA-19.9 log(10) 1.49 1.18-1.95 .001 1.54 1.02-2.33 .055 1.33 0.99-1.79 .014
Peri-neural invasion 2.46 1.55-3.89 <.001 1.35 0.71-2.53 .359 3.67 1.76-7.66 .001
Pancreas vs ampulla 1.54 1.06-2.22 .021 NA NA NA NA NA NA
Any chemotherapy 1.36 0.96-1.92 .086 1.20 0.79-1.84 .391 1.34 0.70-2.57 .381
Age 1.00 0.98-1.03 .910 1.00 0.80-1.02 .792 1.00 0.97-1.03 .913
IDO 0.58 0.35-1.00 .049 0.42 0.21-0.84 .014 1.02 0.45-2.30 .963
PD-L1 0.54 0.36-0.79 .002 0.59 0.38-0.94 .025 0.49 0.23-1.03 .060
Gal-9 0.58 0.41-0.83 .003 0.57 0.37-0.88 .011 0.58 0.32-1.08 .087
HVEM 0.45 0.28-0.72 .001 0.50 0.28-0.89 .018 0.40 0.18-0.91 .028
HLA-G 0.43 0.24-0.76 .004 0.66 0.29-1.51 .324 0.38 0.17-0.87 .021
CD8-TIL 0.65 0.44-0.95 .026 0.67 0.40-1.14 .136 0.77 0.42-1.41 .397
FoxP3-TIL 0.69 0.49-0.97 .034 0.79 0.50-1.15 .197 0.67 0.36-1.25 .209
CD8/FoxP3 ratio 0.55 0.36-0.84 .006 0.67 0.41-1.10 .115 0.40 0.17-0.89 .026
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ABsTrACT
Introduction: Patients with isolated colorectal cancer liver metastases frequently un-
dergo metastatectomy with curative intent. Biomarkers selecting patients for surgical 
intervention are needed. Tumor infiltrating lymphocytes (TIL) have shown significant 
prognostic potential in the setting of primary colorectal cancer, however, their role 
in the setting of colorectal cancer liver metastasis is poorly studied. In our study, we 
quantified tumor infiltrating CD8+ cytotoxic T-cells and Foxp3+ regulatory T-cells in 
relation to their spatial distribution at the metastatic site in the liver and examined their 
association with recurrence and survival.
Methods: TILs were isolated from fresh tumor tissues of 47 patients undergoing resec-
tion for colorectal cancer liver metastasis. Archived paraffin embedded tissue was ret-
rospectively retrieved from the same patients. Patient clinicopathologic characteristics 
and follow up information were retrieved from the electronic records. Immunohisto-
chemistry on full tissue sections was used to examine the presence of CD8+ and FoxP3+ 
cells both in the intra-tumoral and the peri-tumoral compartments. Flow cytometry was 
used to measure the proportions of cytotoxic T-cells (CD8+) and regulatory T-cells (CD4+ 
CD25+ FoxP3+) within CD45+ TIL.
results: By immunohistochemistry, individual concentrations of intra-tumoral or 
peri-tumoral CD8+ and FoxP3+ cells were not prognostic of colorectal cancer survival. 
However, the intra-tumoral, but not the peri-tumoral, CD8+/FoxP3+ ratio was an inde-
pendent predictor of survival (HR 0.31, 95% CI 0.12-0.79, p=.0314) in multivariate analy-
sis. By flow cytometry the intra-tumoral CD8+/regulatory T-cell ratio was also found to 
be an independent predictor of survival (HR 0.45, 95% CI 0.20-0.99, p=.044). From the 
clinicopathologic characteristics only the lymph node status of the primary cancer was 
prognostic of survival. (HR 2.48, 95% CI 1.10-5.60, p=.024).
Conclusion: The ratio of cytotoxic (CD8+) to regulatory (FoxP3+) T-cells, in the intra-
tumoral compartment but not in the peri-tumoral compartment, can predict survival 
after resection of colorectal liver metastases.
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InTroDuCTIon
Colorectal cancer is the third leading cause of cancer related death worldwide and the 
liver is the most common site of metastatic disease 1. Unlike other solid tumors it is 
now standard for patients with isolated colorectal cancer liver metastases (CRCLM) to 
be considered for resection upon presentation. In fact, 20% of patients with CRCLM 
are resected with curative intent 2. However, there is a wide range of clinical outcome 
following hepatic resection, ranging from cancer recurrence and death soon after re-
section to long-term cure from the disease. While clinical characteristics, such as the 
clinical risk score (CRS) 3, can prognosticate patients undergoing resection for CRCLM, 
the prognostication of these patients is far from ideal. New biomarkers to potentially 
select these patients for resection are needed.
The immune system plays an important role in cancer surveillance and elimination 4. 
Tumor infiltrating lymphocytes (TILs) have emerged as potential biomarkers in various 
cancers 5. In primary, non-metastatic, colorectal cancer the presence of TILs represent a 
robust prognostic biomarker that is superior to known clinicopathologic characteristics 
6. Multiple studies have now shown that TILs are associated with improved survival in 
primary colorectal cancer 7-9. The hypothesis stemming from these observations is that 
an immune infiltrate, at the tumor site, represents an active immunologic attack against 
the cancer, which in turn is associated with a better prognosis. A similar relationship 
between TILs and survival has been investigated in the setting of CRCLM. TILs have 
generally been associated with improved outcome in patients with resected CRCLM 10-12.
However, TILs have been heterogeneously defined in the literature. It is known that the 
quality of the immune infiltrate is important since different T-cell subsets have opposite 
effects in the tumor microenvironment 13. CD8+ T-cells represent cytotoxic lymphocytes 
with antitumor properties. On the other hand CD4+CD25+FoxP3+ T-cells represent 
T-regulatory cells (Tregs) which are known to have immunosuppressive and tumor sup-
porting properties. While increased numbers of intra-tumoral CD8+ effector T-cells are 
almost always associated with improved prognosis, there are contradictory findings as 
to the prognostic significance of intra-tumoral Tregs, since some studies find them asso-
ciated with improved prognosis while others with worse prognosis, in various cancers 14.
Another source of heterogeneity in prior studies is the histologically uneven distribution 
of TILs at the tumor site. The majority of TILs appear to concentrate in the peri-tumoral 
area, sometimes not in direct contact with tumor cells. Only a minority of TILs penetrate 
to the tumor tissue itself. It is unclear what the relative significance of these TIL cell 
populations are.
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The aim of the current study was to examine to composition and spatial distribution of 
TILs in CRCLM and to relate the TIL findings to prognosis. We examined the composi-
tion of TILs by quantifying numbers of CD8+ effector T-cells and Tregs. We examined the 
spatial distribution of TILs by using full tissue slides to examine TIL populations in the 
peri-tumoral and tumoral areas separately. We hypothesized that TIL penetration in the 
tumoral area will be more prognostic than TIL populations present in the peri-tumoral 
area, and that the ratio of immune effector (CD8+) to immune suppressive (Tregs) T-cells 
will be more prognostic than the concentrations of each individual cell type alone. We 
used and compared the results from two different techniques, namely immunohisto-
chemistry on paraffin embedded tissues and flow cytometry on TILs freshly isolated 
from tumor tissues.
PATIenTs AnD MeTHoDs
Patient population and tissue samples.
A total of 47 patients who underwent hepatic resection for CRCLM at the Erasmus 
University MC Cancer Institute between September 2009 and November 2011 were 
enrolled in our study. Fresh liver tumor tissue was used to isolate TILs. Formalin fixed 
paraffin-embedded tissue from these same patients was retrieved from the pathological 
archive. Baseline clinicopathologic characteristics as well as follow-up information on 
cancer recurrence and death were retrospectively collected from the electronic patient 
records. The study protocol conforms to the ethical guidelines of the 1975 Declaration of 
Helsinki and was approved by the Medical Ethical Committee of Erasmus MC.
Clinical risk score.
The Clinical Risk Score was calculated according to Fong at. al., 3. The presence of any 
one of the following five parameters was given a score 1 while the absence a score of 0: 
node-positive primary, disease free interval from primary to metastases < 12 months, 
number of hepatic tumors >1, largest hepatic tumor >5 cm and carcinoembryonic 
antigen level > 200 ng/ml.
Immunohistochemistry.
4µm thick sections were mounted on Superfrost PlusTM slides. For the stainings a Ven-
tana Benchmark Ultra automated staining system (Ventana Medical System, Tuscon, AZ, 
USA) was used, in a clinical laboratory setting. For CD8, the sectioned specimens were 
processed for 16 min antigen retrieval using Cell Conditioning Solution (CC1 Ventana 
Ref.: 950-124). After 32 min incubation with the primary antibody (clone SP-57) at 36 oC 
and amplification with Optiview amplification kit (Ventana ref.:760-099), detection and 
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visualization was done with OptiView Universal DAB detection kit (Ventana Ref.: 760-
700). The sections were counterstained with hematoxylin II (Ventana Ref.: 790-2208). For 
Fox-P3 the same protocol was applied with the exception the sectioned specimens were 
processed for 64 min antigen retrieval, the primary antibody (clone 236A/E7) dilution 
was 1:100, and amplification was performed with the Ultraview amplification kit (Ven-
tana ref.:760-080). Figure 1 shows representative stainings for CD8 and FoxP3 as well as 
positive and negative control tissues.
CD8
FoxP3
Intra-tumoral Positive control
Intra-tumoral
Peri-tumoral
Peri-tumoral Positive control
A B C
D E F
figure 1. representative CD8 and foxP3 immunohistochemical stains. A) Intra-tumoral and peri-tu-
moral CD8+ cells in CRCLM. B) CD8+ cells in positive control tonsil tissue. C) Negative control tonsil tissue. 
D) Intra-tumoral and peri-tumoral FoxP3+ cells in CRCLM. E) FoxP3+ positive cells in positive control tonsil 
tissue. F) Negative control tonsil tissue.
evaluation of immunohistochemistry staining.
Stained full tumor slides were electronically scanned using NanoZoomer 2.0HT (Hama-
matsu Photonic, Shizuoka, Japan) at a magnification of 40x. Automated digital image 
analyses was performed using the Visiopharm Integrator System (Visiopharm, Hoer-
sholm, Denmark). In each case 4-6 circular areas with a diameter of 0.54 mm (area = 1 
high power field), from either the intra-tumoral area or the peri-tumoral area, were used 
to measure the concentrations of CD8+ cells and FoxP3+ cells. For the peri-tumoral areas, 
the areas used for analysis were centered the middle of the peri-tumoral infiltrate. For the 
intra-tumoral areas, the areas used for analysis were close to the tumor border in order 
to avoid necrotic areas towards the center of the tumor. A representative image used for 
analysis can be found in Figure 2. CD8+ and FoxP3+ cell concentrations were measured 
as cells/mm2. All cases were visually reviewed to ensure accuracy of the measurements.
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A
B
figure 2. representative example of areas used for analysis of CD8+ and foxP3+ cell concentrations. 
A) Photograph of full slide. B) Zoom-in on red square of picture 2A. Blue circles represent intra-tumoral 
areas used for analysis. Green circles represent peri-tumoral areas used for analysis. The green circular areas 
are 0.23 mm2 or 1 HPF. Note that the areas used for peri-tumoral analysis are centered on the middle of the 
peri-tumoral infiltrate. Red arrows indicate the peri-tumoral infiltrate.
TIL isolation:
Single cell TILs were isolated from tumor tissue via tissue digestion as previously de-
scribed 15-17. Briefly, fresh tumor tissue was cut into small pieces and digested with 0.5 
mg/mL of collagenase (Sigma-Aldrich, St. Louis, MO) and 0.1 mg/mL of DNase I (Roche, 
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Indianapolis, IN) for 30 minutes at 37 oC. Cell suspensions were filtered through cell 
strainers and mononuclear cells (MNCs) were obtained by Ficoll density gradient cen-
trifugation. Viability was determined by trypan blue exclusion.
flow Cytometry Analysis
Mononuclear cells isolated from tumor tissue were analyzed for expression of surface 
and intracellular markers using the following anti-human antibodies: PerCP-labeled 
anti-CD8 (SK-1) and APC-H7-labeled anti-CD4 (SK3) from BD Biosciences; APC-labeled 
anti-FoxP3 (PCH101), PeCy7-labeled anti-CD3 (UCTH1), eFluor®450-labeled anti-CD45 
(HI30) and eFluor®450-labeled anti-CD25 (BC96) from e-biosciences and anti CD56 
(NHK-1) from Beckman Coulter. Cells were incubated with the antibodies 30 min at 4 ºC 
in the dark, then washed and fixed with 1% paraformaldehyde. For intracellular cytokine 
staining, cells were incubated with the FoxP3 antibody using the nuclear staining buf-
fer set from e-biosciences. Dead cells were excluded by using the LIVE/DEAD fixable 
dead cell stain kit with aqua fluorescent reactive dye (Invitrogen). Cells were analyzed 
in a FACSCanto II system (BD Biosciences, San Diego, CA). The gating strategy has been 
previously described 15. Numbers of CD8+ TILs were defined as the proportion of CD8+ 
cells within live CD45+ live cells, while numbers of T-regulatory cells were defined as the 
proportion of CD4+ CD25+ FoxP3+ within live CD45+ cells.
statistical analysis.
All analyses were performed in duplicate. Cancer-specific survival and recurrence-free 
survival were calculated from the date of hepatic metastatectomy to the date of event 
(death from cancer or recurrence of cancer respectively). Survival curves were estimated 
by the Kaplan-Meier method. In case of no event patients were censored at the date 
of last follow-up. The log-rank test was used to evaluate differences between survival 
curves of different groups. The median concentration or proportion values of CD8+ T-
cells or FoxP3+ T-cells were used to discriminate high vs low groups in both immunohis-
tochemistry and flow cytometry. For multivariate analysis, the Cox proportional Hazard 
regression analysis was used with backward variable selection. Patients with missing 
values for the co-variates of interest were excluded from the statistical analysis. The 
associations between clinicopathologic parameters and the TIL subpopulations were 
examined using the χ2 tests or the T-test as appropriate. The statistical analysis was 
performed using the SPSS© 21 software.
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resuLTs
Patients and baseline clinicopathologic characteristics.
Median time to recurrence was 13.1 months and median survival was 50.9 months. 
Cancer recurrence occurred in 37/47 patients while 28/47 patients died from colorectal 
cancer metastasis. Baseline clinicopathologic characteristics can be seen in Table 1. 
The univariate hazard ratios for all the baseline clinicopathologic characteristics can be 
seen in Table 2. Only the lymph node status of the primary cancer was associated with 
colorectal cancer death in our cohort (HR 2.48, 95% CI 1.10-5.60, p=.024). The CRS did 
not predict colorectal cancer death in our cohort.
Table 1 
Baseline characteristics N=47 (% or range) Missing values
Age (median) 63.8 (35.2-84.7)
Gender (male/female) 31 (66.0) / 16 (34.0)
Cl
in
ic
al
 r
is
k 
sc
or
e
Primary cancer lymph node status positive 26 (56.5) 1
Time from primary to CRCLM < 12 months 17 (36.2)
Largest metastatectomy tumor size >5cm 11 (23.4)
>1 metastatic lesion 30 (63.8)
CEA >200 ng/ml 1 (5.9) 30
Recurrence 37 (78.7)
Cancer specific death a 28 (59.6)
a All patients who died, died from colorectal cancer metastasis
Description of CD8+ and foxP3+ TIL distribution.
The majority of TILs were located in the peri-tumoral areas (Figures 1 and 2). Median 
intra-tumoral CD8+ and FoxP3+ TIL concentrations were 58.6/mm2 (range 8.8-795) and 
26.4/mm2 (range 0.44-255) respectively. Median peri-tumoral CD8+ and FoxP3+ TIL con-
centrations were 883/mm2 (range 409-1,731) and 127/mm2 (range 8.4-525) respectively. 
CD8+ peri-tumoral TILs outnumbered intra-tumoral CD8+ TILs by a factor of 15 while 
FoxP3+ peri-tumoral TILs outnumbered intra-tumoral FoxP3+ TILs by a factor of 5.
Prognostic value of intra-tumoral and peri-tumoral CD8+ and foxP3+ TILs by 
immunohistochemistry
Median values were used for cutoffs. Table 2 shows the Hazard Ratios and 95% confi-
dence intervals for the high versus low TIL populations in the intra-tumoral and peri-
tumoral areas while Figure 3 shows the respected Kaplan-Meier curves. Intra-tumoral 
nor peri-tumoral areas CD8+ and FoxP3+ TIL concentrations did not, individually, predict 
colorectal cancer death. An a priori hypothesis was that the ratio of CD8+ to FoxP3+ TILs 
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would be a better prognosticator than the individual TIL sub-populations. Indeed, a 
high intra-tumoral CD8+/FoxP3+ TIL ratio was predictive of improved colorectal cancer 
survival (HR 0.43, 95% CI 0.19-0.95, p=.032). On the other hand, the peri-tumoral CD8+/
FoxP3+ TIL ratio was not predictive of colorectal cancer survival. None of the TIL param-
eters were predictive of colorectal cancer recurrence, although a high concentration of 
intra-tumoral CD8+ TILs (HR 0.51, 95% CI 0.25-1.02, p=.052) showed a trend towards less 
colorectal cancer recurrence.
Table 2 Univariate Cox proportional Hazard regression analysis of patients’ survival
Variables HR 95% CI p-value
Ba
se
lin
e 
cl
in
ic
op
at
ho
lo
gi
c 
ch
ar
ac
te
ri
st
ic
s
Age (per decade increase) 0.99 0.71-1.38 .957
Gender (male vs female) 0.78 0.35-1.64 .485
Primary cancer lymph node status positive 2.48 1.10-5.60 .024
Time from primary to CRCLM < 12 months 1.01 0.47-2.16 .977
Largest metastatectomy tumor size >5cm 1.17 0.50-2.75 .730
>1 metastatic lesion 1.07 0.49-2.31 .871
CEA >200 ng/ml* 7.30 0.66-80.6 .164
CRS (0-5) 1.24 0.87-1.77 .231
TI
L 
pa
ra
m
et
er
s
CD8 peri-tumoral area 0.80 0.38-1.75 .571
FoxP3 peri-tumoral area 1.08 0.50-2.29 .852
CD8/FoxP3 peri-tumoral area 0.91 0.43-1.95 .813
CD8 intra-tumoral area 0.58 0.27-1.27 .169
FoxP3 intra-tumoral area 0.83 0.39-1.77 .622
CD8/FoxP3 intra-tumoral area 0.43 0.19-0.95 .032
* Hazard Ratio for the CEA parameter represents 1 single case of CEA >200 ng/ml out of 17 patients with 
available baseline values.
Prognostic value of intra-tumoral TILs by flow cytometry.
Flow cytometry using freshly isolated TIL was used to validate our immunohistochemi-
cal findings. Flow cytometry was limited to tissue from the intra-tumoral compartment. 
Median values were used for cutoffs. While CD8+ TILs were not predictive of colorectal 
cancer survival (HR 0.88, 95% CI 0.41-1.91, p=.753), high percentages of Tregs within 
CD45+ leukocytes were associated with worse colorectal cancer survival (HR 2.61, 95% 
CI 1.17-5.83, p=.016). In addition, high CD8+/Treg TIL ratio was associated with improved 
colorectal cancer survival (HR 0.45, 95% CI 0.20-0.99, p=.044). Figure 3 shows the repre-
sentative Kaplan-Meier curves. In contrast, TIL measurement by flow cytometry was not 
predictive of colorectal cancer recurrence.
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figure 3. Kaplan Meier curves of potential TIL biomarkers. CD8+ and FoxP3+ cell concentrations 
were measured as numbers of cells/mm2 tissue in immunohistochemistry and as proportions of CD8+ or 
CD4+CD25+FoxP3+ cells within CD45+ leukocytes by flow cytometry. Median numbers or proportions were 
used as cutoff levels. Note that only the intra-tumoral CD8+/FoxP3+ ratios obtained by immunohistochem-
istry and flow cytometry and intra-tumoral Treg proportions as determined by flow cytometry show statisti-
cally significant differences in colorectal cancer survival times.
Comparison of immunohistochemical intra-tumoral CD8+/foxP3+ TIL ratio with 
the CD8+/Treg TIL ratio obtained by flow cytometry
There was no correlation between the intra-tumoral CD8+/FoxP3+ TIL ratio obtained by 
immunohistochemistry and the CD8+/Treg TIL ratio obtained by flow cytometry (Spear-
man’s Correlation Coefficient = .026, p = .871). Patients with high intra-tumoral CD8+/
FoxP3+ TIL ratio determined by immunohistochemistry did not tend to also have high 
CD8+/Treg TIL ratio as determined by flow cytometry (Table 3).
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Table 3 Crosstabs analysis of high vs low intra-tumoral CD8+/FoxP3+ TIL ratio obtained by immunohisto-
chemistry and high vs low CD8+/Treg TIL ratio obtained by flow cytometry
p=.346
CD8+/Treg TIL ratio
(Flow Cytometry)
TotalLow High
Intra-tumoral CD8+/FoxP3+ 
TIL ratio
(Immunohistochemistry)
Low 12 10 22
High 8 12 20
Total 20 22 42
Multivariate analysis
Multivariate analysis was performed by including all known clinicopathologic charac-
teristics and the TIL ratios predictive of colorectal cancer survival (Table 4). Both the 
intra-tumoral CD8+/FoxP3+ TIL ratio obtained by immunohistochemistry and the CD8+/
Treg TIL ratio obtained by flow cytometry are independent predictors of colorectal can-
cer survival. From the clinicopathologic characteristics only lymph node status of the 
primary tumor was an independent predictor of colorectal cancer death.
Table 4a Multivariate Cox proportional Hazard regression analysis of intratumoral CD8+/FoxP3+ TIL ratio 
obtained by immunohistochemistry adjusted for clinicopathologic characteristics
Variables HR 95% CI lower limit 95% CI upper limit p-value
Primary cancer lymph node status 3.80 1.12 2.24 .004
Time to CRCLM < 12 months 0.68 0.28 1.65 .394
Largest tumor size >5cm 0.57 0.20 1.76 .341
>1 metastatic lesion 1.53 0.61 3.84 .361
Intra-tumoral CD8+/FoxP3+ TIL ratio 0.31 0.12 0.79 .014
Table 4b Multivariate Cox proportional Hazard regression analysis of CD8+/Treg TIL ratio obtained by flow 
cytometry adjusted for clinicopathologic characteristics
Variables HR 95% CI lower limit 95% CI upper limit p-value
Primary cancer lymph node status 2.90 1.14 7.40 .026
Time to CRCLM < 12 months 1.06 0.44 2.56 .899
Largest tumor size >5cm 0.48 0.15 1.50 .206
>1 metastatic lesion 0.89 0.36 2.21 .800
CD8+/Treg TIL ratio 0.38 0.16 0.92 .031
DIsCussIon
In our study, we show that the intra-tumoral ratio, but not the peri-tumoral ratio, of 
effector T-cells (CD8+ cells) to immune inhibitory T-cells (FoxP3+ T-cells), measured by im-
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munohistochemistry, is a predictor of cancer survival in the setting of resected CRCLM. 
In contrast, intra-tumoral CD8+ T-cells or FoxP3+ T-cells, individually, could not predict 
cancer survival. In addition, we show that measuring the same ratio of effector T-cells 
(CD8+ cells) to immune inhibitory T-cells (Tregs) by flow cytometry, using freshly isolated 
TILs, can also predict cancer survival following colorectal cancer liver metastasis.
This observation is consistent with the hypothesis that it is not the quantity of the im-
mune infiltrate but the quality that matters the most 18. Specifically, ratios of effector 
to regulatory immune cells may provide a more comprehensive and meaningful view 
of what occurs at the tumor microenvironment than numbers of individual types of 
effector or regulatory immune cells. In fact, a large meta-analysis of TIL phenotyping, 
including 33 studies and nearly 10,000 patients in various cancers, showed that lympho-
cyte ratios, and specifically the CD8/FoxP3 ratio, have more prognostic potential than 
individual lymphocytic subtype concentrations 19. The same reason may also explain 
why high numbers of intra-tumoral Tregs measured by flow cytometry were associated 
with worse survival while intra-tumoral Tregs measured by immunohistochemistry were 
not. In contrast to immunohistochemistry, Tregs measured by flow cytometry are calcu-
lated as proportions of CD45+ leukocytes, thus providing a ratio of regulatory to total 
immune cells.
The fact that we observed a prognostic significance only for the intra-tumoral and not 
for the peri-tumoral CD8+/FoxP3+ ratio also makes sense. While a lymphocytic infiltrate 
may be attracted to the margin of the tumor it does not mean, by default, that such a 
lymphocytic infiltrates lead to tumor disruption. We found much higher concentrations 
of CD8+ T cells and Foxp3+ Tregs around the tumors than in the tumors. Apparently, 
CRCLM prevent the migration of these immune cells into the tumor itself, which may 
be due to chemokine to chemokine receptor mismatch, aberrant microvasculature, 
cytokine production and immunosuppression itself 20. On the other hand, intra-tumoral 
lymphocytes that are in direct contact with tumor cells are more likely to have a signifi-
cant anti-cancer role.
Four prior studies have attempted to examine the prognostic role of TILs in CRCLM. The 
study by Halama et.al., 12 examined full slides taken from 101 patients with CRCLM and 
found that high TIL “density” was associated with improved survival. However, the prog-
nostic significance of TIL for CRCLM resection was examined in only 33 of the patients 
since the rest of the patients (n=68) had unrespectable disease and were treated with 
neo-adjuvant chemotherapy at the time of presentation. TIL infiltration was measured 
in an area within 500 µm from the tumor edge and included both the peri-tumoral and 
the intra-tumoral areas as defined by our study. Total immune infiltrate was defined 
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as a combination of CD3, CD8 and granzyme B staining. Thus, since Halama et.al. did 
not differentiate intra-tumoral from peri-tumoral lymphocytic infiltration in CRCLM it is 
difficult to compare their results with ours. A study by Katz et.al., 11 used three 0.6mm 
TMA cores per patient, taken from 188 patients with CRCLM. They showed that a high 
CD8/FoxP3 ratio (or a low FoxP3/CD8 ratio as defined in their study) predicts improved 
survival following CRCLM resection, a finding which is in agreement with our study. The 
fact that they used only three small TMA cores means they examined a much smaller 
area of tumor than in our study but reached a similar conclusion nonetheless. The TMA 
cores from the Katz et.al. study should correspond to the intra-tumoral areas in our 
study, likely explaining the similarity in our results 11. Katz et.al., however, did not exam-
ine the peri-tumoral areas, given the inability of TMAs to reliably capture the histologic 
complexity of the cancer microenvironment. A study by Lee et.al., 21 examined TMAs 
consisting of 5mm cores taken from 79 patients with synchronous only CRCLM. TILs in 
the liver metastasis was compared to TILs in the corresponding primary tumors. While 
in univariate analysis a higher FoxP3+ density at the metastatic site corresponded to 
better outcome, in multivariate analysis only CD45RO+ cell density at the primary site 
was prognostic of survival. Our study did not examine the relative role of TIL infiltration 
of the corresponding primary sites thus is difficult to compare our findings with the 
study by Lee et.al. More importantly however, it is unclear where the TMA cores were 
taken from. The relatively large 5mm cores may have included both peri-tumoral and 
intra-tumoral infiltrates. In addition, Lee at.al., did not report on the CD8/FoxP3 ratio. 
These differences may explain the different results between the study of Lee et.al on the 
one hand and our study and that of Katz et.al. on the other hand. Finally, a more recent 
study by Nakagawa et.al., 10 examined full slides from 162 patients with CRCLM. Both 
intra-tumoral and peri-tumoral areas were examined according to the authors. High 
peri-tumoral FoxP3 density was found to be associated with improved survival, while 
peri-tumoral CD8 and intra-tumoral CD8 and FoxP3 densities did not predict survival 
individually. Ratios of CD8 to FoxP3 densities were not examined. In addition, no defini-
tion of what constituted peri-tumoral or intra-tumoral areas was given.
It is clear from the above studies that significant heterogeneity is study design and ter-
minology exists. In fact, differences in methodology, rather than differences in biology, 
have been hypothesized before to account in differences amongst study observations 
19. In the case of CRCLM, only two prior studies 10, 12 have used full slides, allowing for 
comparison of intra-tumoral and peri-tumoral TIL populations and none of these stud-
ies commented on the possible significance of the CD8/FoxP3 ratio, which we show to 
be the strongest prognostic marker. On the other hand, the study by Katz et.al., which 
found the CD8/FoxP3 ratio to be prognostic of survival, concordant to our results, did 
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not examine the peri-tumoral infiltrate 11. While we validate the findings of Katz et.al., 
we show, in addition, that it is indeed the intra-tumoral infiltrate that matters the most.
A novelty of our study is the validation of our immunohistochemical observations by 
using flow cytometry of TILs isolated from fresh tissues, collected prospectively, from 
these same patients. We show that a high flow cytometric CD8+/Treg TIL ratio is also 
associated with improved colorectal cancer survival following CRCLM resection. It was 
surprising however, at first sight, that the results obtained by immunohistochemistry 
did not correlate with the results obtained, on a patient by patient basis, by flow cy-
tometry. The reasons for this discrepancy may be several. Firstly, immunohistochemistry 
measures absolute numbers of cells over a specific area of tissue, while flow cytometry 
measures proportions of cells within the total isolated cells (in this case intra-tumoral 
CD45+ leukocytes). Secondly, by simultaneous determination of several molecules on 
the same cells, flow cytometry is able to define cell subpopulations much more specifi-
cally than immunohistochemistry. Tregs were defined as CD45+ CD8+ CD4+ CD25+ FoxP3+ 
by flow cytometry while that level of specificity is impossible by immunohistochemistry, 
where traditionally FoxP3 staining alone is used to define Treg cells. Furthermore, FoxP3 
in humans, in contrast to mice, can also be expressed by activated helper T-cells 22, 23. In 
addition, activation-induced FoxP3 in human T-effector cells does not suppress prolif-
eration or cytokine production 23. Therefore, flow cytometric enumeration of Treg cells is 
more accurate and may account for the differences observed in our study between flow 
cytometry and immunohistochemistry.
While we show that the intra-tumoral CD8+/FoxP3+ ratio is prognostic of colorectal 
cancer survival, no association with colorectal cancer recurrence was seen. It is likely 
however, that overall survival reflects the biologic behavior of colorectal cancer much 
better than recurrence, and it is thus a better endpoint to study in the setting of resected 
CRCLM. While cancer recurrence is undoubtedly a surrogate endpoint of cancer survival, 
many patients with recurrence can still enjoy long term survival, or cure, following ad-
ditional interventions and palliative treatments. In that case, cancer recurrence does 
not represent aggressive biologic behavior of cancer, but rather remaining metastatic 
lesions too small to be clinically detected at the time of the initial resection.
Our study has several strengths. We used full slides to examine the complex histologic 
distribution of TIL in the tumor microenvironment and we carefully defined the intra-
tumoral and peri-tumoral infiltrates. We also looked at the spatial distribution of effector 
to regulatory cells. Finally, we used a second technique, flow cytometry, to better define 
regulatory T-cells in tumors and, at least partially, validate the immunohistochemistry 
findings. Our study, however, has also limitations. The main limitation relates to the 
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sample size of our study (n=47). While our sample size is comparable to the sample 
size of other similar studies using full slides, it is undoubtedly small. The reason for 
this was the need for prospective collection of freshly resected tumor material for flow 
cytometry, which limits the number of patients to more recent resections. At the same 
time, the need for adequate time to follow up excludes patients resected too recently for 
inclusion. . However, despite the small sample size, we were able to statistically confirm 
our a priori generated hypothesis, that a high intra-tumoral CD8+/FoxP3+ ratio would be 
protective in patients following resection for CRCLM. Therefore, our study confirms the 
conclusion of Katz et. al. 11, that the intra-tumoral CD8/FoxP3 ratio is an independent 
predictor of survival after CRCLM resection and adds the observation that peri-tumoral 
CD8+ and Foxp3+ T cells are not associated with survival.
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InVITeD CoMMenTAry
Despite the fact that the link between cancer and inflammation has been first suggested 
by Virchow in the 19th century it has only been in the last 15 years that our understand-
ing of this link has reached the point where therapeutic interventions are possible [1-3]. 
Inflammation is known to be both a cause and a consequence of cancer. For example 
chronic inflammation due to infectious diseases is believed to be responsible for more 
than 15% of known cancers to date [4] while inflammatory mediators are known to 
directly promote malignant transformation in experimental models [5]. On the other 
hand, once cancer progresses it leads to a chronic inflammatory-like state which, through 
altered aminoacid metabolism amongst other mechanisms, causes cachexia, the main 
cause of death in cancer patients [6].
Given that multiple immune and inflammatory markers are part of routine laboratory 
testing their use as prognostic and predictive biomarkers has been extensively exam-
ined. For example a low absolute lymphocyte count (ALC), generally less than 1.5 or 
1.2 x 109/L, is prognostic of poor survival in the setting of multiple cancers such as non-
Hodgkin’s lymphoma, chronic lymphocytic leukemia, acute leukemia, head and neck 
cancer, cancers of the ovary, breast, colon, pancreas and lung as well as sarcomas [7-12]. 
Moreover, low ALC is predictive of poor response to chemotherapy in colorectal, lung 
and breast cancer [10]. In addition to single markers, such as ALC, prognostic scores 
based on combining various inflammatory markers have been developed. Examples 
include the modified Glasgow prognostic score (C-reactive protein and albumin) [13], 
the prognostic index (C-reactive protein and white cell count) [14], the neutrophil to 
lymphocyte ratio (NLR) and the platelet to lymphocyte ratio (PLR). From these bio-
markers the NLR, which has been examined in over 60 studies, has been shown to be 
prognostic of outcomes in multiple cancers [15]. For example a recent meta-analysis in 
colorectal cancer patients, which included 16 studies, showed that an elevated NLR is 
indeed associated with poor survival [16].
Efforts in developing such inflammatory biomarkers have also been made in hepato-
cellular carcinoma (HCC) either following resection, trans-arterial chemoembolization 
or liver transplantation. Halazun et. al. showed that amongst 150 patients undergoing 
liver transplantation for HCC those with an NLR above 5 had a significantly lower overall 
survival (5-year survival, 28% vs. 64%, P = 0.001) and NLR was the only significant factor 
in predicting disease free survival in multivariate analysis [17]. Six additional studies (4 
of them very recent) have now supported the role of the elevated NLR as a powerful 
prognostic marker of HCC recurrence following liver transplantation, although they 
used different cutoffs ranging from ≥ 3 to ≥ 5 [18-23].
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In the study by Lai et. al., in this issue of Transplant International [24], NLR as well as PLR 
was examined as a prognostic biomarker in 181 patients undergoing liver transplan-
tation for HCC. Indeed an elevated NLR (≥ 5.4), in agreement with older and current 
literature, was again prognostic of poor survival in these patients (5-year survival rate 
of 48.2% vs. 64.5%). The novelty of the current study resides in the use of the NLR as a 
predictor of drop-out from the waiting list. The last NLR measurement, performed just 
before transplantation or drop-out, but not the initial value at the time of listing, nor the 
slope, was the best predictor of drop-out of all parameters examined (43% for NLR ≥ 5.4 
vs 21% for NLR < 5.4). While this study introduces an inflammatory biomarker, such as 
the NLR, as a possible predictor of drop-out its clinical utility at the current time is limited 
by the fact that the information, if validated, is available to the clinician too late. Clearly, 
examination of NLR as a predictor of drop-out should be examined in prospective stud-
ies in which regular measurements during the waiting list period are performed, since 
there is a real need for the identification of such biomarkers.
A limitation in the use of peripheral blood inflammatory markers for the prognostication 
of HCC patients undergoing transplantation is the fact that inflammation due to hepatitis 
infection, hepatic cirrhosis, or the use of immunosuppressive drugs post transplantation 
will inadvertently have an impact on these markers irrespective of tumor biology. As a 
result, the composition of the inflammatory milieu at the site of the tumor microenvi-
ronment, while not easily accessible, may be more informative of tumor biology than 
peripheral blood markers. The prognostic ability of the intratumoral immune infiltrate 
has now been shown in all major cancers and is probably best exemplified in colorectal 
cancer where the immune infiltrate at the primary tumor site of more than 400 patients 
was prognostically superior to clinical parameters including the TNM stage [25]. This 
means that information from the immune infiltrate can provide prognostic information 
superior to the size of the cancer (T) or the lymph nodes metastasis status (N) [26]. In 
the liver transplantation field Unitt et. al. showed that reduced lymphocytic infiltration 
in HCC tumors as well as a high intra-tumoral CD4 to CD8 ratio, were independent prog-
nostic factors of poor outcome, consistent with the hypothesis that a reduced number 
of cytotoxic CD8+ effector T lymphocytes at the tumor site is a sign of poor immunologi-
cal reactivity to the malignant cells [27].
Furthermore, it is now clear that the inflammatory reaction associated with cancer is a 
largely ineffective anti-tumor response, and that the local tumor environment is often 
infiltrated by immunosuppressive as well as tumor growth-promoting cells [28, 29]. 
Anti-tumor effector immune-type cells include cytotoxic CD8+ T cells, NK cells, NKT cells, 
Th1 helper cells and M1 macrophages, which secrete and are supported by cytokines 
such as IL-2, TNF-α and IFN-γ. Among immunosuppressive and tumor supporting cells, 
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which are recruited into tumors, are the T regulatory cells, myeloid derived suppressor 
cells, Th2 helper cells and tumor associated macrophages. These immunosuppressive 
cells secrete and are supported by cytokines such as IL-10 and TGF-β and VEGF, and their 
presence in tumor tissues of HCC patients is well documented [30-33]. Interestingly, al-
though they can exert both tumor-promoting and tumor-killing functions, intratumoral 
neutrophils are a poor prognostic factor in HCC [34]. A further complicating issue is the 
expression by both immune cells and cancer cells of immune inhibitory ligands and 
other immunosuppressive molecules such as PD-L1, B7-H3, B7-H4, Gal-9, indoleamine 2, 
3-dioxygenase (IDO), all of which inhibit antitumor immune responses and are currently 
the target of new cancer drugs [35].
Clearly routine laboratory tests, such as ALC, C-reactive protein and composites such 
as the NLR or other inflammatory indices, cannot capture the complexity of cancer 
inflammation and cancer immune responses or accurately represent tumor biology. In 
addition, knowledge of the immune interactions at the tumor microenvironment can 
provide clinicians with targets for treatment in an era where personalized medicine is 
the ultimate goal. This complexity however makes even the more remarkable the fact 
that such crude routine blood tests, such as the NLR, can demonstrate, in at least 8 stud-
ies now [17-24], such powerful prognostic ability in liver transplantation for HCC. While 
we are waiting for tumor immunologists to unravel all the secrets of the immune system 
there may just be time for patients to benefit from the cheap and easily accessible infor-
mation available from a routine blood draw.
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ABsTrACT
Background: Tumor expression of co-inhibitory ligands, such as PD-L1 and Galectin-9, 
has prognostic value in Hepatocellular Carcinoma (HCC) and other types of cancer. In 
addition, intra-tumoral PD-L1 expression seems predictive for the therapeutic effect of 
anti-PD-1 antibodies, in some types of cancer. Determination of tumor tissue expression 
of these molecules requires tumor biopsy or surgical intervention. To facilitate prognos-
tication, less invasive prognostic biomarkers, such as circulating PD-L1 or Galectin-9, 
would be preferable. Therefore, the aims of the study were to access the prognostic 
significance of circulating levels of PD-L1 and Galectin-9 in HCC patients and to compare 
the prognostic significance to the intra-tumoral expression of these molecules.
Methods: Archived tissues and stored peripheral blood samples from 81 patients who 
underwent HCC resection or liver transplantation, with curative intent, were used. Im-
munohistochemistry was performed to determine intra-tumoral expression of PD-L1 
and Galectin-9, while ELISA was used to quantify their circulating levels.
results: High circulating PD-L1 (HR 0.12, 95%CI 0.16-0.86, p=.011) and high circulating 
Galectin-9 (HR 0.11, 95%CI 0.15-0.85, p=.010) levels were both associated with improved 
HCC-specific survival and recurrence. Surprisingly, there was no correlation between 
circulating levels of PD-L1 and Galectin-9 and their intra-tumoral expression levels. In 
fact, circulating levels of PD-L1 and Galectin-9 were predictive of HCC-specific survival 
independently of intra-tumoral levels and baseline clinicopathologic characteristics. 
Combined analysis of circulating levels and intra-tumoral expression of PD-L1 (HR 0.33, 
95%CI 0.16-0.68, p=.002) and Galectin-9 (HR 0.27, 95%CI 0.13-0.57, p=.001) resulted in 
more confident prediction of survival.
Conclusion: Circulating PD-L1 and Galectin-9 levels prognostically differentiate resect-
ed HCC patients, independently of their intra-tumoral expression. Combined circulating 
and intra-tumoral expression levels of PD-L1 or Galectin-9 are associated with more 
confident prognostic immune biomarker profiles.
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InTroDuCTIon
Worldwide over half a million people die from HCC every year (1, 2). Only 20% of pa-
tients with HCC are diagnosed early enough to be candidates for curative treatments 
such as resection, local ablation or liver transplantation (3). Once advanced disease is 
diagnosed, HCC is incurable and overall survival can be only modestly extended with 
sorafenib (4, 5).
Developments in our understanding of tumor immunology (6) have brought forth new 
therapeutic strategies against cancer (7). Currently, the most successful immunothera-
peutic strategies are those that are designed to overcome immune resistance mecha-
nisms by using antibodies that abrogate co-inhibitory receptor-ligand interactions, the 
so-called negative immune checkpoint inhibitors (8). Recent approval of anti-CTLA-4 
and anti-PD-1 antibodies for the treatment of advanced melanoma, non-small cell lung 
cancer, renal cell carcinoma and bladder cancer (9-14) has made it clear that immuno-
therapy is the new wave of anti-cancer treatments. Immunotherapy clinical trials are 
now ongoing in many cancers, including HCC, and it is likely that these therapies will 
be approved in the future in other cancer types as well. In view of the high costs and 
occasional severe toxicity of these novel therapies, immune specific biomarkers that 
can predict which patients will benefit are urgently needed. Two such recent promising 
biomarkers in HCC are Programmed Death Ligand-1 (PD-L1) and Galectin-9 (Gal-9).
PD-L1 is a ligand that binds PD-1, a co-inhibitory receptor expressed on activated T 
cells. Binding of the ligand PD-L1 to its receptor PD-1 transduces a negative signal into 
T-cells inhibiting their activation (15). In HCC the PD-L1/PD-1 interaction impairs effector 
T-cell function and in vitro disruption of this interaction restores the function of tumor-
derived effector T-cells (16, 17). PD-L1 is known to be expressed by HCC cells (16-23). We 
have previously shown that tumor PD-L1 protein expression is a promising prognostic 
biomarker in HCC (24). In addition, tumor PD-L1 protein expression has shown promise 
as a predictive biomarker to identify cancer patients that respond to anti-PD1 immuno-
therapy (25, 26).
Gal-9 is a glycan-binding protein and an important modulator of T-cell function (27). Gal-
9 causes T-cell inhibition and apoptosis through its binding to the co-inhibitory receptor 
TIM-3, and blockade of the interaction between Gal-9 and TIM-3 reinvigorates ex vivo re-
sponses of T-cells of HCC and melanoma patients to tumor antigens (28, 29). Humanized 
antagonistic antibodies against TIM-3 are currently in preclinical development (30). In 
addition, binding of Gal-9 to CD44 enhances the differentiation of immunosuppressive 
T regulatory cells (31). A direct anti-metastatic role for Gal-9 has also been described (32, 
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33). We and others have demonstrated that Gal-9 is also expressed by HCC cells and that 
Gal-9 protein expression is a potential prognostic biomarker in HCC (24, 29, 34).
However, in addition to cell-bound expression, soluble forms of PD-L1 and Gal-9 exist 
in the circulation. These circulating forms of PD-L1 and Gal-9 have been poorly studied 
in cancer patients. For example, while circulating levels of PD-L1 have been examined 
in renal-cell cancer (35), diffuse large B-cell lymphoma (36), lung cancer (37) and gastric 
cancer (38), no study has examined circulating levels of PD-L1 in HCC patients. Elevated 
levels of circulating Gal-9 have been observed in metastatic colon cancer (39) and in 
benign inflammatory liver diseases such as chronic hepatitis-C and active chronic 
hepatitis-B infection (40-42). No study has investigated circulating Gal-9 levels in rela-
tion to cancer survival in any cancer.
One may hypothesize that circulating forms of PD-L1 or Gal-9 would correlate with 
their tumor tissue expression status, since release from tumor cells, or from the tumor 
microenvironment, may be the source of these molecules in the circulation. In that 
case, circulating PD-L1 and Gal-9 may act as preferred biomarkers given the accessi-
bility of peripheral blood when compared to tumor tissue. On the other hand, these 
physiologic molecules may have functions in the circulation that are independent of 
the immune interactions ongoing in the tumor microenvironment. Thus, the potential 
for the circulating levels of PD-L1 and Gal-9 to act as independent prognostic biomark-
ers, or independent predictors of immunotherapy treatment efficacy, exists. No study 
has correlated tissue protein expression status of these co-inhibitory ligands with their 
circulating levels. Thus, the aims of our study were to examine how circulating levels of 
PD-L1 and Gal-9 compare to tissue expression of these molecules and whether circulat-
ing levels have the potential to replace tissue expression, or add to tissue expression, as 
potential immune biomarkers in HCC.
PATIenTs AnD MeTHoDs
Patient population and tissue samples
Archival blood samples (59 serum samples and 22 plasma samples) and formalin fixed 
paraffin-embedded tissue samples from 81 patients who underwent hepatic resection or 
liver transplantation for HCC at Erasmus MC-University Medical Center between January 
2007 and March 2013, were used for this study. All patients had undergone procedures 
with curative intent. Medical ethical approval was obtained from the Medical Ethical 
Committee of Erasmus MC. The study protocol conforms to the ethical guidelines of the 
1975 Declaration of Helsinki.
Circulating PD-L1 and Galectin-9 in HCC 139
enzyme-linked immunosorbent assay
Sera or plasma samples were drawn no earlier than 4 months before the operation and 
were stored in -80oC. Soluble PD-L1 ELISA was performed as previously described (35) in 
the laboratory of Dr. Haidong Dong (Mayo Clinic, MN., US). Soluble Gal-9 was performed 
using an ELISA kit according to the manufacturers protocol (Uscn Life Science Inco, Wu-
han China). All samples were tested in duplicate and mean values were used for analysis.
Tissue microarray (TMA) construction
TMAs were constructed as previously described (24). In brief, three 0.6 mm cores were 
taken from the tumorous areas and two 0.6mm cores were taken from the surrounding 
tumor free liver (TFL) tissue of each tissue block. The tumorous areas with vital tissue 
were marked by an experienced pathologist (KB) using archived H&E glass slides. The 
TMAs were made using an automated tissue-arrayer ATA-27 (Beecher Instruments, Silver 
Springs MD, USA).
Immunohistochemistry and scoring
Immunohistochemistry was performed as previously described (24). In brief 4 µm thick 
sections were mounted on Superfrost PlusTM slides. The sections were deparaffinized 
and rehydrated. Endogenous peroxidase activity was blocked with 0.3% H2O2 for 15 
minutes. Antigen retrieval was performed in a microwave for 10 minutes using the ap-
propriate antigen retrieval buffer. After serum block, primary antibodies were applied at 
4oC overnight. The primary antibodies were PD-L1 clone 405.9A11 (43) (kindly provided 
by Dr. Gordon J. Freeman, Dana-Farber Cancer Institute, Boston, MA, USA), and Gal-9 
goat polyclonal (41) (R&D systems). HRP-conjugated anti-mouse or anti-goat IgG poly-
mer secondary antibody (EnvisionTM, DAKO) was then applied for 1 hour, followed by 
diaminobenzadine (DAB) as the chromogen detection method. The slides were stained 
with haematoxylin followed by dehydration. Negative controls consisted of omission 
of the primary antibody and appropriate positive control tissues included in the TMAs 
were used to evaluate specificity of all antibodies. Scoring was performed by 2 inde-
pendent investigators (KS and HS) blinded to clinical outcome and differences resolved 
by mutual agreement. Only cytoplasmatic staining was observed for both antibodies. 
Intensity of tumor cell and hepatocyte staining was scored in a scale from zero to three. 
Intra-core heterogeneity of staining intensity of tumor cells or hepatocytes was rarely 
observed, thus percentages of positive tumor cells were not analyzed. Average values of 
the scores of the different cores were used for analysis.
statistical analysis
All analyses were performed in duplicate. Survival curves were estimated by the Kaplan-
Meier method. Survival was calculated from the date of surgery to the date of event 
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(recurrence or death), or date of last follow up. The patients who died from causes other 
than HCC were censored at their time of death. The log-rank test was used to assess 
differences between survival curves of different groups, while for biomarkers with three 
linearly associated levels the linear trend for factor levels was used. Optimal high vs low 
values were established by examining a grid of cutoffs and choosing the cutoff with the 
lowest -2 log likelihood. For multivariate analysis, the Cox proportional Hazard regres-
sion analysis was used. The associations between clinicopathologic parameters with 
immune biomarkers, as well as the co-relationship of the immune biomarkers with each 
other were examined using the χ2 tests or the T-test as appropriate. Sensitivity analysis 
was performed in relation to sample source (serums versus plasma) and type of surgery 
(resection versus liver transplantation). The statistical analysis was performed using the 
SPSS© 21 software.
resuLTs
Patients and clinicopathologic characteristics
Circulating PD-1 and Gal-9 levels were study in 81 HCC patients who underwent hepatic 
resection or liver transplantation. Median time to cancer recurrence was 29.7 months 
and median survival was 34.2 months. Baseline clinicopathologic characteristics can be 
found in Table 1. In univariate analysis, tumor size > 3cm (HR 3.0, 95%CI 1.1-8.2, p=.032) 
predicted HCC-specific mortality and a pre-operative AFP level > 100 µgl-1 (HR 2.1, 95%CI 
0.9-5.3, p=.092) showed a trend toward predicting HCC-specific mortality. Number of le-
sions, tumor differentiation and vascular invasion did not predict HCC-specific mortality 
in our cohort. Size > 3cm also predicted HCC recurrence (HR 2.5, 95%CI 1.2-5.3, p=.012).
Association of circulating PD-L1 and Gal-9 with recurrence and survival
Median circulating PD-L1 concentration was 383 pg/ml (IQR 206-774 pg/ml), and me-
dian circulating Gal-9 concentration was 21 pg/ml (IQR 3-44 pg/ml). With a cutoff of 700 
pg/ml, high circulating PD-L1 was associated with improved HCC-specific survival (HR 
0.12, 95%CI 0.16-0.86, p=.011), and with a cutoff of 42 pg/ml high circulating Gal-9 was 
also associated with improved HCC-specific survival (HR 0.11, 95%CI 0.15-0.85, p=.010). 
The respected Kaplan-Meier curves are shown in Figures 1A and 1B. Using the same 
cutoff’s, similar significant relationships between circulating PD-L1 and Gal-9 and HCC 
recurrence were found (Figures 1C and 1D). There was no correlation between circu-
lating PD-L1 and Gal-9 levels (R2=.002, p=.68). In multivariate analysis, together with 
clinicopathologic characteristics, circulating Gal-9 (p=.022) could independently predict 
HCC-specific survival, while circulating PD-L1 (p=.077) and AFP > 100 µgl-1 (p=.060) 
showed a strong trend to association with HCC-specific survival.
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Table 1 
Baseline characteristics N or median (% or range)
Age 60 (23-79)
Gender (male/female) 58 (71.6) / 23 (28.4)
Type of Surgery Resection 58 (71.6)
Liver Transplantation 23 (28.4)
AFP before resection 7.5ug/l (1-15,000)
Cirrhosis 44 (54.3)
Viral hepatitis Hepatitis-B a 17 (21.0)
Hepatitis-C b 10 (12.3)
Tumor size (cm) 3.6 (1-25)
Number of lesions Single 59 (72.8)
Multiple 22 (27.2)
Vascular invasion 46 (56.8)
Tumor differentiation Well 26 (32.1)
Moderate 45 (55.6)
Poor 10 (12.3)
HCC recurrence 36 (44.4)
HCC specific death 21 (25.9)
a HBsAg(+) and/or anti-HBc positive
b Anti-HCV positive
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figure 1. Kaplan-Meier graphs of circulating PD-L1 and Galectin-9. (A) HCC-specific mortality in HCC 
patients with high or low circulating PD-L1 concentrations. (B) HCC-specific mortality in HCC patients with 
high or low circulating Gal-9 concentrations. (C) Recurrence-free survival in HCC p tients with high or low 
circulating PD-L1 concentrations. (D) Recurrence-free survival in HCC patients with high or low circulating 
Gal-9 concentrations.
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sensitivity analysis
In the majority of patients PD-L1 and Gal-9 were measured in sera but from 22 patients 
only plasma samples were available. When the patients with available plasma samples 
were excluded from the analysis the Kaplan-Meier survival curves, for the remaining 
59 patients, are similar to Figures 1A and 1B (see Supplementary Figures 1A and 1B 
for comparison). In addition, the Kaplan-Meier survival curves of the 22 patients with 
plasma samples follow the same general direction as the patients with serum samples 
(Supplementary Figures 1C and 1D). Similarly, when the cohort is split between patients 
who underwent hepatic tumor resection versus liver transplantation, the Kaplan-Meier 
survival curves of circulating PD-L1 and circulating Gal-9 levels look similar and follow 
the same direction (Supplementary Figures 2A-2D). Thus, our results do not depend on 
the use of serum versus plasma samples or the type of surgery performed.
Association of intra-tumoral PD-L1 and Gal-9 with recurrence and survival
Examples of PD-L1 and Gal-9 stains of tumor tissues were shown in our previous paper 
on expression of these co-inhibitory ligands in HCC tumors (24). In this current cohort, 
PD-L1 expression in tumor cells was seen in 78% of cases for PD-L1 and 84% for Gal-9. 
Patients with any evaluable PD-L1 or Gal-9 staining on their tumor cells were consid-
ered to have high expression while patients with complete absence of staining were 
considered to have low expression. Patients with high intra-tumoral PD-L1 (HR 0.41, 
95%CI 0.16-1.04, p=.051) and Gal-9 (HR 0.26, 95%CI 0.10-0.68, p=.003) had an improved 
HCC-specific survival (Figures 2A and 2B). The respective relationships of intra-tumoral 
PD-L1 and Gal-9 with HCC recurrence can be seen in Figures 2C and 2D. In multivariate 
analysis, intra-tumoral Gal-9 (p=.004), intra-tumoral PD-L1 (p=.035) and AFP > 100 µgl-1 
(p=.004) were independent predictors of HCC-specific survival.
Circulating versus intra-tumoral and tumor-free liver PD-L1 and Gal-9
Next we examined if circulating levels of PD-L1 and Gal-9 reflected intra-tumoral ex-
pression. There was no correlation between intra-tumoral PD-L1 and circulating PD-L1 
(R2=.03, p=.130) or between intra-tumoral Gal-9 and circulating Gal-9 (R2=.01, p=.349). 
In multivariate analysis, both intra-tumoral Gal-9 (p=.010) and circulating Gal-9 (p=.029) 
independently predicted HCC-specific survival, together with AFP > 100 µgl-1 (p=.016). 
In the case of PD-L1 , both intra-tumoral PD-L1 (p=.056) and circulating PD-L1 (p=.067) 
showed a strong trend towards independently predicting HCC-specific survival, together 
with AFP > 100 µgl-1 (p=.039). In addition, there was no correlation between circulating 
levels and expression levels of PD-L1 or Gal-9 on hepatocytes in TFL.
Circulating PD-L1 and Galectin-9 in HCC 143
Figure 1
Circulating PD-L1 survival
0 20 40 60 80 100
0
20
40
60
80
100
Low (n=55)
High (n=24)
Survival (%) p = .011
0 20 40 60 80 100
0
20
40
60
80
100
Low (n=59)
High (n=21)
Survival (%) p = .010
Circulating Gal-9 survival
0 20 40 60 80 100
0
20
40
60
80
100
Low (n=16)
High (n=55)
p = .051
Intra-tumoral PD-L1 survival
Figure 2 0 20 40 60 80 1000
20
40
60
80
100
Low (n=12)
High (n=65)
p = .003
Intra-tumoral Gal-9 survival
Figure 3 0 20 40 60 80 100
0
20
40
60
80
100
Both low (n=12)
One high (n=38)
Both high (n=19)
Survival (%) p = .002
Combined PD-L1 survival
0 20 40 60 80 100
0
20
40
60
80
100
Both low (n=11)
One high (n=45)
Both high (n=20)
Survival (%) p = .001
Combined Gal-9 survival
0 20 40 60 80 100
0
20
40
60
80
100
Low (n=55)
High (n=24)
Survival (%) p = .010
Circulating PD-L1 recurrence
0 20 40 60 80 100
0
20
40
60
80
100
Low (n=59)
High (n=21)
Survival (%) p = .005
Circulating Gal-9 recurrence
0 20 40 60 80 100
0
20
40
60
80
100
Low (n=16)
High (n=55)
p = .452Recurrence (%)
Intra-tumoral PD-L1 recurrence
Recurrence (%) Recurrence (%)
0 20 40 60 80 100
0
20
40
60
80
100
Low (n=12)
High (n=65)
p = .005Recurrence (%)
Intra-tumoral Gal-9 Reccurence
Combined PD-L1 recurrence Combined Gal-9 recurrence
0 20 40 60 80 100
0
20
40
60
80
100
Both low (n=12)
One high (n=38)
Both high (n=19)
p = .031Recurrence (%)
0 20 40 60 80 100
0
20
40
60
80
100
Both low (n=11)
One high (n=45)
Both high (n=20)
p = .001Recurrence (%)
A
A
A
B
B
B
C
C
C D
D
D
Months Months
Months Months
Months Months
Months Months
Months Months
Months Months
figure 2. Kaplan-Meier graphs of intra-tumoral PD-L1 and Galectin-9. (A) HCC-specific mortality in pa-
tients with high or low intra-tumoral PD-L1 staining. (B) HCC-specific mortality in patients with high or low 
intra-tumoral Gal-9 staining. (C) Recurrence-free survival in patients with high or low intra-tumoral PD-L1 
staining. (D) Recurrence-free survival in patients with high or low intra-tumoral Gal-9 staining.
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figure 3. Kaplan-Meier graphs of combined circulating and intra-tumoral PD-L1 and Galectin-9. (A) 
HCC-specific mortality of combined circulating and intra-tumoral PD-L1. (B) HCC-specific mortality of com-
bined circulating and intra-tumoral Gal-9. (C) Recurrence-free survival of combined circulating and intra-
tumoral PD-L1. (D) Recurrence-free survival of combined circulating and intra-tumoral Gal-9.
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Combining circulating and intra-tumoral expression
Given the lack of association between intra-tumoral expression and circulating levels 
of the respected ligands, and their independence for predicting survival in multivariate 
analysis, we examined if combining both improved the prognostication of patients with 
resected HCC. Figures 3A and 3B show the Kaplan-Meier survival curves of the combined 
(intra-tumoral and circulating) PD-L1 and Gal-9 biomarkers in relation to HCC death, 
respectively. Interestingly, patients with both high levels of circulating and intra-tumoral 
PD-L1 showed 100% survival (HR 0.33, 95%CI 0.16-0.68, p=.002). In addition, combined 
analysis of circulating and intra-tumoral Gal-9 could distinguish 3 groups of patients 
with distinct survival curves (HR 0.27, 95%CI 0.13-0.57, p=.001). Figures 3C and 3D show 
similar relationships of combined analysis of circulating and intra-tumoral PD-L1 and 
Gal-9 with HCC recurrence. In multivariate analysis both the PD-L1 combined biomarker 
and the Gal-9 combined biomarker, together with AFP > 100 µgl-1, are independent 
predictors of HCC-specific survival (Table 2).
Table 2 Multivariate Cox proportional Hazard regression analysis of patients’ survival
Variables HR 95% CI p-value
Size > 3cm 2.58 0.74-8.95 .136
Number of lesions 0.47 0.13-1.75 .260
Tumor differentiation 0.97 0.40-2.38 .953
Cirrhosis 3.25 1.10-9.60 .033
AFP > 100 µgl-1 4.60 1.32-16.0 .017
Combined PD-L1 0.38 0.17-0.88 .023
Combined Gal-9 0.16 0.05-0.47 .001
DIsCussIon
We show that both circulating PD-L1 and Gal-9 are able to differentiate resected HCC 
patients prognostically. High levels of circulating PD-L1 and Gal-9 are associated with 
delayed recurrence and better survival of patients undergoing curative intent surgery 
for HCC. Interestingly, circulating levels of PD-L1 and Gal-9 were not correlated to 
intra-tumoral expression, and showed prognostic value independently of intra-tumoral 
expression. We also show that when intratumoral expression and circulating levels of 
PD-L1 and Gal-9 are combined prognostication improves even further.
No study to our knowledge has examined circulating PD-L1 in HCC. Circulating Gal-9 has 
not been studied in relation to survival in any cancer type. In contrast to our findings in 
HCC patients, high levels of circulating PD-L1 have been shown to be associated with 
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worse survival in renal cell cancer (35), diffuse B-cell lymphoma (36) and lung cancer 
(37). On the other hand, in agreement with our study, high levels of circulating PD-L1 
have been shown to be associated with better survival in gastric adenocarcinoma (38). It 
is thus possible that the prognostic significance of these circulating biomarkers is tumor 
specific.
This study focused on the circulating levels of PD-L1 and Gal-9. In contrast, intra-tumoral 
or peri-tumoral protein expression of PD-L1 and Gal-9 in HCC have been examined in 
several studies before (16-23, 29, 34). Indeed our group has previously studied the prog-
nostic value of intra-tumoral expression of PD-L1 and Gal-9 (24). While our current results 
regarding intra-tumoral expression of PD-L1 and Gal-9 (Figure 2) are in agreement with 
our previous observations, this agreement was expected given the significant overlap 
in patients between the two studies. Specifically, 58 patients of our previous cohort of 
154 resected HCC patients had stored peripheral blood and were thus included in the 
current study. To these patients, an additional 23 patients were added. However, despite 
the significant smaller size of the current cohort we show, again, that high intra-tumoral 
expression of PD-L1 and Gal-9 are associated with improved survival.
The paradoxical observation that high intra-tumoral levels of immune inhibitory mol-
ecules are related to better, rather than worse, survival has been noted before and it is 
attributed to the phenomenon of adaptive immune resistance. Specifically, it has been 
observed that immune inhibitory molecules can be overexpressed on tumor cells and 
hepatocytes in response to IFN-γ or lymphocytic infiltration (44-47). Our observation 
that high circulating levels of PD-L1 and Gal-9 are also associated with better survival, 
may potentially be attributed to the same principle, namely that the presence of these 
molecules in the blood may signify active anti-tumor immunity.
Our original hypothesis was that circulating PD-L1 and Gal-9 would represent molecules 
that are passively released from tumor cells and therefore would reflect intra-tumoral 
expression of these molecules. However, similar to a recent study in B-cell lymphoma 
(36), we found that circulating levels of both PD-L1 and Gal-9 were not correlated to 
intra-tumoral expression. In addition, circulating PD-L1 and Gal-9 levels, in the current 
study, did not correlate with their expression on hepatocytes in tumor-free liver tissues. 
Instead, we found that circulating levels and intra-tumoral expression contributed inde-
pendently to prognostication. It is thus possible that intra-tumoral and circulating forms 
of PD-L1 and Gal-9 have different pathophysiologic origins and/or functions.
One other hypothesis for the source of circulating PD-L1 is that it can be actively shed 
from membrane-bound PD-L1 expressing tumor cells and/or hepatocytes. Soluble PD-
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L1 has indeed been shown to be released into cell culture supernatants by several, but 
not all, membrane PD-L1 expressing tumor cell lines (35), suggesting that expression of 
soluble and membrane-bound PD-L1 are differentially regulated. Another possibility, is 
that it is released from tumor associated macrophages. It is known that tumor associated 
macrophages and Kupffer cells express high levels of PD-L1 in the tumor microenviron-
ment in HCC (17, 21, 23) and myeloid cells, especially mature dendritic cells, have been 
shown to release soluble PD-L1 in vitro (48). Moreover, it has been recently shown that 
circulating activated macrophages in ovarian cancer patients also express high levels of 
PD-L1 (49, 50). Whatever the source of circulating PD-L1 may be, the circulating ligand is 
known to retain its PD-1 binding domain and immunosuppressive properties (35).
Like PD-L1, Gal-9 is not only expressed on tumor cells, but also at high levels on 
tumor-associated macrophages in HCC (29). Gal-9 does not have a signal peptide, and 
its secretion must involve a non-classical pathway. Cleavage from the cell surface by 
matrix-metalloproteinases has been suggested as a secretion pathway (51), while other 
studies showed that cancer cells can secrete Gal-9 via exosomes (52). Therefore, circulat-
ing levels of these molecules are probably not passive reflections of tissue expression. In 
addition, while their expression in tumor tissues probably determines their local effects, 
their circulating counterparts may exert systemic effects, e.g. by inhibiting systemic 
immunity or, in case of Gal-9, prevent formation of distant metastasis by hampering 
extravasation of tumor cells into other tissues (32, 33). This means that future studies 
on the role of PD-L1 and Gal-9 as prognostic or predictive markers should take both 
intra-tumoral and circulating levels into consideration to maximize the potential for 
biomarker optimization.
Our study has several strengths. It is the first to study circulating levels of PD-L1 and 
Gal-9 in HCC. In addition, few studies have studied circulating levels of these molecules 
in other cancers, thus this is a fairly unexplored field of research. Most importantly 
both the intra-tumoral expression and the circulating levels of these molecules were 
studied. The observation that intra-tumoral and circulating levels do not correlate, but 
may independently contribute to prognostication, is novel. Testing for the expression 
of these molecules in the surrounding TFL tissue also allowed us to show that it is not 
the expression in the diseased liver that determines circulating levels of PD-L1 and Gal-
9. Our study has also limitations. Stored peripheral blood samples were only available 
from 81 patients, therefore independent validation of these results is required. Given 
the importance of developing optimal immune specific biomarkers in the “era” of im-
munotherapy additional studies should confirm or refute these findings.
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In summary, circulating levels of PD-L1 and Gal-9 do not correlate to their expression in 
tumor tissue, but have prognostic value in HCC patients independently of their expres-
sion in tumor tissue. Combined circulating levels and intra-tumoral expression of PD-L1 
and Gal-9 are associated with more confident prognostic immune biomarker profiles.
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supplementary figure 1: Kaplan-Meier graphs of circulating PD-L1 and Galectin-9 in patients with 
serum versus plasma. (A) HCC-specific mortality in relation to serum PD-L1 concentration. (B) HCC-specific 
mortality in relation to serum Gal-9 concentration. (C) HCC-specific mortality in relation to plasma PD-L1 
concentration. (D) HCC-specific mortality in relation to plasma Gal-9 concentration.
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supplementary figure 2: Kaplan-Meier graphs of circulating PD-L1 and Galectin-9 in patients with 
resection versus liver transplantation. (A) HCC-specific mortality in relation to PD-L1 concentration of 
patients with resection. (B) HCC-specific mortality in relation to Gal-9 concentration of patients with resec-
tion. (C) HCC-specific mortality in relation to PD-L1 concentration of patients with liver transplantation. (D) 
HCC-specific mortality in relation to Gal-9 concentration of patients with liver transplantation .
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ABsTrACT
Introduction: Identification of tumor-antigens is crucial for the development of vaccina-
tion strategies against hepatocellular carcinoma (HCC). Most studies come from eastern-
Asia, where hepatitis-B is the main cause of HCC. However, tumor-antigen expression is 
poorly studied in low-endemic, western, areas where the etiology of HCC differs.
Methods: We constructed tissue-microarrays from resected HCC tissue of 133 patients. 
Expression of a comprehensive panel of cancer-testis (MAGE-A1, MAGE-A3/4, MAGE-A10, 
MAGE-C1, MAGE-C2, NY-ESO-1, SSX-2, sperm protein 17), onco-fetal (AFP, Glypican-3 ) 
and over-expressed tumor-antigens (Annexin-A2, Wilms tumor-1, Survivin, Midkine, 
MUC-1) was determined by immunohistochemistry.
results: A higher prevalence of MAGE antigens was observed in patients with hepatitis-
B. Patients with expression of more tumor antigens in general had better HCC specific 
survival (p=.022). The 4 tumor-antigens with high expression in HCC and no, or weak, 
expression in surrounding tumor-free-liver tissue, were Annexin-A2, GPC-3, MAGE-C1 
and MAGE-C2, expressed in 90%, 39%, 17% and 20% of HCCs, respectively. Ninety-five 
percent of HCCs expressed at least one of these 4 tumor-antigens. Interestingly, GPC-3 
was associated with SALL-4 expression (p=.001), an oncofetal transcription-factor highly 
expressed in embryonal stem-cells. SALL-4 and GPC-3 expression were correlated with 
vascular-invasion, poor-differentiation and higher AFP levels before surgery. Moreover, 
patients who co-expressed higher levels of both GPC-3 and SALL-4 had worse HCC-
specific survival (p=.018).
Conclusion: We describe a panel of 4 tumor-antigens with excellent coverage and 
good tumor specificity in a western area, low-endemic for hepatitis-B. The association 
between GPC-3 and SALL-4 is a novel finding and suggests that GPC-3 targeting may 
specifically attack the tumor stem-cell compartment.
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InTroDuCTIon
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death with over half 
a million deaths per year worldwide (El-Serag et al., 2001; Jemal et al., 2011). HCC is 
more prevalent in Eastern Asia (Jemal et al., 2011) where hepatitis-B (HBV) accounts for 
65% of HCC cases (Perz et al., 2006). In contrast, Western Europe is a low-endemic area 
where HBV is not the main cause of HCC, (Perz et al., 2006), and HCC is often diagnosed 
in non-cirrhotic livers (Verhoef et al., 2004; Witjes et al., 2012). However, it is estimated 
that the incidence of HCC is expected to continue to rise significantly in Western Europe 
and North America due to the hepatitis C virus infections during the 1960’s and 1970’s 
(IARC, 2011).
Primary treatment for early stage disease includes resection, local ablation and, in 
selected cases, liver transplantation. However, only 20% of patients are candidates for 
curative procedures (El-Serag et al., 2008). Once the cancer is advanced cure is no longer 
possible and median survival is a dismal 6-8 months, which can be extended to 10-13 
months with the addition of sorafenib, a tyrosine kinase inhibitor (Abou-Alfa et al., 2010; 
Llovet et al., 2008).
Recognition of the important role of the immune system in cancer surveillance and 
elimination (Zou, 2005) has led to the development of various immunotherapeutic 
strategies against cancer (Mellman et al., 2011). One such strategy, cancer vaccination, 
holds great promise, as has been recently demonstrated in prostate cancer (Kantoff et 
al., 2010a; Kantoff et al., 2010b). In HCC, cancer vaccine trials have shown promising 
results, in particular after local therapy to prevent relapses (Kuang et al., 2004; Lee et al., 
2005; Peng et al., 2005a).
However, despite the promise of cancer vaccines, success has been limited due to a 
number of factors. One of these is the proper identification of tumor antigens. Important 
requirements for inclusion of tumor antigens in therapeutic vaccines are immunoge-
nicity, prevalence of expression within the cancer population, tumor tissue specificity, 
and biologic significance (Cheever et al., 2009; Kvistborg et al., 2013; Lang et al., 2009). 
Multiple studies have described expression of tumor antigen panels in HCC but the vast 
majority of these studies were conducted in east Asian populations (Chen et al., 2001; 
Liang et al., 2013; Luo et al., 2002; Nakamura et al., 2006; Peng et al., 2005b; Sera et al., 
2008; Shirakawa et al., 2009; Xia et al., 2013; Yan et al., 2011; Yorita et al., 2011) where 
the etiology of HCC is predominately related to HBV. Very few such studies have been 
performed in western, low-endemic areas (Riener et al., 2009).
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Tumor tissue specificity refers to the predominant, most preferably exclusive, expression 
of the tumor antigen in cancer and not in normal tissues (Kvistborg et al., 2013). A strict 
interpretation of this requirement would limit tumor antigens to antigens resulting 
from somatic mutations, chromosomal translocations resulting in neo-antigens, or viral 
derived antigens. However, exome sequencing has recently shown that somatic muta-
tion patterns in HCC are strongly variable between individual patients and therefore 
not suitable for design of off-the-shelf therapeutic vaccines (Fujimoto et al., 2012). The 
most promising alternative tumor antigens are cancer-testis antigens, which are exclu-
sively expressed in germ cells but not in other normal tissues (Hofmann et al., 2008), and 
oncofetal antigens, expressed primarily during embryogenesis but not broadly in adult 
humans (AFP, Glypican-3). Both types of antigens are aberrantly expressed in various 
types of cancer. In addition, self-antigens that are overexpressed in cancer (Survivin, 
Wilms tumor-1, Midkine, Annexin-A2) are also considered tumor antigens, and several 
clinical trials are underway in HCC and other cancers, targeting these types of overex-
pressed self-antigens. Many of the existing studies in HCC do not include tumor antigen 
expression in the corresponding surrounding tumor free liver (TFL) compartment and 
thus tissue specificity cannot be assessed.
In this study we used immunohistochemistry on tissue-microarrays (TMAs) to examine 
on the protein level the expression pattern in HCC of a comprehensive panel of 15 tumor 
antigens belonging to different categories, including the cancer testis antigens MAGE-A1, 
MAGE-A3/4, MAGE-A10, MAGE-C1, MAGE-C2, NY-ESO-1, Sperm Protein 17 (SP17) and SSX-
2, the oncofetal proteins AFP and Glypican-3 (GPC-3), the over-expressed tumor antigens 
Annexin-A2, Wilms tumor-1 (WT-1), Survivin, Midkine (MDK) and the glycoprotein MUC-1. 
All these antigens have previously demonstrated immunogenicity in human studies. In 
addition, we tested for the expression of SALL-4, a transcription factor involved in the 
maintenance of embryonic and cancer stem cells (Zeng et al., 2014). SALL-4 has recently 
been shown to be expressed in an HCC subtype with stem-cell like features and to be 
associated with poor prognosis (Oikawa et al., 2013; Yong et al., 2013b; Zeng et al., 2014). 
The goal of the study was to identify a panel of biologically relevant tumor antigens with 
a) broad expression in a Western European population of HCC patients and b) specific 
expression in the tumor tissue with no, or little, expression in surrounding TFL tissue.
MATerIALs AnD MeTHoDs
Patient population and tissue samples
Archived formalin fixed paraffin-embedded tissue samples from 133 patients who un-
derwent hepatic resection (n=94) or liver transplantation (n= 39) for HCC in our center, 
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between July 2004 and October 2013, were used for this study. Clinicopathologic char-
acteristics are shown in Table 1. All patients had undergone procedures with curative 
intent and none had received systemic therapy prior to resection or transplantation. 
Patients with evidence of residual cancer after resection were excluded. Informed con-
sent for the use of tissue for research purposes was obtained from all patients.
TMA construction
Three 0.6mm cores were taken from the tumorous area of 133 patients and two 0.6mm cores 
were taken from the corresponding TFL tissue of 105 of these patients. The tumorous as well 
as the TFL areas with vital tissue were marked by an experienced pathologist using archived 
H&E glass slides. In each TMA we included cores of testis, placenta, tonsil, ovary, stomach, 
prostate, bladder, kidney, lung and liver as control tissues. The TMAs were made using a 
Beecher© automated tissue-arrayer ATA-27 (Beecher Instruments, Sun Prairie WI, USA).
Immunohistochemistry
Immunohistochemistry was performed on 4µm thick sections mounted on Superfrost 
PlusTM slides (Erie Scientific LLC, Portsmouth NH, USA). The sections were deparaffinized 
and rehydrated. Endogenous peroxidase activity was blocked with 0.3% H2O2 for 15 min-
utes. Antigen retrieval was performed in a microwave for 10 minutes using the appropriate 
antigen retrieval buffer for each antigen (table 2). After serum block, primary antibodies 
were applied at 4c overnight. The primary antibodies (Table 2) were carefully selected to 
be monoclonal (with the exception of AFP and SP17) and to have been validated in sci-
entific literature. HRP-conjugated anti-mouse or anti-rabbit polymer secondary antibody 
(EnvisionTM, DAKO, Glostrup, Denmark) was then applied for 1 hour, followed by diami-
nobenzadine (DAB) as the chromogen detection method. The slides were stained with 
haematoxylin followed by dehydration. The above protocol was used for all antibodies 
with the exception of GPC-3 and AFP where an automated BenchMark ULTRA™ instrument 
(Ventana Medical Systems, Inc, Tuscon AZ, USA) was used in a clinical laboratory setting. 
Scoring was performed by 2 independent investigators and differences resolved by 
mutual agreement. Intensity was scored as either none, weak, moderate or strong, while 
percentage of positive cells was scored as <5%, 5-25%, 25-75% and >75%. For a staining to 
be considered positive at least 5% of cells had to be stained. Negative controls consisted 
of omission of the primary antibody and appropriate positive control tissues were used for 
all antibodies. H-scores were calculated by multiplying the intensity score (0 to 3) with the 
level of % of positive cells where 1 = <5%, 2 = 5-25%, 3 = 25-75% and 4 = >75%.
statistical analysis
The association of the expression level of tumor antigens with the various subgroup 
populations was analyzed using the Chi-square test. The association of the tumor 
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Table 1. Patient characteristics
Characteristics No. of patients 133 (%)
Age (years)
Median 60.4
Range 22.9-86.6
Gender
Male 95 (71.4)
Female 38 (38.6)
ethnicity
Western-European 103 (77.4)
Non western-Europeana 30 (22.7)
etiologyb
No known liver disease 37 (27.8)
Hepatitis B 24 (18.0)
Alcohol abuse 22 (16.5)
Hepatitis C 18 (13.5)
Cryptogenic 10 (7.5)
NASH 9 (6.8)
Hemochromatosis 5 (3.8)
Primary biliary cirrhosis 3 (2.3)
Other 5 (3.8)
Viral hepatitis statusc
Hepatitis B positived 30 (22.6)
Hepatitis C positivee 19 (14.3)
Cirrhosis present
Yes 69 (51.9)
No 64 (48.1)
Tumor differentiation
Good 44 (31.4)
Moderate 73 (52.1)
Poor 23 (16.4)
Vascular invasion
Yes 71 (62.3)
No 47 (37.7)
number of lesions
Single 90 (67.7)
Multiple 43 (32.3)
size of largest lesion
Median 4.5cm
Range 0.5-25
AfP level before resection
Median 8ug/l
Range 1-63,000
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antigen expression with the clinicopathologic parameters was analyzed using the 
Chi-square tests for categorical variables and the student T-test for continues variables. 
Survival analyses was performed using the Kaplan–Meier method and the log-rank test. 
Univariate and multivariate hazard ratios, 95% confidence intervals, and correspond-
ing p-values were obtained using Cox regression analysis. The statistical analysis was 
performed using the SPSS© 21 software.
← Table 1. Patient characteristics
a  Non-western European patients are from East-Europe (n=3), Suriname (n=7), Middle-East (n=8), Sub-
Sahara Africa (n=3) and South-East Asia (n=9). See Supplementary Table 1.
b  Patients with more than 1 etiologic factor were listed based on the most dominant cause of liver disease.
c  Three patients had both hepatitis B and hepatitis C.
d  HBsAg(+) and/or anti-HBc positive, e anti-HCV positive
Table 2. Primary antibodies
Antigens Primary antibody source Clone retrieval 
buffer
Antibody 
dilution
references
MAGE-A1 Santa Cruz Biotechnology MA454 Tris EDTA 1:50 (Jungbluth et al., 2000)
MAGE-A3/4 Prof. G.C. Spagnolia 57B Tris EDTA 1:100 (Landry et al., 2000)
MAGE-A10 Prof. G.C. Spagnolia 3GA11 Citric acid 1:10 (Schultz-Thater et al., 2011)
NYESO-1 Santa Cruz Biotech. E978 Tris EDTA 1:50 (Vaughan et al., 2004)
SSX-2 Prof. A.G. van Kesselb E3AS Tris EDTA 1:25 (dos Santos et al., 2000)
MAGE-C1 Santa Cruz Biotech. CT7-33 Tris EDTA 1:50 (Xia et al., 2013)
MAGE-C2 Prof. Boquan Yinc CT-10 Tris EDTA 1:100 (Zhuang et al., 2006)
MUC-1 Sanbio MA695 Citric acid 1:100 (Langner et al., 2004)
AFP Dako Polyclonal Tris EDTA 1:400 Dakod
GPC-3 Santa Cruz Biotech. 1G12 Tris EDTA 1:200 (Shirakawa et al., 2009)
Annexin-A2 BD Biosciences 5 Tris EDTA 1:200 (Yee et al., 2007)
WT-1 Novus Biologicals 6F-H2 Tris EDTA 1:400 (Nakatsuka et al., 2006)
Survivin Santa Cruz Biotechnology D-8 Tris EDTA 1:50 (Brennan et al., 2008)
MDK GeneTex EP1143Y Citric acid 1:400 (Liang et al., 2013)
SP17 Proteintech Polyclonal Citric acid 1:100 Proteinteche
SALL-4 Santa Cruz Biotech. EE-30 Tris EDTA 1:50 (Yong et al., 2013b)
a  MAGE-A3/A4 and MAGE-A10 antibodies graciously provided by Professor Giulio Spagnoli, Department 
of Surgery, Research Laboratory, University Hospital Basel, Basel, Switzerland (Landry et al., 2000; Schultz-
Thater et al., 2011)
b  SSX-2 antibody graciously provided by Professor Ad Geurts van Kessel, Department of Human Genetics 
University Hospital Nijmegen, 6500 HB Nijmegen, The Netherlands (dos Santos et al., 2000)
c  MAGE-C2 antibody graciously provided by Professor Boquan Yin, Department of Immunology, Fourth 
Military Medical University, Xi’an 710032, PR China (Zhuang et al., 2006)
d  http://www.dako.com/nl/ar38/p102130/prod_products.htm Accessed 8-9-14
e  http://www.ptglab.com/PView/SPA17-Antibody-13367-1-AP-PVIEW.htm Accessed 8-9-14
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resuLTs
Tumor antigen expression in HCC and TfL tissue
The expression of the 15 tumor antigens in both tumor and TFL tissue is shown in Table 
3. No expression of SSX-2 and MUC-1 was observed, although the antibodies prop-
erly stained testis (seminiferous duct cells) and gastric control tissue respectively. The 
prevalence of expression of MAGE-A3/4, NY-ESO-1, AFP, MAGE-A1 and MAGE-A10 was 
low (< 10% of patients), while increasing numbers of HCC showed expression of MAGE-
C1, MAGE-C2, GPC-3, MDK, Survivin, WT-1, SP17 and Annexin-A2 (prevalence ranging 
from 17% to 90% - Table 3). However, the overexpressed self-antigens MDK, Survivin, 
WT-1 and SP17 showed equal expression in tumors and in TFL tissues. Thus, the tumor 
antigens with the highest differential expression level between tumor tissue and TFL 
tissue are Annexin-A2 (90.2% vs 37.1), GPC-3 (39.1% vs 0%), MAGE-C2 (19.5% vs 0%) and 
MAGE-C1 (17.3% vs 0%). This conclusion did not change when we analyzed only the 
105 patients with paired tumor and TFL tissue as compared to the entire cohort of 133 
patients. Representative immunohistochemical stainings of these four tumor antigens 
in HCC and TFL tissue are shown in Figure 1, while representative immunohistochemical 
stainings of all the tumor antigens can be seen in Supplementary Figure 1. The distribu-
tion of intensity and the percentage of stained cells in tumor tissue, and in the case of 
Annexin-A2 in TFL tissue, is shown in Figure 2. MAGE-C1 and GPC-3 showed cytoplasmic 
expression in tumor cells, while MAGE-C2 showed nuclear expression in tumor cells. 
Table 3. Tumor antigen expression
Antigens % positive stainings in tumor tissue 
(n=133)
% positive stainings in TfL tissue 
(n=105)
SSX-2 0 0
MUC-1 0 0
MAGE-A3/4 3.0 0
NYESO-1 3.8 0
AFP 6.8 0.9
MAGE-A10 7.5 0
MAGE-A1 9.8 0
MAGE-C1 17.3 0
MAGE-C2 19.5 0
GPC-3 39.1 0
MDK 57.7 64.4
Survivin 79.5 91.1
WT-1 85.6 84.6
SP17 87.0 88.0
Annexin-A2 90.2 37.1
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Annexin-A2 showed membranous and cytoplasmic expression in hepatocytes in HCC 
and TFL tissue, and stained sinusoidal endothelium. These expression patterns are in 
agreement with previous observations in HCC (Liang et al., 2013; Longerich et al., 2011; 
Riener et al., 2009). Only hepatocyte and not sinusoidal staining was scored for Annexin-
A2. Moreover, Annexin-A2 expression showed a weaker intensity in the hepatocytes of 
the TFL tissue than the corresponding tumor cells (Figure 2D and E). Looking at etiologic 
factors, there was a significantly higher prevalence of expression of MAGE-A3/4 (p=.011), 
MAGE-A1 (p=.034) and MAGE-C1 (p=.008) in patients with HBV infection compared to 
patients without HBV infection, while MAGE-C2 (p=.264) and GPC-3 (p=.334) showed 
a statistical trend towards higher expression in patients with HBV infection (Figure 3).
Tumor antigen index.
As in previous studies (Liang et al., 2013) a tumor antigen index (TAA) was calculated 
based on the total number of antigens co-expressed in a given tumor tissue. Patients 
Tumor tissue TFL tissue negative control positive control
MAGE-C1
MAGE-C2
GPC-3
Annexin-A2
figure 1. representative stainings for tumor tissue and TfL tissue with negative and positive con-
trols for MAGe-C1, MAGe-C2, GPC-3 and Annexin-A2. Strong tumor cell stainings for MAGE-C1, MAGE-
C2, GPC-3 and Annexin-A2 are seen in the leftmost column. The second column shows lack of staining in 
the corresponding TFL tissues with the exception of Annexin-A2 where staining of sinusoids is seen. The 
third column shows the corresponding negative controls and the last column shows the corresponding 
positive controls which are testis tissue for MAGE-C1 and MAGE-C2, fetal liver tissue for GPC-3 and pancre-
atic cancer tissue for Annexin-A2.
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were grouped based on whether they co-expressed 0-2 tumor antigens, 3-6 tumor anti-
gens or 7-9 tumor antigens. No patients co-expressed more than 9 out of the 15 tumor 
antigens. The higher the TAA index the better the HCC-specific survival was (p=.020, 
Supplementary Figure 2). In multivariable analysis this was an independent prognostic 
factor for HCC-specific survival (Table 4).
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figure 2. Distribution of staining intensity and percentage of positive cells for MAGe-C1, MAGe-C2, 
GPC-3 and Annexin-A2. GPC-3 cancer staining (A), MAGE-C1 cancer staining (B), MAGE-C2 cancer staining 
(C), Annexin-A2 cancer staining (D), Annexin-A2 TFL staining (E). Intensity 1=weak; 2=moderate; 3=strong.
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Co-expression patterns of MAGe-C1, MAGe-C2, GPC-3 and Annexin-A2
Further analysis was performed on the 4 antigens with the greatest differences in 
expression between tumor and TFL tissue, namely MAGE-C1, MAGE-C2, GPC-3 and 
Annexin-A2. Expression of at least 1 of these antigens was observed in tumor tissues of 
95% of patients, while 48% of patients expressed only 1 antigen, 30% expressed 2 anti-
gens, 11% expressed 3 antigens and 6% expressed 4 antigens (Figure 4a). Co-expression 
of these antigens in individual patients is shown in Figure 4b. Ninety-two percent of 
patients express, individually, or in combination, Annexin-A2 and GPC-3. Of the patients 
that do not express Annexin-A2 or GPC-3, 3% express both MAGE-C1 or MAGE-C2. In 
11% of patients MAGE-C1 and MAGE-C2 add a second tumor antigen to patients that 
otherwise express only 1 antigen, either GPC-3 or Annexin-A2. Finally, in 10% of pa-
tients MAGE-C1 and MAGE-C2 add a third antigen to patients that co-express GPC-3 
and Annexin-A2. Interestingly, MAGE-C1 and MAGE-C2 are significantly and strongly 
co-expressed in tumors of our HCC patients (p<.001, Pearson’s correlation coefficient = 
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figure 3. Antigen expression based on hepatitis B status. * = p<0.05.
Table 4. Cox proportional Hazard regression analysis of patients’ overall survival
Variables
Univariate Multivariate
HR 95% CI p-value HR 95% CI p-value
AFP >400 ug/l 2.867 1.176-6.992 .021 2.682 0.947-7.601 .063
>3 vs ≤3 lesions 4.438 1.594-12.353 .004 3.771 1.276-11.141 .016
TAA index 0-2 vs 3-6 antigens 0.266 0.076-0.925 .042 0.238 0.062-0.909 .033
0-2 vs 7-9 antigens 0.070 0.007-0.711 0.048 0.004-0.557
High H-score for both GPC-3 and SALL-4 3.119 1.154-8.430 .025 3.674 1.120-12.055 .032
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.68). This panel of 4 antigens also covers tumors of most HBV-negative patients (95%), 
of which 52% expressed 1 antigen, 29% expressed 2 antigens, 9% 3 antigens and 5% 4 
antigens. Together, these data show that this panel of 4 tumor antigens may be suitable 
for vaccination studies in HCC patients in western low-endemic areas.
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figure 4. Co-expression of MAGe-C1, MAGe-C2, GPC-3 and Annexin-A2 antigens. Distribution of total 
number of antigens expressed in the tumors of HCC-patients (A). Heat-map representation of 133 indi-
vidual patients with expression of each antigen per patient (B).
expression of sALL-4 and co-expression with GPC-3
SALL-4 is a transcription factor involved in the maintenance of embryonic and cancer 
stem cells (Zeng et al., 2014) and has recently been shown to be expressed in an HCC 
subtype with stem-cell like features associated with poor prognosis (Oikawa et al., 2013; 
Yong et al., 2013b; Zeng et al., 2014). In our study SALL-4 nuclear expression was seen 
in 26% of tumors and in none (0%) of the TFL samples. Like in previous studies (Zeng et 
al., 2014), SALL-4 was more frequently expressed in tumors of patients with HBV infec-
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tion (40% vs 22%, p=.05) and its expression was correlated with poor differentiation 
(p=.002) and higher AFP levels before surgery (p=.007), while there was a trend towards 
correlation with vascular invasion (p=.081). Interestingly, there was a significant correla-
tion between SALL-4 expression and GPC-3 expression (p=.001, Pearson’s correlation 
coefficient =.29, Figure 5). While neither SALL-4 or GPC-3 were individually associated 
with HCC-specific survival, there was a trend towards worse HCC-specific survival in 
patients co-expressing both GPC-3 and SALL-4 (p= .190, Supplementary Figure 3a). In 
addition, when the strength of the staining was taken into consideration in the form 
of the H-score (intensity x % of positive cells) patients who co-expressed high levels of 
both SALL-4 (H-score>2) and GPC-3 (H-score>3) had a significantly worse HCC-specific 
survival (p= .018, Supplementary Figure 3b). This was an independent prognostic factor 
in multivariate analysis (Table 4).
GPC-3 SALL-4 negative control
p=.001 
Pearson's 
coeﬃcient = .29 
SALL-4 
− + Total 
GPC-3 
− 68 (51.1%) 
13 
(9.8%) 81 
+ 30 (22.5%) 
22 
(16.5%) 52 
Total 98 35 133 
A
B
figure 5. Co-expression of GPC-3 and sALL-4. Representative case co-expressing GPC-3 and SALL-4 (A). 
2x2 table of expression status of GPC-3 and SALL-4 in the entire cohort (B).
relationship of individual tumor antigen expression to known prognostic 
markers
Of all the tumor antigens tested, GPC-3 was the one most strongly associated with 
known prognostic factors. Specifically, GPC-3 was associated with poor tumor differ-
entiation (p=.004), the presence of vascular invasion (p=.002), and higher AFP before 
resection (p=.03).
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DIsCussIon
The aim of this study was to identify a panel of tumor antigens suited for immunothera-
peutic approaches, such as vaccination, for HCC in western-European, low-endemic 
areas, where HBV infection is not the main etiology of HCC and where the diagnosis is 
often made in non-cirrhotic livers (Verhoef et al., 2004; Witjes et al., 2012). In our cohort, 
only 23% of patients were HBV positive, 14% HCV-positive and 48% had no liver cirrho-
sis. In addition 77.4% of our patients are of western-European decent. Supplementary 
Table 1 describes the hepatitis-B status of patients per patient region of origin. Groups 
other that western-European are too small for subgroup analysis of antigen expression.
The observed prevalence of expression of testis and oncofetal antigens was generally 
lower than previous studies reported. Most of these prior studies have been conducted 
in East Asia where HBV infection is the most prevalent cause of HCC and the majority 
of HCC patients have liver cirrhosis. For example, a previous East Asian study reported 
that 36% of patients expressed MAGE-C1 (Xia et al., 2013), while we found only 17% ex-
pression. Supporting the association between cancer testis antigens and HBV infection, 
we found increased prevalence of MAGE-A1, MAGE-A3/4, and MAGE-C1 expression in 
HBV-positive patients. The prevalence of MAGE-C1 expression in HCC tissues in our HBV 
positive patients was similar to that reported by Xia et. al. (32% in HBV positive versus 
13% in HBV negative patients). The only other large western study that has examined 
several of these antigens by immunohistochemistry is by Riener et. al.(Riener et al., 
2009) who studied 146 HCC patients from Switzerland, of which only 12% had HBV. In 
that study MAGE-C1 expression was found expressed in 12% of patients, NY-ESO-1 in 2% 
and MAGE-A3/4 in 0%, results which are similar to our findings. Likewise, expression of 
the oncofetal protein GPC-3 was found in 61-84% of patients in four Asian studies with 
HBV positivity ranging between 25-85% (Liang et al., 2013; Shirakawa et al., 2009; Yan et 
al., 2011; Yorita et al., 2011), and all these studies showed evidence of increased GPC-3 
expression in the HBV positive patients compared to the HBV negative patients. In our 
study GPC-3 expression was found in 39% of all patients but in 48% of HBV-positive 
patients.
Another explanation for the relatively low prevalence of tumor antigen expression 
observed in our study is that many prior studies have used RT-PCR measuring mRNA 
expression (Chen et al., 2001; Luo et al., 2002; Peng et al., 2005b), while we have 
measured protein expression by immunohistochemistry. In fact, large discrepancies 
between tumor antigen expression in HCC by RT-PCR and immunohistochemistry have 
been reported. For example, Nakamura et. al.(Nakamura et al., 2006) found 18/41 of HCC 
samples (43%) expressing NY-ESO-1 by RT-PCR while only 3 (7%) expressed the protein. 
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It is likely that protein expression rather than RNA expression is a reliable predictor of 
suitability of tumor antigens for vaccination studies.
While the absence of MUC-1 expression in HCC is in agreement with previous work (Cao 
et al., 1999), the absence of SSX-2 in our study (0%) is in contrast to the study by Liang 
J et. al.(Liang et al., 2013) where a prevalence of 75% was reported. The use of different 
antibody clones may be one explanation. Clone 4D10, used in the Liang J at. al. study, 
was not tested in TFL samples to examine tumor specificity. In addition, two studies 
(Luo et al., 2002; Wu et al., 2006) using RT-PCR have shown expression in 2/21 and 13/36 
HCC-patients respectively, indicating that it is unlikely that the true protein expression 
level of SSX-2 in HCC is very high. Finally, despite the lack of staining in tumor or TFL 
tissue, antibody clone E3AS, which we used, showed proper staining of positive control 
seminiferous duct cells in testis tissue (Supp. Figure 1).
AFP was found to be expressed in few HCC samples (7%) in our study. While an incidence 
as low as 2% has been reported (Ferrandez-Izquierdo & Llombart-Bosch, 1987) most 
studies show expression of AFP in around 17-50% of HCC tumors (Brumm et al., 1989; 
Ganjei et al., 1988; Lau et al., 2002; Minervini et al., 1997; Tsuji et al., 1999). To ensure 
accuracy of AFP staining in our study AFP expression was determined twice, under clini-
cal laboratory conditions (automated BenchMark ULTRA™ instrument), which yielded 
identical results. On further examination AFP expression was strongly correlated with 
serum AFP level before resection (p<.001). Of the patients with a serum AFP >400 ug/l 
29% expressed AFP in their tumors versus only 3% in patients with a serum AFP <400ug/l 
(p=.001). This correlation of AFP serum levels with tumor AFP expression has been dem-
onstrated before (Li et al., 2011). In our cohort, however, only 17% of our patients had an 
AFP value above 400ug/l. Thus, one possible explanation for the low incidence of AFP 
staining is the relative low number of patients with high serum AFP levels. Indeed, most 
contemporary series report high AFP serum levels (> 400ug/l) in 27 to 45% of patients 
undergoing resection (Liu et al., 2014; Ma et al., 2013; Wang et al., 2009).
While MDK, SP17, WT-1 and Survivin were expressed in the majority of tumors, we ob-
served similar expression in adjacent TFL tissues, suggesting they might be unsuitable 
for vaccination studies in HCC due to lack of tumor-tissue specificity. Indeed these 4 
antigens have been shown to be expressed in tissues other than cancer (Deguchi et 
al., 2002; Kannangai et al., 2005; Monma et al., 2013; Scharnhorst et al., 2001), or other 
than cancer and testis in the case of SP17 (Frayne & Hall, 2002; Lacy & Sanderson, 2001). 
Although in some reports the expression of MDK, SP17 and WT-1 has been shown to be 
lower in TFL tissue than in HCC tissue (Koide et al., 1999; Sera et al., 2008; Xia et al., 2013; 
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Zhu et al., 2013), in the case of Survivin another report corroborates the equal or higher 
TFL, compared to tumor, expression (Chau et al., 2007).
It has been previously shown by Liang et.al. (Liang et al., 2013), that the higher the num-
ber of tumor antigens expressed by a given tumor the better the survival is. The hypoth-
esis is that the higher the number of tumor antigens present the more the immunologic 
targets available to the immune system. In our study, in agreement with Liang et.al., we 
show that the higher the number of tumor antigens present in a given tumor the better 
the HCC-specific mortality is (table 4, Supplementary Figure 2). While our findings are 
supportive of the above hypothesis, further validation and experimentation is necessary 
to prove the concept.
Therapeutic vaccination with a panel of tumor antigens, as opposed to a single antigen, 
would have the advantage of better coverage of the target tumor cell population as 
well as covering patients who express different antigens in their tumors. The panel that 
we selected (MAGE-C1, MAGE-C2, GPC-3, Annexin-A2) covers 95% of patients, with 
nearly 50% of them expressing at least 2 antigens. In addition, since in many patients 
expression of each individual antigen is limited to only 5-25% of tumor cells (Figure 2), 
targeting multiple antigens per patient may be needed to realize a successful clinical 
outcome. In addition, our antigen panel lacks, for the most part, expression in TFL tissue, 
which is an advantage, since it may reduce unwanted side effects. Even in the case of 
Annexin-A2, where a sizable proportion of TFL samples expressed the antigen (37%), 
the level of expression was much lower than that in the corresponding tumor samples 
(Figure 2D and E).
Biologically, GPC-3, a heparin sulfate proteoglycan expressed during embryogenesis, 
has been shown to be a poor prognostic factor in multiple studies (Liang et al., 2013; Shi-
rakawa et al., 2009; Yan et al., 2011; Yorita et al., 2011). We confirm that GPC-3 expression 
is associated with higher serum AFP level (Liang et al., 2013; Yorita et al., 2011), worse 
tumor differentiation (Shirakawa et al., 2009; Yan et al., 2011; Yorita et al., 2011), and the 
presence of vascular invasion (Yorita et al., 2011). The immunogenicity of GPC-3 has been 
well demonstrated, and a phase I clinical cancer vaccine trial has already demonstrated 
tolerability and biologic efficacy (Sawada et al., 2012). In addition, gene expression pro-
filing has shown that GPC-3 is significantly overexpressed in CD90+ HCC stem cells (Ho 
et al., 2012), suggesting that targeting GPC-3 may enable eradication of the tumor stem 
cell compartment. Our newly reported association of GPC-3 with SALL-4 strengthens the 
notion that GPC-3 is involved in stem cell biology in HCC. In fact, we show that patients 
who co-express high levels of both GPC-3 and SALL-4 have worse HCC-specific survival 
(Supplementary Figure 3b), indicating that the co-expression is biologically significant. 
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However, it should be noted that strong co-expression is a relatively infrequent event 
occurring in 7.5% of patients. While other studies (Yan et al., 2011; Yong et al., 2013a) 
have shown worse overall survival for patients expressing individually GPC-3 or SALL-4 
we did not show such an association. This is likely due to the fact that our study is smaller 
in size and was not designed to test the presence of biomarkers in HCC. In fact, when 
considering patients with higher GPC-3 staining, or patients with higher SALL-4 staining, 
statistical trends towards worse HCC-specific survival are apparent and consistent with 
the smaller size of our cohort (Supplementary Figures 3c, 3d). Finally, although both 
GPC-3 and SALL-4 are considered possible therapeutic targets in HCC (Filmus & Capurro, 
2013; Yakaboski et al., 2014), information on immunogenicity of SALL-4 is lacking. There-
fore, further research on immunogenicity of SALL-4 is needed before we can suggest to 
include SALL-4 in a therapeutic vaccine.
Annexin-A2, a calcium dependent phospholipid binding protein, is involved in mem-
brane formation, exocytosis and interaction with the extracellular matrix (Gerke & Moss, 
2002). It is overexpressed in HCC (Mohammad et al., 2008; Yu et al., 2007) and multiple 
other cancers (Zhang et al., 2012), is involved in invasion and metastasis (Zhao et al., 
2010), and immunogenicity has been demonstrated (Liu et al., 2011; Zheng & Jaffee, 
2012). Our results are in agreement with Liu et. al.(Liu et al., 2013) in that Annexin-A2 
is expressed in the majority of patients with HCC and expression is significantly more 
pronounced in the tumor cells as compared to the surrounding TFL tissue. Our study is 
one of the very few to examine the protein level expression of Annexin-A2 in a “western” 
cohort. Longerich et. al.(Longerich et al., 2011) demonstrated Annexin-A2 expression 
in HCC in a small western European patient cohort, but did not study expression in TFL 
tissue.
MAGE-C1 and MAGE-C2 are involved in embryogenesis, their expression is known to 
be reactivated in various cancers, and they are known immunogens (Li et al., 2004). The 
strong co-expression between MAGE-C1 and MAGE-C2 was not surprising since the 2 
genes are located close to each other on chromosome X (q27) and are likely translated 
together. However, despite their strong co-expression, a little less than half of positive 
cases expressed either one of the 2 antigens alone indicating a potential value in includ-
ing both of these antigens in a tumor vaccine.
In conclusion, we show that there are etiological differences in tumor antigen expres-
sion in HCC. In addition, we describe a panel of 4 antigens, MAGE-C1, MAGE-C2, GPC-3 
and Anexxin-A2, which combine several favorable characteristics for future vaccination 
studies in patients in western low-endemic areas, such as combined coverage for the 
majority of patients, as well as tumor specificity. Finally, we demonstrate for the first 
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time a relationship between GPC-3 and SALL-4 expression, which further substantiates 
that targeting GPC-3 may enable eradication of the HCC tumor stem-cell compartment.
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supplementary figures
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supplementary figure  1. representative stainings for tumor tissue, TfL tissue, negative control 
and positive control for all antigens. The positive control tissues are: Testis tissue for the testis antigens 
(MAGE-A1, MAGE-A3/4, MAGE-A10, NYESO-1, SP-17 and SSX-2), liver cancer tissue for MDK, renal glomeruli 
for WT-1, stomach tissue for Survivin and MUC-1, and placenta tissue for AFP.
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supplementary figure 1 (continued). representative stainings for tumor tissue, TfL tissue, negative 
control and positive control for all antigens. The positive control tissues are: Testis tissue for the testis 
antigens (MAGE-A1, MAGE-A3/4, MAGE-A10, NYESO-1, SP-17 and SSX-2), liver cancer tissue for MDK, renal 
glomeruli for WT-1, stomach tissue for Survivin and MUC-1, and placenta tissue for AFP.
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supplementary figure 2. TAA index and HCC specific survival
p=.018
GPC-3 and/or SALL-4 low
GPC-3 AND SALL-4 high
p=.108
NOT coexpressed
Coexpressed
p=.190
p=.132
A B
C D
Co-expression of GPC-3 and SALL-4 High H-score for both GPC-3 and SALL-4 
High vs low H-score for GPC-3 alone High vs low H-score for SALL-4 alone
supplementary figure 3. Analysis of GPC-3 and sALL-4 co-expression for survival.
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supplementary Tables
supplementary Table 1. Patient region of origin and hepatitis-B status
Region of origin Frequency Percent% Hepatitis-B prevalence in 
our HCC cohort
Hepatitis-B population 
prevalence per CDC1
Western European 103 77.4 10/103 (9.7%) Low (<2%)
Eastern European 3 2.3 0/3 (0%)
Intermediate
 (2%-4%)
Suriname 7 5.3 7/7 (100%)
Middle Eastern 8 6.0 4/8 (50%)
Sub-Sahara African 3 2.3 1/3 (33%)
High (>5%)
South-East Asian 9 6.8 8/9 (89%)
1Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates 
of age-specific seroprevalence and endemicity. Vaccine. 2012.30(12):2212–9.
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GenerAL DIsCussIon
Interest in the immune system’s relationship to cancer has skyrocketed ever since treat-
ments specifically aimed at manipulation of the immune system have entered clinical 
practice. The most successful of these treatments, namely the immune checkpoint 
inhibitors, are producing impressive results in several cancers (1-5). However, biomark-
ers that predict their efficacy are lacking. The current thesis is primarily concerned with 
examining the role of multiple different molecules as immune specific biomarkers in 
gastrointestinal cancers. To better understand the potential role of these biomarkers we 
have examined their protein expression in tumor tissues in Hepatocellular Carcinoma 
(HCC), Pancreatic cancer and Ampullary cancer, using tissue microarrays (Chapters 3, 4), 
as well as measured the circulating levels of two of these molecules in HCC (Chapter 7). In 
addition, we have investigated the prognostic value of Tumor Infiltrating Lymphocytes 
(TIL) in Colorectal Cancer Liver Metastasis (CRCLM) using full slides, enabling us to get 
a more global view of the tumor microenvironment (Chapter 5). Finally, in the process, 
we have studied expression of an important tumor antigen panel as potential vaccina-
tion targets in HCC (Chapter 8). However, several points regarding this thesis need to be 
reflected upon further.
Tumor infiltrating lymphocytes: importance of location and quality of infiltrate
Lymphocytic infiltration of tumors was first noted by Virchow in 1863 (6). However, it 
was only recently that tumor tissue from large cohorts of patients with cancer has been 
systematically examined for TILs. Some of the first breakthroughs came, interestingly, in 
primary colorectal cancer, where several large cohorts of patients showed that the more 
TILs present at the tumor site the better the survival of patients with colorectal cancer 
is (7-10). This same observation has been made in several other cancers (11). However, 
generic lymphocytic infiltration, while consistently prognostic, has not yet made it to 
clinical practice as a clinically useful biomarker. The reasons are several. First, TIL loca-
tion is important. In a study by Galon et.al. (12), for example, it was shown that it is 
primarily the TILs at the invasive end of the tumor that are prognostically important. 
This may make sense, since it is at the invasive front of the tumor (the side where the 
tumor invades the bowel wall) that perhaps the immune system is putting up most of 
the fight against the cancer. Another important factor is the types of cells that constitute 
TILs. Simply looking at the generic amount of the lymphocytic infiltrate is not enough 
to produce clinically useful biomarkers. More specificity may come from looking at the 
quality, rather than the quantity, of the infiltrate such as the relative ratio of effector 
to regulatory cells. Both of these important factors, location and quality, need to be 
systematically addressed in all future studies concerning TILs in cancer.
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In this thesis we consistently show that TILs are important in the cancer types we studied. 
We found that high CD8+ TILs are associated with better cancer survival in HCC (Chapter 
3) and high CD8+/FoxP3+ TIL ratio is associated with better cancer survival in pancre-
atic, ampullary and colorectal cancers (Chapters 4-5). Regarding the issue of location, 
some special considerations should be discussed regarding our observations. TILs were 
studied using three 0.6mm TMA cores in HCC and five 1mm TMA cores in pancreatic 
and ampullary cancers. TMA cores capture, by design, the intratumoral environment of a 
tumor. Thus, our results for HCC, pancreas and ampullary cancers cannot be generalized 
to lymphocytes present outside the tumors. But what about the difference between TILs 
at the invasive front and the center of the tumor, as has been distinguished for colorec-
tal cancer in the study by Galon et.al. (12)? Unlike primary colorectal cancer, where an 
invasive front can be anatomically identified, such invasive fronts are not systematically 
present in HCC, pancreatic and ampullary cancers, or CRCLMs. HCC and CRCLM lesions 
are generally symmetrical and don’t have a “leading edge”. Pancreatic and ampullary 
cancers are associated with large amounts of fibrosis and it is frequently challenging 
to identify viable cancer cells, let alone distinguish an invasive front. However, in the 
design of our studies, we have avoided including necrotic areas and have, therefore, 
collected TMA cores from areas with viable cancer cells that are as close to the edge 
of the tumor as possible, without risking cutting through the peri-tumoral areas. It is 
unlikely to be able to improve the issue of “tumor location” further in HCC, pancreas and 
ampullary cancers and CRCLM.
To further understand the issue of tumor location we used full slides to study CRCLM. 
The fact that we show that it is the intra-tumoral TILs, and not the peri-tumoral TILs, 
that are prognostically significant makes sense and provides evidence to strengthen the 
hypothesis that it is not the amount of lymphocytes that are attracted to the tumor that 
are important but the lymphocytes that are able to enter the tumor itself that make the 
difference. It can also explain why studies in CRCLM, using TMAs, have reached similar 
conclusions to our study (13). TMA cores represent the areas in the tumor microenviron-
ment that are most important; namely the intra-tumoral area.
Regarding the quality of the infiltrate, we have studied both the presence and propor-
tion of effector lymphocytes (CD8+) and regulatory lymphocytes (FoxP3+). Many studies 
have failed to do so, focusing either on the effector side (7-9, 14), or never comparing the 
relative presence of effector to regulatory lymphocytes (10, 15-17). In fact, we show both 
in pancreatic and ampullary cancers, as well as in CRCLM, that it is the ratio of effector to 
regulatory cells, and not the individual cell types, that are the most prognostic (Chapters 
4 and 5). A large immune infiltrate may not be helpful if a large percentage of Treg cells 
are present. A smaller amount of effector T-cells, in the relative absence of Treg cells, 
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may be more effective. In fact our lab has shown convincingly that this proportion is 
important in vitro (18). It is of interest, however, that we were not able to study the pres-
ence of FoxP3+ cells in HCC. FoxP3 staining produced too few positive cells in out TMA 
cores (Figure 1). In fact, only 4% of cases were found to have > 5 FoxP3+ cells per core 
and in the vast majority of cases no FoxP3 positive cells were seen. However, FoxP3+ cells 
were clearly identified in the peri-tumoral infiltrate and in the positive control tissues 
(Figure 1). Two reasons may account for this observation. First, FoxP3+ cells are not very 
abundant in HCC tumors. Second, larger cores are required to study FoxP3+ cells in HCC. 
We had no trouble of studying FoxP3+ cells, for example, in pancreatic and ampullary 
cancer where five 1mm cores were used (the equivalent of 16.5 high powered fields). In 
future immunohistochemical HCC studies this issue should be taken into consideration.
Differences with prior studies: attention to antibody quality
Given that immune checkpoint inhibitors targeting the PD-1 and PD-L1 axis have 
already been approved (1-5) it is of no surprise that issues regarding PD-L1 generate 
the most attention. Thus, when in both our studies in HCC (Chapter 3) and pancreatic 
and ampullary cancers (Chapter 4) we found results opposite to previously published 
literature there was added interest to properly and thoroughly validate our results. Spe-
cifically, while we found that low PD-L1 is associated with poor prognosis, prior studies 
in both HCC (19) and pancreatic cancer (20) had suggested the opposite. One of our 
main arguments regarding the differences in results rests on differences in the antibody 
clone used. While at first this may sound a somewhat simplistic argument, when closely 
looking at the evidence the issue of antibody validation becomes extremely important.
A popular PD-L1 antibody clone used for immunohistochemistry in the past was MIH1. 
In fact, all prior studies in HCC (19) and pancreatic cancer (20) have used this specific 
antibody clone. However, in two prior studies, the specificity of this clone for PD-L1 
immunohistochemistry on formalin-fixed paraffin-embedded (FFPE) tissues has been 
questioned. For example, in the study by Valcheti et.al. (21), the authors tested 4 differ-
ent PD-L1 antibodies for immunohistochemistry including the MIH1 clone. They found 
that the MIH1 clone failed to show the proper expected staining pattern in placenta 
tissue (that is staining in the trophoblastic cells of human placenta but absence of stain-
ing in the mesenchymal stromal cells and vessels of the chorionic villi). In the study 
by Gadiot et.al. (22), where again multiple PD-L1 antibodies were tested for immuno-
histochemistry, the MIH1 clone failed to properly stain human tonsil tissue. Therefore, 
eBioscience does not recommend this anti-PDL1 antibody for immunohistochemistry 
on FFPE tissues.
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To further ensure that this was the case we did two things. First we stained human FFPE 
placenta tissue and human FFPE tonsil tissue with the MIH1 antibody and compared this 
to the staining of the validated antibody we have used (clone 405.9A11). We found that, 
while the 405.9A11 clone selectively stains trophoblastic cells in human placenta tissue 
and cells around the crypts of tonsil tissue, similar to what has been shown by Lyford-
Pike et al (23), the MIH1 antibody, in agreement with the studies by Valcheti et.al., and 
Gadiot et.al., did not stain these control tissues properly (photographs shown in Chapter 
Figure 1
Various FoxP3 positive control tonsil tissues showing strong FoxP3 staining in selected cells
Typical tumor cores with complete absence of FoxP3 staining. 
This patern accounted for the vast majority of tumor cores.
Tumor cores with 5 or more FoxP3 positive cells. These cores accounted for less than 4% of cases
in the periphery of the tumor and thus not captured by the vast majority of TMA cores.
figure 1. 
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3, Supplementary Figure 5). Second, we used the MIH1 antibody to stain HCC TMA cores, 
and compare the results to our stainings of the TMA cores with the 405.9A11 clone. In 
order to compare the two antibody clones, we first focused on tumor cores that did not 
express PD-L1 upon staining with the 405.9A11 clone. From the 6 cases that showed 
no staining with the 405.9A11 clone all but one showed considerable staining with the 
MIH1 clone (Chapter 3, Supplementary Figure 5). In addition, all other cases that showed 
any level of staining with the 405.9A11 clone, also showed staining with the MIH1 clone 
(pictures not shown).
The fact that our negative cases are mis-characterized as positive by the MIH1 clone can 
by itself explain the differences between ours and the prior studies. The MIH1 clone lacks 
specificity for PD-L1 in FFPE tissues and the observation that the cases with lack of PD-
L1 staining have the worse prognosis cannot be made using the MIH1 clone. Issues of 
antibody specificity and validation are of the outmost importance for developing future 
immune biomarkers against cancer.
A similar situation exists regarding antibodies used in prior studies for HLA-G. The three 
prior studies on HLA-G expression in pancreatic cancer have issues with antibody qual-
ity. One study has used clone 4H84 (24), which has been shown to clearly be non-specific 
for HLA-G in multiple studies (25, 26), another study used a polyclonal antibody (27) and 
a third study did not provide details on the antibody used (28). In addition, none of the 
above studies provided photographs with positive control stainings for their antibodies. 
Issues of study quality could explain differences in results between different studies.
Intratumoral expression of immune inhibitory molecules: adaptive immune 
resistance at work?
There is a general agreement in our findings that lack of expression, or low expression, 
of immune inhibitory molecules is associated with poor cancer survival. This was shown 
for PD-L1, Gal-9 and HVEM in HCC (Chapter 3) and for PD-L1, Gal-9, HVEM and HLA-G in 
pancreatic and ampulary cancers (Chapter 4). The same observation has been made in 
several other cancers. For example, in the case of PD-L1, low expression of PD-L1 was 
found to be associated with poor survival in melanoma (29), gastrointestinal-stromal 
tumors (30), colorectal cancer (31) and non-small cell lung cancer (21). The above results 
are consistent with the adaptive immune resistance hypothesis that states that expres-
sion of immune inhibitory molecules is secondary to an active immune system and thus 
signifies an effective anti-tumor attack (29). Further supporting this hypothesis, in vari-
ous cancers, are observations of PD-L1 overexpression in response to immune infiltrate 
(29) and IFN-γ (32, 33), as well as overexpression of PD-L1, IDO and T-regulatory cells in 
response to CD8 T-cell infiltration (34). Looking closer in our studies, the positive correla-
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tion between PD-L1 and numbers of CD8+ TILs in both HCC (Chapter 3) and pancreatic 
and ampulary cancers (Chapter 4) is consistent with the hypothesis that enhanced ex-
pression of immune inhibitory molecules by tumor cells may reflect adaptive immune 
resistance.
Beyond adaptive immune resistance: other hypotheses
However, this may be only half the story. After all, immune inhibitory molecules suppose 
to “inhibit” the immune system, and not always signify a positive association to survival. 
In fact, several studies, in various cancers, have shown opposite results. For example, 
poor survival has been associated with over-expression of PD-L1 in melanoma (35), 
colorectal cancer (36) and renal cell cancer (37). It is known that cancers can induce an 
immunosuppressive tumor microenvironment by recruitment of immunosuppressive 
cells such as T-regulatory cells (Tregs), Myeloid Derived Suppressor Cells and Tumor 
Associated Macrophages and secretion of anti-inflammatory cytokines, such as TGF-β 
and IL-10. In addition, cancers can express a variety of immune inhibitory ligands, such 
as the molecules under study in the current thesis, but also others. Together, this im-
munosuppressive tumor microenvironment leads to the inactivation of the host anti-
tumor immuno-surveillance system, as well as reduction of immunogenicity of cancer 
cells, leading to immune privilege of cancer cells. These factors may potentially explain 
findings linking high expression of PD-L1, and other immunosuppressive molecules, to 
poor prognosis.
Yet, additional studies, show no prognostic significance of PD-L1 in various cancers 
(22, 38-40). Indeed, especially regarding PD-L1, there is a current controversy: “how 
can expression of PD-L1, an immunosuppressive molecule, be associated with both a 
good and a poor cancer prognosis, over several studies and cancer types”? While differ-
ences in technique, such as validity of the antibody clone used, measuring expression 
specifically in cancer cells versus the tumor micro-environment, as well as differences 
in patient cohorts (cancer type, early vs late stage of disease, completeness of patient 
follow up) may explain some of the differences, it likely does not explain everything. 
Instead, it is likely that the relationship of tumor microenvironment immune biomarkers 
and prognosis is not linear. Other immunologic factors come into play.
The answer may be that looking at individual immune inhibitory molecules, one at a 
time, may be too narrow. The wider context needs to be taken into consideration, before 
the prognostic role of these molecules can be discerned. For example PD-L1 is likely 
best viewed in the context of the immune infiltrate, and not by itself. Expression of PD-
L1 in the context of an active immune infiltrate is likely to indicate adaptive immune 
resistance (PD-L1 expressed by cancer cells in response to the immune infiltrate), as has 
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been demonstrated before in melanoma (29) and recently in HCC (41). On the other 
hand, the absence of PD-L1 in a setting of an immune infiltrate could indicate immune 
tolerance to the tumor or the presence of molecular suppressors of PD-L1. Similarly, ab-
sence of PD-L1 staining in the context of an absent, or inactive, immune infiltrate is likely 
to indicate immune ignorance (the immune system is “unaware” of the cancer). Finally, 
high expression of PD-L1 in the absence of an immune infiltrate can signify intrinsic 
induction of PD-L1, secondary, for example, to chromosomal amplification (42) (and 
thus unrelated to an immune infiltrate). Such a contextual model for PD-L1 expression 
has already been suggested by Teng MW et.al (43). Since the findings in this thesis can 
only be partially explained by the adaptive immune resistance hypothesis, other factors 
are likely playing an important role on a patient to patient basis.
A similar argument can be made by looking at the presence of Tregs. Despite the fact 
that Tregs are clearly immunosuppressive, their presence does not necessarily, by itself, 
signify a poor prognosis. In our study in pancreas and ambulatory cancers (Chapter 4) 
elevated numbers of FoxP3+  cells were associated with good prognosis. This has been 
shown before, as for example in the large study (967 stage II and stage III colorectal can-
cers) by Salama et. al., (10). It is likely that the number of FoxP3+ cells is more important in 
the context of the total immune infiltrate (you need an immune infiltrate to have FoxP3+ 
cells after all). So both a very high absolute number of FoxP3+ cells (dominating and 
suppressing the immune infiltrate), as well as a very low absolute number of FoxP3+ cells 
(associated with a small immune infiltrate, indicating reduced immunogenicity and 
absence of immune surveillance) may be associated with poor prognosis.
Basically, the prognostic role of immune-regulatory molecules, such as PD-L1, or the 
prognostic role of the immune infiltrate, can be influenced by the relative proportions 
of multiple tumor microenvironment factors, which may in turn depend on the cancer 
subtype, the cancer stage (very early, vs advanced, vs metastatic), and/or prior treat-
ments. This could account for discrepancies between studies. But also it could account 
for the inability of individual immune molecules to serve as important biomarkers. In 
fact, our approach to examine the prognosticating role of PD-L1 in HCC, pancreatic 
and ampullary cancers, in the context of the quality of the immune infiltrate (CD8+ and 
FoxP3+ cells), as well as other immune molecules (Gal-9, HVEM, HLA-G), is justified con-
sidering the above. We show that combining multiple individual potential biomarkers 
can lead to more useful cancer immune biomarkers (Chapters 3 and 4).
At this point it is important to bring into focus our findings on the Tumor Associated 
Antigen Index (TAA index) in HCC (Chapter 8). TAA index is a direct representation of the 
number of TAA expressed by a given cancer. A high TAA index (more TAA expressed) has 
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previously been found to be associated with a better survival in HCC (44). We found simi-
lar findings using a broader panel of TAAs in HCC (Chapter 8). We showed that patients 
who express 7 or more TAAs have a significantly better prognosis than patients who 
expressed 2 or fewer TAAs (Chapter 8, Supplementary Figure 2). One may hypothesize 
that patients who express few TAAs exhibit a form of immune ignorance. If that is true 
then one would expect tumors with fewer expressed TAAs to have fewer TILs and tumors 
with high TAA index to have more TILs. In the subsequent unpublished table from our 
study, we see that indeed there is a relationship between CD8+ TIL and TAA index in HCC 
in the direction we hypothesize.
Crosstabs analysis of CD8+ cells in relation to TAA index in HCC
Mantel-Haenszel test 
of trend p=.048
CD8+ TILs/core
TAA index <100 >100 % Total
0-2 7 0 0% 7
3-6 93 13 12% 106
7-9 10 4 29% 14
Total 110 17 127
Tempting as it may be, however, it should be noted that causation cannot be established 
from this association. It is unclear if the expressed TAAs are due to the presence of TILs or 
vice-versa. The regulation of expression and immunogenicity of many TAAs, such as the 
testis antigens, have not been well studied at the moment. Thus, while it is possible that 
TAA expression is also related to the phenomena discussed above, one needs to wait 
until more is known on the function of many of the molecules involved before specific 
inferences can be made. One first step, for example, would be to examine if HCC cell lines 
express testis tumor antigens when exposed to T-cell derived cytokines such as IFN-γ, or 
are co-cultured with tumor isolated effector T-cells.
Beyond PD-L1: The argument for using multiple biomarker panels
To date the only immune biomarker available for prediction of effect of immunothera-
peutic agents is tumor tissue immunohistochemical evaluation of PD-L1 (45, 46). While 
the current thesis focuses on the development of prognostic biomarkers, these same 
biomarkers could in the future become predictive biomarkers to different immunothera-
peutic strategies. In addition, the pitfalls regarding the use of PD-L1 IHC as a predicative 
biomarker are instructive and can be generalized to other settings. There are several 
reasons that PD-L1 IHC, by itself, is far from an ideal biomarker at the moment. We will 
focus on differences between antibody clones, the differences between membranous 
and cytoplasmatic staining and the poor predictive biomarker ability of these assay.
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The currently available diagnostic immunohistochemistry assays, generally, accompany 
treatment with immune checkpoint inhibitors targeting the PD-1/PD-L1 axis. Higher 
expression of PD-L1 is associated, in all cases, with improved response to these immune 
checkpoint inhibitors. However, different antibodies are used in companion diagnostic 
assays for immunohistochemical evaluation of tumor PD-L1 expression delivered by 
pharmaceutical companies with different PD-L1/PD-1 immune checkpoint inhibitors 
(47). Treatment with Nivolumab is accompanied with a companion kit using PD-L1 
antibody clone 28-8, treatment with Pembrolizumab with clone 22C3, treatment with 
Atezolizumab with clone SP142 and treatment with Durvalumab with clone SP263. The 
reason for the difference is that the companies developing and testing the individual 
drugs also developed their own companion biomarker tests. Going beyond these com-
panion tests there are several other validated PD-L1 clones used in non-treatment IHC 
studies such as E1L3N, 5H1 and 9A11 (the clone used for our studies). It is of interest 
that many of the above PD-L1 clones bind the extracellular domain of PD-L1, while oth-
ers (SP142, E1L3N and 9A11) bind the intracellular domain. As a result, differences in 
results are possible when using so many different types of assays to measure the same 
molecule. In fact, each tests has, during the biomarker optimization process, acquired a 
different threshold for what constitutes positive PD-L1 expression, ranging from 1% to 
50% positive membranous staining (47).
In addition, all the above assays measure membranous expression of PD-L1. However, 
both membranous and cytoplasmatic staining have been described, for PD-L1, in vari-
ous cancers before (29, 48-50). In fact, in HCC, pancreatic and ampullary cancers we only 
observed cytoplasmatic staining. This is despite the fact that the antibody we used 
for immunohistochemistry, namely clone 9A11, was developed specifically to bind 
the intracellular domain of PD-L1, in hopes that this would enhance the membranous 
staining pattern (51). Nevertheless, cytoplasmatic staining has been generally ignored. 
It is thought that cytoplasmatic staining is poorly reproducible between studies and 
simply interferes with the evaluation of membranous staining. However, that does not 
mean that cytoplasmic staining is of no biologic significance. One hypothesis if that 
cytoplasmatic staining represents intracellular stores of PD-L1 that are transported to 
the cellular membrane (29), or secreted as a functional soluble molecule (52), upon 
contact with or effector TILs or the presence of IFN-γ. In fact, transport of cytoplasmatic 
stores to the membrane, upon activation, has been demonstrated for another important 
immune inhibitory molecule, namely CTLA-4 (53, 54). It is not known yet if that is the 
case with PD-L1. Regardless, the fact that we consistently found, in 3 different cancers, 
that cytoplasmatic expression of PD-L1 is prognostic for survival makes a strong case 
for not ignoring cytoplasmatic PD-L1 expression, although standardization may require 
computer assisted imaging technology.
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Finally, unlike biomarkers such as EGFR, which represent the status of driver oncogenes, 
blocking the PD-1/PD-L1 axis is only one of several immune inhibiting mechanisms avail-
able to cancer. While patients without an activating EGFR mutation have no benefit, or 
even harm, from anti-EGFR therapy in lung cancer (55), patients with a negative PD-L1 
test have a 6% to 41% chance to respond to treatment targeting the PD-1/PD-L1 axis (56). 
For the development of ideal predictive biomarkers this should be reduced to near 0%.
Optimization of immunohistochemical detection of PD-L1 as a single biomarker, given 
the above issues, is highly unlikely. In addition, PD-L1 cannot represent the complete 
immunologic status of the tumor microenvironment. Thus, looking at multiple biomark-
ers simultaneously, such as PD-L1 expression in the context of the immune infiltrate, or 
other immune inhibitory molecules such as Galectin-9, HVEM or HLA-G is inevitable, if 
ideal immune biomarkers are to be developed.
Circulating immune biomarkers: a story of their own?
Cancer is known to be associated with systemic inflammation since the 19th century (6). 
It is unclear, however, if systemic inflammation is good or bad for the patient. Multiple 
observations of spontaneous regression of cancers following immunestimulation, such 
as fever and infections, indicate a positive role of inflammation in fighting cancer (57). 
However, the fact that cancer progression is frequently associated with clinical signs of 
inflammation, in addition to the well known causative role of chronic inflammation in 
cancer, indicate an averse role (58).
Previously we discussed how the quality of the immune infiltrate, at the tumor micro-
environment, is more important that the quantity of the immune infiltrate, regarding 
prognosis. Could a similar hypothesis be supported regarding systemic inflammation? 
In Chapter 6 we discuss how various inflammatory indices are associated with prognosis 
in various cancers. It is known that non-specific measures of inflammation, such as the 
c-reactive protein, is associated with poor prognosis in various cancers (59). This may be 
due to the fact that systemic inflammation is a consequence of cancer, such as recogni-
tion of tumor antigens by immune cells in a growing cancer. Since the inflammation is 
not effective against the cancer, elevated c-reactive protein or elevated neutrophil count 
are not protective against the cancer. However, an equally interesting observation is that 
low absolute lymphocyte count (ALC), is also associated with poor survival in various 
cancers (60). In fact, the strongest systemic prognostic biomarkers in cancer are ratios of 
inflammatory markers such as the neutrophil to lymphocyte ratio (NLR) (61). Here, the 
lymphocytes represent the effective side of the immune system while neutrophils rep-
resent non-specific, ineffective, inflammation. So far these immune markers represent 
laboratory tests available to all clinicians, a remarkable fact in its own right. However, 
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one may go deeper and examine different lymphocytic subsets. A high proportion of 
circulating T-regulatory cells are associated with poor prognosis in various cancers (62-
64). Thus not all lymphocytes are good, but it depends on the particular dominating 
subtype. This means that just like inflammation in the tumor microenvironment, it is 
the quality and not the quantity of systemic inflammation that is more important in 
determining prognosis, or even perhaps the ability of patients to respond to the various 
new immunotherapeutic strategies.
Regarding our cohorts we also examined the NLR as a possible prognostic marker, 
although the results are not published yet. In pancreatic and ampullary cancers a high 
NLR, before resection, is associated with worse cancer specific survival after resection 
(HR 1.89, 95%CI 1.08-3.33, p=.027). In patients with resected HCC a high NLR is associated 
with a trend towards worse HCC specific survival (HR 2.64, 95%CI 0.84-8.36, p=.098). This 
indicates that at least the NLR should be more carefully examined as a clinical biomarker 
in these diseases.
In Chapter 7 we examine the prognostic role of circulating forms of immune inhibitory 
molecules in HCC patients undergoing tumor resection or liver transplantation and 
compare their circulating levels to intratumoral expression of the same molecules, a 
novel idea. From all the immune inhibitory molecules studied in the current thesis only 
PD-L1 and Galectin-9 had quality Elisa kits available at the time. IDO metabolites have 
also previously been studied by HPLC but the expense of measuring these metabolites 
is significant. We were surprised to find out that circulating PD-L1 and Galectin-9 were 
not reflective of either the intratumoral expression or the TFL expression of these mol-
ecules. In addition, the circulating levels of PD-L1 and Galectine-9 provide independent 
prognostic information compared to their respective intra-tumoral expression. Finally, 
circulating levels could be added to intratumoral levels to improve prognostication. In 
fact, patients with both high circulating and intra-tumoral PD-L1 or Gal-9 rarely ever 
died from cancer, indicating a complementary relationship for these immune biomark-
ers. All this implies that the source and pathophysiologic role of circulating PD-L1 and 
Galectine-9 is different than their respective source and pathophysiologic role in the 
tumor microenvironment.
Regarding the source, while tumor cells express immune inhibitory molecules (as we 
have shown confidently in this thesis), other cells, such as various types of immune 
cells, and normal cells such as hepatocytes, are also known to express these molecules. 
Release of PD-L1 into the circulation has been shown to occur by various tumor cell 
lines (52), mature dendritic cells (65) and by circulating macrophages (66, 67). Regarding 
Galectine-9, while cancer cells are known to secrete this molecule by exosomes (68), the 
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fact that elevated levels have been found in various benign inflammatory liver diseases 
indicates additional sources (69-71). The pathophysiologic role of these molecules in the 
circulation is also poorly studied. However, it is known that the circulating form of PD-L1 
retains its PD-1 binding domain and immunosuppressive properties (52). Since PD-L1 
and Galectine-9 are known to be expressed in tumor cells and immune cells in response 
to inflammation (i.e. IFN-γ), it would be interesting to study if PD-L1 is also released into 
the circulation in response to effective, anti-tumor, inflammation. If so, it is likely that the 
presence of these molecules in the circulation is, at least partly, a reflection of adaptive 
immune resistance.
Tumor associated antigen expression in HCC
In Chapter 8 we do not look at the expression of immune inhibitory molecules or TILs in 
cancer but at the expression of Tumor Associated Antigens (TAAs). TAAs are important 
components for a different type of immunotherapy, namely cancer vaccination. While 
cancer vaccination is lagging behind in overall success in comparison to the immune 
checkpoint inhibitors, it was nevertheless the first immunotherapy to be approved 
against cancer (72, 73) and there are currently hundreds of cancer vaccination clinical tri-
als underway. It is very likely that in the future cancer vaccination will play an important 
role in the fight against cancer. Thus identification of TAAs is of the outmost importance. 
In Chapter 8 we show that Annexin-A2, Glypican-3, MAGE-C2 and MAGE-C1 is a panel of 
TAAs that combine the highest prevalence of expression in tumor tissues with a lack of 
expression (or in case of Annexin-A2 limited expression) in TFL tissue. This makes them 
potentially good candidates to include in tumor vaccination studies against HCC since 
they meet important criteria of what constitutes ideal tumor antigens (74). We show that 
in 95% of patients at least one of these antigens is expressed while in 47% of patients 
two or more of these antigens are expressed.
Given that single peptide vaccines have been generally unsuccessful in treating cancer, 
to date the focus of the international research community is to develop new vaccine 
strategies. One of these novel techniques is vaccination using the messenger mRNA of 
the corresponding tumor antigen. Upon injection, RNA is taken up by dendritic cells 
and translated into proteins, which are degraded into peptides and presented to both 
CD4+ and CD8+ T cells. Initial trials have already established safety as well as the genera-
tion of appropriate T-cell responses (75).
To further develop our findings from Chapter 8, our research group has acquired mRNA 
from Glypican-3 and MAGE-C2. The mRNA is transferred to antigen presenting cells by 
electroporation and the ability of these cells to stimulate appropriate T-cell responses, 
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in vitro, is evaluated. The next step is to treat patients with HCC, who express these 
antigens, with mRNA based vaccination.
TMAs versus full slides
Given the fact that cancer is extremely complex the question arises: are TMAs suitable 
for studying cancer? To properly answer this question one must consider what the spe-
cific research question under consideration is. TMAs allow a significant reduction in the 
workload and cost of immunohistochemistry, allow better control of the experimental 
conditions used (since multiple tissues are present on one microscopic glass slide) and 
lead to sparing significant amounts of tumor tissue (76). For example, the tissue blocks 
we used for constructing our TMAs for Chapters 3 and 4 can still be used by us, or other 
investigators, to study additional research questions. Regarding the criticism that focal 
expression of biomarkers can be missed by small TMA cores it should be noted that a 
strong correlation between the results of TMA and full slides has been demonstrated 
in several studies (77-82). In fact, in Chapter 4 of this thesis we show that there was no 
difference in staining evaluation between TMA cores and full slides for selected cases 
(Supplementary Figure 4, Chapter 4). The correlation between TMAs and full slides is 
true even for biomarkers that are known to be focally expressed (76). The correlations in 
the case of focally expressed biomarkers, however, is inversely proportional to the size 
of the study cohort. Thus TMAs are suitable when large cohorts of patients are studied.
However, TMAs are not suitable for answering questions of complex spatial relationships 
in the tumor microenvironment. In Chapter 5, where both the intra-tumoral and the 
peri-tumoral composition of the immune infiltrate was studied, in a small cohort of 
patients with CRCLM, the use of TMAs would have been inappropriate. However, if the 
results of our Chapter 5 are validated, namely that it is the intra-tumoral composition 
of the immune infiltrate that is most important, then one may return to TMAs to study 
larger cohorts of patients with CRCLM.
Moreover, in Chapter 4, we were not able to study the expression of immune inhibitory 
ligands in the surrounding non-tumoral tissue. Indeed we cut and stained 2 x 1mm cores 
from the surrounding “normal pancreas” area from each block. However, we now feel 
strongly that 2 x 1 mm cores are not enough to fully characterize the peri-tumoral area 
in pancreatic and ampullary cancer. This is because of the significant heterogeneity in 
histology we observed. The histology ranged from completely normal pancreatic tissue, 
to stromal tissue without invasive cancer cells, to areas of destructed “normal tissue” with 
significant atypia. Capturing the complexity of the peri-tumoral environment requires 
perhaps full slides or significant more TMA cores (from the non-tumorous areas). In fact, 
the molecules we examined are expressed, in several cases, by atypical, non-invasive 
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cells and occasionally by normal pancreas. However, a systematic determination of 
staining patterns could not be confidently made using 2 TMA cores, thus we do not 
discuss findings in stainings in the peri-tumoral areas. Proper future systematic study of 
the peri-tumoral microenvironment in pancreatic and ampullary cancers would require 
full tissue slides.
expansion of biomarker panels
The molecules we examined in our thesis are not exhaustive. We focused on molecules 
with a well validated antibody and relatively understood biology. However, as knowl-
edge on the interaction of the immune system with cancer expands, more molecules 
need to be tested. Regarding TIL markers one may focus on molecules beyond CD8 
and FoxP3. For example, markers of cellular cytotoxicity, such as granzyme B (83, 84), 
myeloperoxidase (85), or NKT cell markers, such as CD1d or TCR Vα24-Jα18 (86, 87), may 
prove useful. In addition, the memory T-cell marker CD45RO has shown promise in the 
setting of colorectal cancer (88). Regarding immune inhibitory molecules other mem-
bers of the B7 superfamily, which includes PD-L1 (B7-H1), such as B7-H3 (89) and B7-H4 
(90, 91) deserve attention. At the moment a clear link between the immune system and 
galectins other than Galectin-9 has not been established. HLA-E, another non-classical 
HLA molecule (92), should also be tested.
future directions: Clinical development of immune biomarker profiles
Several issues regarding future development of immune biomarkers have already been 
discussed: use of properly validated antibodies, appropriate use of TMAs, incorporation 
of cytoplasmatic staining when applicable, use of circulating molecules, expansion of 
the molecules under study and development of biomarker panels with multiple mol-
ecules. However, several steps are required before such an antibody panel reaches clini-
cal development. Once information on promising potential biomarkers is established 
on TMAs, the potential biomarker panel will need to be validated on full slides. This is 
because decisions for individual patients are performed on full slides. Even if the issue 
of heterogeneity is minimized by the use of large cohorts in TMA research (76), hetero-
geneity is a significant issue when decisions on individual patients need to be made. 
Here again, the hope is that with the use of a biomarker panel heterogeneity in one 
molecule may be less detrimental than in a single biomarker situation. However, issues 
of heterogeneity and reproducibility will need to be resolved.
Of necessity will be the repetition of the stainings, for the chosen molecules, on a large 
well characterized cohort of patients with a given disease. At this step systematic work 
with an experienced pathologist(s), establishing diagnostic criteria, is required. Once 
confidence is build regarding staining evaluation, the results will need to be validated in 
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an independent external cohort, using the same antibodies and assays. Then a prognos-
tic biomarker can be introduced to clinical care.
Of more importance than prognostic biomarkers are predictive biomarkers to immuno-
therapeutic strategies. Here, tissue from completed randomized controlled studies need 
to be accessed and the biomarker panel retested. Ideally, this step requires both (re)
discovery and validation cohorts. The final goal is incorporation of the biomarker panel 
in a clinical trial, which requires significant standardization of the biomarker assay, in 
addition to other recommended criteria (93).
Selection of patients highly unlikely to benefit from immunotherapy, or patients highly 
likely to benefit from immunotherapy, will have an immediate obvious clinical benefit. 
Moreover, discovery of predictive immune biomarkers will allow future clinical trials to 
enrich their testing cohorts with patients more likely to benefit, thus speeding up overall 
research efforts. Finally, it is likely, that a well-developed immune biomarker panel, which 
characterizes the complexity of the tumor immune microenvironment to a reasonable 
extent, will not be specific to a given treatment but will extend its usefulness to include 
other types of immune checkpoint inhibitors, or even other immunotherapeutic strate-
gies entirely.
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enGLIsH suMMAry
The first observation that immune cells can infiltrate tumors was made by Virchow in 
1863. Ever since, it was suspected that the immune system plays an important role in 
cancer. However, it is only recently that treatments activating the immune system (im-
munotherapy) have been approved for treating patients with cancer such as melanoma 
and cancer of the prostate, lung, kidney and bladder. Even though these treatments are 
successful not all patients benefit and in fact the treatments can sometimes be toxic. 
Thus, finding biomarkers that predict the patients who benefit from immunotherapy is 
of the outmost importance.
In the current thesis we examine the role of several immune molecules as possible 
biomarkers in cancers of the gastrointestinal tract (hepatocellular carcinoma, pancreatic 
cancer, ampullary cancer and colon cancer). These molecules are frequently expressed 
by cancer cells to protect themselves from the immune system. We also examine the role 
of tumor infiltrating lymphocytes as possible biomarkers. In the process we also identify 
a panel of tumor antigens that can serve as potential targets for vaccination.
In chapter 1 we give a general introduction on the importance of the immune system 
in cancer and the rationale behind the work of this thesis. In chapter 2 we continue our 
introduction by focusing on immune inhibitory mechanisms, as well as experimental im-
munotherapies, in pancreatic cancer. In chapter 3 we discuss the role of several potential 
immune biomarkers in hepatocellular carcinoma. We show that a panel of markers, 
namely PD-L1, Galectin-9 as well as CD8+ immune infiltrating cells, can be an important 
prognostic biomarker. Interestingly, the patients who express the immune inhibitory 
molecules PD-L1 and Galectine-9 survive longer than patients who do not express these 
molecules, the opposite of what one would expect. In chapter 4 we focus on cancers of 
the pancreas and the ampulla. We also show that the combination of PD-L1, Galectine-9 
and other molecules, such as HVEM and HLA-G, in combination with the presence of 
immune infiltrating cells (CD8/FoxP3 ratio) can be an important biomarker in these 
cancers. We also show, again, that patients who express these molecules survivelonger 
than patients who do not express them.
Why is it that expression of molecules that protect cancer cells from the immune system 
are associated with better patient survival. In chapters 3 and 4, as well as in the general 
discussion in chapter 9, we discuss possible reasons. One of the most important reasons 
may be what is known as “adaptive immune resistance”. This means that cancers that 
express immune inhibitory molecules do so because they are under active attack from 
immune cells. These molecules are a sign that the immune system still recognizes and 
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attacks the cancer cells. When a cancer cell does not express these molecules any more it 
may be beyond the detection of the immune system and thus a bad sign for the patient.
In chapter 5 we examine the importance if immune infiltrating cells in liver metastasis 
from colorectal cancer. In this work we use larger tumor sections in order to understand 
if the location of the infiltrating immune cells is important. It is known that the majority 
of immune cells attracted to cancer stay around the tumor and not penetrate inside the 
tumor. We show that it is the immune cells that infiltrate into the cancer itself that are 
important for patients survival and not the cells that stay outside. We also show that it 
is not the amount of cells that penetrate inside the tumor but the relative proportion 
of effector immune cells that fight cancer (CD8+) to the regulatory immune cells that 
help cancer (FoxP3+). This last observation, namely that it is the quality rather than the 
quantity of the immune cells that is important in survival, we also made in chapter 4 
about pancreatic and ampullary cancers.
In chapters 6 and 7 we move beyond cancer cell expression of biomarkers and discuss 
possible biomarkers that are present in the circulating blood. In chapter 6 we discuss 
what is known about routine laboratory tests of the immune system and their relation-
ship to cancer survival. We discuss how routine laboratory tests, such as neutrophils, 
lymphocytes and platelets, or combinations of these markers, have the ability to predict 
which patients with cancer will live longer. In chapter 7 we investigate the role of PD-L1 
and Galectin-9 in circulating blood of patients with hepatocellular carcinoma. We show 
the levels of these immune inhibitory molecules in the circulating blood also predict 
cancer survival, in a similar way as with their expression by cancer cells (chapter 3). 
However, the patients with high PD-L1 and Galectine-9 in the blood are not always the 
same as the patients with who express high PD-L1 and Galectine-9 in the cancer cells. 
Thus, information from the circulating blood is independent, to a certain extent, from 
information from the cancer site. Patients who have high PD-L1 or Galectine-9 in both 
the blood and the cancer site have a very good cancer prognosis, while patients who 
have low PD-L1 or Galectine-9 in both the blood and the cancer site have a very poor 
prognosis.
In chapter 8 we investigate tumor associated antigens that can become possible targets 
for vaccination in hepatocellular carcinoma. We show that a panel of four antigens, 
namely Annexin-A2, Glypican-3, MAGE-C1 and MAGE-C2, are expressed in a significant 
amount of patients, while at the same time they are expressed little (Annexin-A2) or 
not at all (Glypican-3, MAGE-C1 and MAGE-C2) in the surrounding normal liver. These 
characteristics make them possible good targets for vaccination and our lab is currently 
working on developing such a vaccination strategy in hepatocellular carcinoma. In addi-
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tion, in chapter 8, we also show that patients who express lots of these tumor antigens 
(7 or more) do better that patients who express very few of these tumor antigens (2 or 
fewer). In the general discussion, in chapter 9, we hypothesize that perhaps, similarly 
to the expression of the immune inhibitory molecules, expression of too few tumor 
antigens could mean that the cancer cells are beyond detection of the immune system, 
explaining the poor prognosis of these patients.
In chapter 9 we provide a general discussion of our thesis. We focus on issues that 
require more discussion, such as providing additional hypothesis that explain our find-
ings. We also discuss technical aspects of our thesis, such as the importance of antibody 
quality used for immunohistochemistry and the differences, and appropriateness, of 
using tissue microarrays versus full tissue slides. Finally, we also provide ideas on how to 
continue this research forward, with the goal of successfully developing clinically useful 
immune specific biomarkers for the era of cancer immunotherapy.
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neDerLAnDse sAMenVATTInG
De eerste waarneming dat immuuncellen tumoren kunnen infiltreren is gedaan door 
Virchow in 1863. Sindsdien werd lang vermoed dat het immuunsysteem een  belang-
rijke rol speelt bij kanker. Het is echter pas sinds kort dat behandelingen die het im-
muunsysteem activeren (immunotherapie) zijn goedgekeurd voor de behandeling 
van patiënten met kanker, zoals melanoom en prostaat-, long-, nier- en blaaskanker. 
Hoewel deze behandelingen succesvol zijn, hebben niet alle patiënten hier baat bij en 
zijn deze behandelingen soms zelfs toxisch. Derhalve is het van het grootste belang om 
biomarkers te vinden die kunnen voorspellen welke patiënten baat kunnen hebben bij 
immunotherapie, en welke niet.
In dit proefschrift onderzoeken we verschillende immuunmoleculen als potentiele 
biomarkers in gastrointestinale kankers (i.e. hepatocellulair carcinoom, pancreascar-
cinoom, papilcarcinoom en colorectaal carcinoom). Deze moleculen worden vaak tot 
expressie gebracht door kankercellen om zich te beschermen tegen het immuunsys-
teem. We onderzoeken ook de rol van tumor-infiltrerende lymfocyten (TIL) als mogelijke 
biomarker. Daarnaast identificeren we een panel van tumor antigenen die als potentiële 
componenten van toekomstige kanker vaccins kunnen dienen.
In hoofdstuk 1 geven we een algemene inleiding over het belang van het immuunsys-
teem bij kanker en leggen we de grondgedachte voor het werk van dit proefschrift. In 
hoofdstuk 2 gaan we door met de inleiding door te focussen op immuunremmende 
mechanismen, evenals experimentele immuuntherapie bij pancreascarcinoom. In 
hoofdstuk 3 onderzoeken we m.b.v. coupes van kleine stukjes tumorweefsel (zoge-
naamde weefsel microarrays) de rol van de verschillende potentiële immune biomarkers 
in hepatocellulair carcinoom. We laten zien dat immunohistochemische bepaling van 
een panel van immuunmoleculen, namelijk PD-L1, Galectine-9, op tumorcellen, en 
cytotoxischer CD8+ TIL, een accurate prognostische biomarker is voor overleving na 
chirurgische resectie van HCC. Een interessante bevinding is dat de patiënten die de 
immuunremmende moleculen PD-L1 en Galectine-9 op hun tumorcellen tot expressie 
brengen langer overleven dan patiënten die deze moleculen niet tot expressie brengen. 
Dit is het tegenovergestelde van wat men zou verwachten.
In hoofdstuk 4 richten we ons op pancreascarcinoom en papilcarcinoom. We laten zien 
dat immunohistochemische bepaling van de expressie van een panel van PD-L1, Ga-
lectine-9, HVEM en HLA-G op tumorcellen in combinatie met de ratio van cytotoxische 
CD8+ T cellen en regulatoire FoxP3+ T cellen in TIL een accurate prognostische biomarker 
is voor overleving na chirurgische resectie van deze kankers. Opnieuw laten we zien dat 
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patiënten die deze moleculen tot expressie brengen langer overleven dan diegenen die 
dat niet doen. Hoe komt het dat de expressie van moleculen die de kankercellen tegen 
het immuunsysteem beschermen is geassocieerd met een betere overleving voor de pa-
tiënt? In hoofdstuk 3 en 4, maar ook in de algemene discussie in hoofdstuk 9 bespreken 
we mogelijke redenen. Een van de belangrijkste redenen is dat kankers die immuunrem-
mende moleculen tot expressie brengen, dit doen omdat ze actief worden aangevallen 
door het immuunsysteem. Deze moleculen zijn een teken dat het immuunsysteem de 
kankercellen nog herkent en aanvalt. Als een kankercel deze moleculen niet meer tot 
expressie brengt, kan het betekenen dat deze niet meer wordt gedetecteerd door het 
immuunsysteem. En dit is een slecht voorteken voor de patiënt.
In hoofdstuk 5 gaan we in op het belang van TIL in levermetastases van patienten met 
een colorectaal carcinoom. In deze studie gebruiken wij grote tumorcoupes i.p.v. weef-
sel microarrays om te onderzoeken of de locatie van de TIL belangrijk is. Het is bekend 
dat de meeste immuuncellen die aangetrokken zijn door het kankerweefsel aan de rand 
van de tumor blijven en niet doordringen tot in de tumor. We tonen aan dat de TIL die 
doordringen tot in de tumor juist belangrijk zijn voor de overleving van patiënten en 
niet de cellen die buiten de tumor blijven. We tonen ook aan dat het belang niet zit in de 
absolute hoeveelheid TIL die binnendringen in de tumor maar in de proportie van het 
aantal cytotoxischer (CD8+) immuuncellen (dat is cellen welke kankercellen bestrijden) 
in relatie tot het aantal regulerende (Foxp3+) immuuncellen (i.e. cellen die kankercellen 
helpen door het immuunsysteem te remmen). Deze laatste observatie, namelijk dat 
kwaliteit belangrijker is dan kwantiteit van de immuuncellen in termen van overleving, 
komt ook terug in hoofdstuk 4 over pancreascarcinoom en papilcarcinoom, alhoewel in 
die studie gebruik gemaakt werd van weefsel microarrays.
In de hoofdstukken 6 en 7 maken we de overgang van kankercelexpressie van biomar-
kers naar mogelijke biomarkers welke aanwezig zijn in de bloedcirculatie. In hoofdstuk 
6 bespreken we de bestaande literatuur over routine laboratoriumtesten, zoals aantal 
neutrofielen, lymfocyten en bloedplaatjes, of combinaties hiervan, als potentiele bio-
markers voor overleving. In hoofdstuk 7 onderzoeken we de prognostische rol van de 
PD-L1 en Galectine-9 moleculen in de bloedcirculatie van patiënten met hepatocellulair 
carcinoom. We laten hier zien dat er een verband bestaat tussen een hogere concentra-
tie van deze immuunremmende moleculen in de bloedcirculatie en betere kankerover-
leving. Dit is vergelijkbaar met wat we zagen in hoofdstuk 3 voor de kankercelexpressie 
van deze moleculen. Het is echter verrassend dat de patiënten met een hoge PD-L1 
en Galectine-9 concentratie in het bloed niet altijd een hoge expressie van PD-L1 en 
Galectine-9 in de kankercellen hebben. Dit betekent dat bloed concentratie en kanker-
celexpressie onafhankelijk van elkaar prognostische informatie bevatten. Patiënten met 
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hoge PD-L1 of Galectine-9 gehalte in zowel het bloed als in kankercellen hebben een 
uitstekende prognose, terwijl patiënten met lage PD-L1 of Galectine-9 gehalte in bloed 
en kankercellen een zeer slechte prognose hebben.
In hoofdstuk 8 onderzoeken we een aantal tumor-geassocieerde antigenen als moge-
lijke componenten voor toekomstige vaccins voor hepatocellulair carcinoom. We laten 
zien dat een panel van vier antigenen, namelijk annexine-A2, glypican-3, MAGE-C1 en 
MAGE-C2, tot expressie worden gebracht door kankercellen in een significant aantal pa-
tiënten, terwijl ze tegelijkertijd zeer weinig (Annexine-A2) of helemaal niet (glypican-3, 
MAGE-C1 en MAGE-C2) in het omringende normale leverweefsel tot expressie worden 
gebracht. Deze eigenschappen maken dat ze geschikt zijn als targets voor vaccinatie. 
Ons laboratorium is momenteel bezig met het ontwikkelen van een dergelijke vac-
cinatiestrategie voor hepatocellulair carcinoom. In hoofdstuk 8, in overeenstemming 
met de rest van dit proefschrift, blijkt eveneens dat patiënten die veel (7 of meer) van 
deze tumorantigenen tot expressie brengen langer overleven dan patiënten die zeer 
weinig (2 of minder) van deze tumor-antigenen tot expressie brengen. In de algemene 
discussie, hoofdstuk 9, veronderstellen we dat misschien, vergelijkbaar met de expres-
sie van immuunremmende moleculen, de expressie van te weinig tumorantigenen kan 
betekenen dat de kankercellen niet meer worden gedetecteerd door immuunsysteem. 
En dit zou de slechte prognose van deze patiënten kunnen verklaren.
Hoofdstuk 9 is een algemene bespreking van dit proefschrift. Wij richten ons op be-
vindingen die een diepere discussie behoeven en verstrekken additionele hypotheses 
en wetenschappelijke ideeën om deze bevindingen te verklaren. We gaan daarnaast 
in op de technische aspecten van onze experimenten, zoals bijvoorbeeld het belang 
van de kwaliteit van antilichamen die worden gebruikt in immuunohistochemie en de 
geschiktheid van het gebruik van weefsel microarrays versus volledige weefselcoupes. 
Tot slot dragen we ook ideeën aan voor toekomstige vervolgstappen van dit onderzoek. 
Ons uiteindelijke doel is het ontwikkelen van klinisch bruikbare en immuunspecifieke 
biomarkers in het huidige tijdperk van kanker immunotherapie.
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